Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
10-28-2014 12:00 AM

Regulation of the High-Affinity Choline Transporter Activity and
Trafficking in Alzheimer’s Disease-Related Pathological
Conditions
Leah K. Cuddy, The University of Western Ontario
Supervisor: Jane Rylett, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree
in Pharmacology and Toxicology
© Leah K. Cuddy 2014

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Medical Molecular Biology Commons, and the Medical Pharmacology Commons

Recommended Citation
Cuddy, Leah K., "Regulation of the High-Affinity Choline Transporter Activity and Trafficking in Alzheimer’s
Disease-Related Pathological Conditions" (2014). Electronic Thesis and Dissertation Repository. 2513.
https://ir.lib.uwo.ca/etd/2513

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

REGULATION OF THE HIGH-AFFINITY CHOLINE TRANSPORTER
ACTIVITY AND TRAFFICKING IN ALZHEIMER’S DISEASE-RELATED
PATHOLOGICAL CONDITIONS
(Thesis format: Integrated Article)

by

Leah Katherine Cuddy

Graduate Program in Pharmacology

A thesis submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Leah Katherine Cuddy 2014

Abstract
Cholinergic neurons play a key role in cognitive processes through the action of the
neurotransmitter acetylcholine (ACh). Dysfunction of these neurons occurs in several
neurodegenerative disorders, including Alzheimer’s disease (AD). The high-affinity
choline transporter CHT recycles choline back into synaptic terminals, which is the ratelimiting step to ACh production. CHT proteins traffic between the cell surface and
subcellular organelles in a constitutive manner, which maintains plasma membrane
transporter levels, thereby regulating CHT activity and maintaining cholinergic
transmission. Pathological conditions associated with AD may alter CHT function in a
manner that reduces choline uptake activity and impairs cholinergic neurotransmission.
Thus, my experiments focused on understanding the mechanisms regulating the
subcellular distribution and activity of CHT in neural cells stably expressing the
transporter exposed to AD-related pathological conditions. Important AD risk factors that
can lead to pathological changes in the cholinergic nerve terminal microenvironment
include increased generation of the reactive oxygen species (ROS) peroxynitrite
(ONOO-), high serum cholesterol level at midlife and mutations in genes encoding the
amyloid precursor protein (APP). My investigation revealed that ONOO- alters CHT
function through changes to CHT subcellular trafficking, as opposed to nitrosative or
oxidative modification to CHT itself. Moreover, CHT movement through subcellular
endosomes and lysosomes was not altered by ONOO-, but blocking proteasome function
attenuated ONOO- mediated inhibition of CHT function. Second, I evaluated how CHT
activity and trafficking is regulated by plasma membrane cholesterol and its association
with cholesterol-rich lipid rafts. The results of these experiments showed that membrane
cholesterol and lipid rafts play an important role in regulating CHT trafficking and
activity by retaining functional CHT at the cell surface. Finally, my studies revealed that
CHT function is inhibited by both wild-type and Swedish mutant APP but the underlying
mechanisms differ. Wild-type APP facilitates CHT endocytosis, whereas Swedish mutant
APP mediated inhibition of CHT function is caused by the susceptibility of CHT to Aβ
released into the extracellular environment. My studies help define the molecular
regulation of CHT proteins under pathological conditions. Information from studies such
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as these will aid the design of therapeutic strategies to treat pathologies involving
cholinergic dysfunction.
Keywords: Alzheimer’s disease, cholinergic neurons, high-affinity choline transporter,
oxidative stress, cholesterol, amyloid precursor protein
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Chapter 1

1

General Introduction

1

1.1 Significance of this PhD thesis
Cholinergic neurons play an important role in the central nervous system and are
responsible for a wide array of activities, including memory and cognition, through the
action of the neurotransmitter acetylcholine (ACh). Dysfunction of these neurons occurs
in many neurologic and psychiatric disorders, with the best studied being Alzheimer’s
disease (AD). Many reports have suggested that the cognitive deficits seen in AD are
related to the loss and dysfunction of cholinergic signalling. However, the specific
changes that occur in the aging brain that result in cholinergic dysfunction, and the extent
to which they can be prevented or reversed, is still unclear. While the cause of AD is
unknown, several risk factors have been identified. These risk factors include increasing
age, brain injury, high serum cholesterol level at midlife, mutations in genes encoding the
amyloid precursor protein (APP) and increased generation of reactive oxygen species
(ROS) and reactive nitrogen species (RNS) in the brain. Greater understanding of the
molecular events occurring in the cholinergic presynaptic nerve terminal under these
pathological situations is essential for developing new treatment methods, and is the
focus of current research today.

1.2 The cholinergic system
1.2.1

Cholinergic projections

In the periphery, ACh is the main neurotransmitter used at pre- and post-ganglionic
parasympathetic synapses, at pre-ganglionic sympathetic synapses and at the
neuromuscular junction. In the central nervous system (CNS), ACh signalling is widely
distributed through several major cell groups and pathways. Cholinergic neurons project
to most regions of the brain as interneurons or by projection neurons. The cholinergic
neurons that undergo neurodegeneration during aging associated with memory
impairments are primarily found within the basal forebrain (1-3). This cholinergic
complex is comprised of the medial septum, horizontal and vertical diagonal band of
Broca, and nucleus basalis of Meynert, and provides the major cholinergic projections to
the cerebral cortex, hippocampus, amygdala and olfactory bulb (4, 5). The medial septum
2

provides the main source of cholinergic projections to the hippocampus (6) and directly
synapses with both neurons and interneurons (7, 8). Several cholinergic projections do
not directly synapse with post-synaptic sites, indicating a role for cholinergic bulk
transmission (9).

1.2.2

Acetylcholine signalling and metabolism

At the pre-synaptic cholinergic nerve terminal, ACh is produced in the cytoplasm by the
combination of acetyl-CoA and choline by choline acetyltransferase (ChAT) and
packaged into synaptic vesicles (SV) by the vesicular acetylcholine transporter (VAChT).
It is stored intracellularly until depolarization of the neuron causes movement of SV to
the plasma membrane and release of ACh into the extracellular environment. Once in the
synaptic cleft, ACh can bind to pre-synaptic or post-synaptic G protein-coupled
muscarinic ACh receptors (mAChR) or cation-permerable, cys-loop ligand-gated
nicotinic ACh receptors (nAChR) (10-12). The binding of ACh to nAChR can cause
depolarization or alterations in intracellular calcium levels of the post-synaptic cell,
which lead to changes in neurotransmitter release, signal transduction cascades, cell
survival, and gene transcription (13-15). The mAChR are subdivided into five major
groups according to their G-protein coupling with M1, M3 and M5 receptors selectively
coupling to the Gq/G11 family and the M2 and M4 receptors couple to the Gi/Go Gproteins (16, 17). ACh stimulation of these receptors leads to several biochemical and
electrophysiological responses, which depend on the location and identity of the receptor
that is activated (18).
Alternatively, the ACh that does not bind to post-synaptic receptors is hydrolyzed rapidly
into choline and acetate by the enzyme acetylcholinesterase (AChE). For the re-synthesis
of ACh, the high-affinity choline transporter CHT is responsible for recycling choline
back into the pre-synaptic nerve terminal, which is thought to be the rate-limiting step to
ACh production (19, 20). The synthesis, storage, degradation and release of ACh are
shown schematically in Figure 1-1. The significance of CHT in cholinergic
neurotransmission is highlighted by the fact that the CHT specific antagonist

3

Figure 1-1 Acetylcholine metabolism.
At the pre-synaptic cholinergic nerve terminal, ACh is produced in the cytoplasm
by the combination of acetyl-CoA with choline catalyzed by choline
acetyltransferase (ChAT) and packaged into synaptic vesicles (SV) by the
vesicular acetylcholine transporter (VAChT). Depolarization of the neuron causes
movement of SV to the plasma membrane and release of ACh into the
extracellular environment. Once in the synaptic cleft, ACh can bind to presynaptic or post-synaptic G protein-coupled muscarinic ACh receptors (mAChR)
or ligand-gated nicotinic ACh receptors (nAChR). ACh that does not bind to postsynaptic receptors is hydrolyzed rapidly into choline and acetate by the enzyme
acetylcholinesterase (AChE). For the re-synthesis of ACh, the high-affinity
choline transporter CHT is responsible for recycling choline back into the presynaptic nerve terminal, which is thought to be the rate-limiting step to ACh
production (19, 20).
4

hemicholinium-3 (HC-3) administration to animals causes lethal respiratory failure and
that CHT knockout mice die at birth from hypoxia also due to respiratory failure (21).

1.2.3

Molecular features of CHT

For many years, the high-affinity choline uptake system has been well established in
brain synaptosomes (22, 23, 20) and thought to be unique to cholinergic neurons (24).
However, the gene for the transporter responsible, CHT, was only recently cloned in the
year 2000 from Caenorhabditis elegans (25). The subsequent cloning of several
mammalian cDNAs encoding CHT, including rat (25), mouse (26) and human (27, 28),
have allowed various studies characterizing CHT distribution and regulation.
Human CHT shares 93% sequence identity with rat CHT, contains 580 amino acids and
has a predicted molecular weight of approximately 63kDa. CHT provides cells with highaffinity, sodium and chloride- dependent, HC-3 - sensitive choline uptake and is a
member of the solute carrier 5 (SLC5) family of solute transporters (assigned as
SLC5A7) (29), sharing approximately 20-25% amino acid sequence identity with
members of this family (25). CHT contains 13 predicted transmembrane domains (TMD),
an extracellular amino-terminus (30) and an intracellular carboxy-terminus (Figure 1-2)
(31). Cysteine scanning analysis has provided recent experimental evidence to confirm
this predicted transmembrane topology of CHT (32). Primary amino acid sequence
analysis predicts that human CHT has two extracellular asparagine (N) residues that may
serve as putative glycosylation sites, and experimental evidence indicates that CHT is
indeed glycosylated (31). CHT has several consensus phosphorylation sites for various
kinases (27), a strong putative dimerization motif (GxxxGxxxG) in TMD 12 and a second
GxxxG motif in TMD 2, similar to those identified recently in other neurotransmitter
transporters (33). Several candidate sequences for putative cholesterol binding motifs
have been identified in CHT (34). Finally, it has been identified that CHT contains a
dileucine-like internalization motif [Leu-531, Val-532] in its carboxyl-terminal tail that is
required for its clathrin-mediated endocytosis (30).
CHT is predominantly found within cholinergic neurons (35, 36), although there have
been studies where CHT expression has been observed in non-neuronal tissues (375

Figure 1-2 Schematic representation of transmembrane topology of rat high-affinity
choline transporters.
CHT is a 13 trans-membrane domain (TMD) protein with an extracellular aminoterminus, an intracellular carboxyl-terminus that contains at least 15 putative
phosphorylation sites (shown in pink) as predicted by NetPhos 2.0 software, and an
extracellular aspargine residue, which serves as a consensus site for glycosylation. The
dileucine-like trafficking motif is located at residues leucine-531 and valine-532 and is
shown in orange. The positions of putative CRAC-like and CARC cholesterol binding
sequence motifs are shown in TMDs 4, 11, 12, and 13. The positioning of transmembrane
domains shown is based on data for human CHT [Q9GZV3] submitted recently to
UniProtKB/Swiss-Prot at http://www.uniprot.org/uniprot/Q9GZV3 [Last modified July
24, 2013]; rat and human CHT share 93% sequence identity.
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41). The human CHT gene is approximately 25kb in length and contains 9 coding exons
(25). CHT activity is regulated both post-translationally and at the transcriptional level.
At the transcriptional level, CHT expression is regulated by several factors, including
intraneuronal cyclic adenosine monophosphate (cAMP) concentration (42), nerve growth
factor (NGF)-TrkA signalling (35, 43), post-synaptic activity dependent retrograde
signalling (47). Also, mouse neurons that express the p75 neurotrophin receptor express a
much higher level of CHT mRNA than do those that lack this receptor (45, 46). At the
post-translational level, CHT trafficking is a critical regulatory mechanism of CHT and
can be influenced by protein modifications to, or protein-protein interactions with, CHT.

1.2.4

Regulation of high-affinity choline uptake by CHT trafficking

CHT is active while present at the plasma membrane, but experimental evidence
indicates that the majority of the transporter is found intracelluarly within endocytic and
synaptic vesicles (30, 31, 36, 47). Several observations show that an increase in neuronal
activity leads to an increase in choline uptake (48-51), which is likely related to enhanced
trafficking of CHT to the cell surface, as has been observed in HC-3 bindings assays and
subcellular fractionation experiments (52). Because CHT is located mainly within SV,
and depolarization of neurons increases the exocytosis of SV, release of ACh into the
synaptic cleft enhances CHT trafficking to the cell surface, it is hypothesized that
increased high-affinity choline uptake during depolarization is responsible for
maintaining high levels of ACh release during neuronal stimulation (53).
Several reports support the idea that CHT trafficking is critical in regulating high-affinity
choline uptake. For example, it has been observed in attentional task-performing rats that
CHT plasma membrane levels and choline uptake activity are increased (54). Other
studies show that despite reduced total CHT proteins in mice that are heterozygous for
CHT compared to wild-type mice, HC-3 binding and high-affinity choline uptake are
unchanged, suggesting a compensatory mechanism in the CHT heterozygous mice
involving the recruitment of CHT to the cell surface (21). Aberrant CHT trafficking is
observed in mice lacking adaptor protein-3, which is thought to be involved in the
formation of synaptic vesicles from endosomes (55). These experiments showed that
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while cell surface levels of CHT were reduced by 30%, choline uptake activity was
unaffected and likely due to the recruitment of intracellular CHT reserve stores (56).
Studies using an endosomal ablation protocol to block CHT movement into early
endosomes revealed that CHT surface expression and uptake activity is reduced in a
time-dependent manner (57). Taken together, the results of these studies highlight the
importance of understanding the mechanisms involved in CHT trafficking since this
maintains a steady-state level of transporter at the plasma membrane, thereby regulating
CHT activity and ACh synthesis.

1.2.5

CHT subcellular trafficking

There is only a small amount of transporter at the plasma membrane, which constitutively
traffics between the cell surface and intracellular organelles (Figure 1-3). This was shown
by experiments utilizing an amino-terminal FLAG-tagged CHT and cell surface
biotinylation experiments where it was observed that only 15% of CHT is located at the
cell surface in HEK293 cells (30), similar to the amount found in nerve endings from rat
brain (31, 36). Experiments employing the carboxyl-terminal fragment of AP180
(AP180C) and a dominant negative (DN) mutant of dynamin (Dyn K44A), which block
clathrin-dependent endocytosis (58) and some forms of clathrin-independent endocytosis
(59, 60), revealed that CHT is internalized through a clathrin-dependent mechanism (30).
Once internalized, CHT colocalizes with GFP-tagged Rab-5 proteins (30, 47) and is
recycled back to the cell surface rapidly through Rab-4 positive endosomes or through
slow Rab-11 positive recycling endosomes (61). It has also been proposed that CHT
recycles back to the cell surface through synaptic vesicles during depolarization-mediated
exocytotic release of ACh (30, 47, 61). Alternatively, CHT can be transported through
Rab-7 and Rab-9 positive late endosomes to lysosomes for degradation (62).
The mechanisms involved in the recruitment of CHT from intracellular stores to the cell
surface, the internalization of CHT into early endosomes, or the recycling of CHT back to
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Figure 1-3 Pathways of CHT subcellular trafficking.
CHT is internalized from the plasma membrane through a clathrin-dependent mechanism.
Once internalized, CHT colocalizes with GFP-tagged Rab-5 proteins and is recycled back
to the cell surface rapidly through Rab-4 positive endosomes or through slow recycling
endosomes. It has also been proposed that CHT recycles back to the cell surface through
synaptic

vesicles

during

depolarization-mediated

exocytotic

release

of

ACh.

Alternatively, CHT can be transported through Rab-7 and Rab-9 positive late endosomes
to lysosomes for degradation.
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the cell surface, are not well understood. It is well known that post-translational
modifications of transmembrane proteins, such as phosphorylation and ubiquitination,
can alter protein trafficking and activity. Early studies showed that HC-3 binding and
choline uptake in brain preparations is altered by phosphorylation (63-66), and more
recently it was demonstrated that this is related to changes in CHT trafficking, as CHT
internalization and choline uptake activity is reduced by protein kinase C (PKC)
activators and protein phosphatase PP1/PP2A inhibitors (67,68). Other early studies
identified ubiquitin as a post-translational modification that inhibits high-affinity choline
uptake activity and ACh synthesis (69,70). A recent study found that CHT is
ubiquitinated in HEK293 cells by the ubiquitin ligase Nedd-42 and that this negatively
regulates its cell surface expression (71).
The interaction of CHT with other cellular proteins is another mechanism by which the
subcellular trafficking of the transporter is regulated, but only a few proteins have been
identified to date. Prostate apoptosis response-4 (Par-4), which is up-regulated during
neurodegeneration and AD, has been shown to interact with CHT and inhibit highaffinity choline uptake by reducing the incorporation of CHT on the cell surface (72).
The SEC-14 like protein 1 (SEC14L1), which may act as a phospholipid transfer protein,
interacts with CHT and inhibits choline uptake activity, likely through alterations in CHT
trafficking (73). Interestingly, wild-type APP (APPwt) has been shown to interact with
CHT through the carboxyl-terminal of APP. The interaction is thought to mediate CHT
presynaptic localization in both the mouse neuromuscular junction and central
cholinergic neurons, while over-expression of CHT and APP in HEK293 cells increases
its rate of internalization from the cell surface into early endosomes (74). Finally, it has
been shown that CHT co-immunoprecipitates with β-amyloid (Aβ) peptides in rat brain
hippocampal synaptosomes, which could alter either high-affinity choline uptake activity
or CHT trafficking (75).

1.3 Cholinergic dysfunction in AD
AD is characterized by specific neuronal and synaptic loss, the deposition of amyloid
plaques and neurofibrillary tangles, and the loss of neurotransmitter systems. While
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several neurotransmitter pathways are known to be involved in AD, the loss of
cholinergic neurons is thought to be particularly important (76, 77). Basal forebrain
cholinergic neurons, which play a key role in attention, learning, memory, perception,
and consciousness (78, 79), are thought to undergo selective degeneration during the
course of AD. This is supported by several early studies that examined post-mortem brain
tissue from individuals with AD and found substantial deficits of ChAT expression (8082), reduced ACh release and loss of cholinergic perikarya from the nucleus basalis (83,
84). In the following years, the observations that clinical dementia ratings associated with
the loss of presynaptic cholinergic proteins including ChAT, mAChR, nAChR, and
reduced ACh levels (85-87), led to the hypothesis that cholinergic dysfunction is related
to the cognitive decline and memory loss seen in AD (77).
Support for this hypothesis was based on post-mortem analysis of brains from patients in
the advanced stages of late-onset AD; however, whether loss and dysfunction of
cholinergic neurons occurs in the early stages of the disease is controversial (88, 89).
Positron emission tomography (PET) studies using specific AChE tracers revealed a
slight loss of AChE activity in the hippocampus of patients with mild cognitive
impairment (MCI) or in the early stages of AD (90, 91), while other studies observed no
differences in ChAT activity measured in several brain regions between individuals with
MCI or in the early stages of AD, compared to non-impaired controls (92, 93). In contrast
to this, a separate study found that ChAT activity was significantly increased above
controls in the hippocampus and superior frontal cortex of individuals with MCI (94).
While the numbers of ChAT or VAChT-positive basal forebrain cholinergic neurons in
patients with MCI are unchanged compared to non-impaired control individuals, a
decrease in the levels of high-affinity NGF receptor TrkA and the p75 low-affinity
neurotrophin receptor, which are required for trophic support of basal forebrain
cholinergic neurons, has been reported in individuals with early AD or MCI (95, 96).
Furthermore, there is evidence from experimental lesions in animals and from postmortem human studies to suggest that many cholinergic neurons shrink in size during AD
pathology rather than die. (97-99). Taken together, these observations suggest that
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cholinergic neurons may undergo dysfunction rather than die in individuals with mild AD
or MCI.
While studies examining cortical and hippocampal ChAT activity have been used
extensively to assay cholinergic function, there have only been a few reports on CHT in
neurodegeneration and in AD patients. These studies have been contradictory, with some
studies showing a significant enhancement of [3H]HC-3 binding to the transporter in
cortical regions in post-mortem AD brain (100) while others show significantly lower
densities of [3H]HC-3 binding sites in both the frontal cortex and hippocampus of AD
brains compared to controls (101, 102). In terms of high-affinity choline uptake, one
study showed a decrease in necropsy brain of AD subjects (103), and others indicate that
while there is a general loss of cholinergic projections as measured by a decrease in
ChAT activity, high-affinity choline uptake is increased significantly in the remaining
nerve terminals (104).

1.4 Evidence of oxidative stress in AD
A common feature of several neurodegenerative disorders is the evidence of extensive
oxidative stress, which appears to occur particularly early on in AD and contributes to the
pathology of the disease by mediating the loss and dysfunction on neuronal cells (105,
106). Oxidative stress occurs when the production of ROS such as hydrogen peroxide
(H2O2), nitric monoxide (NO), superoxide anion (O2-), peroxynitrite (ONOO-) and
reactive hydroxyl radical (OH·), is unregulated and is greater than antioxidant capacity.
The brain is particularly susceptible to ROS because it is low in antioxidant defense
systems, has a high oxygen consumption and it is rich in polyunsaturated fatty acids,
which are easily attacked by free radicals (107). Increased production of ROS in the brain
can result in the oxidation of lipids, proteins, RNA and DNA, which leads to
inflammation, tissue damage and subsequent cellular apoptosis of neurons or glial cells
(108). The oxidative stress hypothesis of AD is formulated based on the observations that
a primary risk factor for the disease is age, and during aging antioxidant capacity is
reduced and ROS accumulates in the brain.
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This hypothesis is supported by several lines of evidence that show that the signature
markers of oxidative stress are up-regulated in AD pathology. The concentration of (E)4-hydroxy-2-nonenal (HNE), an electrophilic breakdown product of lipid peroxidation
formed by the attack of ROS on the double bond arachidonic acid (109), is significantly
increased in brain tissue (110) and cerebrospinal fluid (CSF) of individuals with AD
(111). Lipid peroxidation products acrolein, malondialdehyde and F2-isoprostanes are all
increased in AD brains compared to controls (112), with F2-isoprostanes being elevated
in the cortex and hippocampus, but not in the cerebellum, an area not typically affected
by AD lesions, and in the post-mortem ventricular and lumbar CSF from patients with
AD (113, 114). Increased oxidative damage occurs to all four bases of DNA in the brains
of AD patients compared to cognitively intact control subjects (115) and extensive
protein carbonylation (116) and nitration is observed in brains of individuals with MCI or
AD (117, 118). Finally, the endogenous antioxidant defence enzymes catalase,
superoxide dismutase, glutathione peroxidase and glutathione reductase are up-regulated
in the hippocampus and amygdala in AD brains (119, 120).

1.5 Sources of ROS in the AD brain
1.5.1

Overview

ROS are produced in the brain by direct interactions between redox-active metals and
oxygen species, or through indirect pathways involving the activation of phospholipases,
nitric oxide synthases and xanthine oxidase, which occurs as a result of dysregulation of
calcium homeostasis (121). It is not clear whether disruption of calcium homeostasis is a
cause or result of ROS production as some studies have shown that increases in
intracellular calcium induce the production of ROS, while others show low
concentrations of ROS cause an increase in cytosolic calcium levels (122, 123). The most
investigated potential sources of ROS within the AD brain are altered mitochondrial
activity, the presence of unbound metal ions and Aβ peptides themselves. There is an
extensive literature that supports mitochondrial dysfunction and subsequent oxidative
damage during AD. Mitochondria generate O2- and NO as physiologically important byproducts of cellular respiration and contain many redox enzymes and respiratory
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complexes capable of transferring single electrons to oxygen, generating O2-. While
mitochondria contain several antioxidant defence systems, insults to the mitochondria,
including ROS itself, can cause an imbalance between ROS production and removal
leading to an overall net production of ROS (124).

1.5.2

Metal ions as a source of ROS

An important source of oxidative stress in the brain comes from the presence of metal
ions. Metal ions are believed to play a role in the pathogenesis of AD (125). The
concentrations of iron and zinc in various brain regions affected by AD are elevated in
patients with AD compared to cognitively intact controls while copper levels are reduced
(126, 127). Copper and iron are active redox metals that are toxic when present in excess
due to their involvement in many processes related to ROS generation. The reactivity of
copper and iron with molecular oxygen promotes the formation of H2O2, O2- and the
highly reactive OH· through the well-known Haber-Weiss and Fenton reactions (128,
129). It is thought that metal ions contribute to AD pathogenesis and increase cellular
ROS production by binding to Aβ. APP has a copper binding site in its amino-terminal
domain, which reduces Cu2+ to Cu1+ (130) and a zinc binding site, which is thought to
play a structural role (131), and Aβ itself also contains specific high and low affinity
Cu2+ and Zn2+ binding sites. The reduction of Cu2+ and Fe3+ by interacting with Aβ results
in a redox-active peptide-metal ion complex which catalyzes the production of H2O2,
using O2- and biological reducing agents, such as cholesterol, vitamin E and
catecholamines as substrates (132-135). The redox-active Aβ-metal ion complex itself
can subsequently reduce H2O2 to OH·. The aggregation of Aβ is fundamental to Aβmediated toxicity; however, emphasis has shifted away from amyloid fibrils as the
predominant toxic species to the soluble oligomeric forms of Aβ. Interestingly, the
interaction with copper, zinc, or iron with Aβ mediates the aggregation of the peptide
(136, 137) while chelation of the metal ions can reverse the aggregation of synthetic Aβ
and dissolve amyloid in post-mortem human brain samples (138, 139). Studies examining
the time course of H2O2 generation during Aβ aggregation showed that H2O2 generation
reaches a maximum during the early stages when oligomers are the main species present
and declines as fibrils are formed (140, 141). A very recent study revealed that the latter
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observation is due to conversion of H2O2 into OH· through redox activity of mature
fibrils in the presence of redox-active ions, challenging the idea that the end stage fibrils
are non-toxic structures (142).

1.5.3

Aβ as a source of oxidative stress

In addition to its ability to induce ROS formation through metal ion binding, internalized
Aβ can generate oxidative stress by exerting direct effects on the mitochondrial
membrane resulting in damage to the electron transport chain compromising neuron
viability through energy depletion (143). This has been observed in PC12 cells, where Aβ
causes mitochondrial dysfunction by impairing glycolysis, which results in depletion of
cellular ATP levels (144). The iron-sulfur center containing enzyme complexes of the
electron transport chain, α-ketoglutarate dehydrogenases and aconitase, have been shown
to be vulnerable to damage by Aβ in various model systems (145, 146) and Aβ has been
shown to potentiate induction of the mitochondrial permeability pore (147, 148), which
causes depolarization of the mitochondrial membrane, calcium efflux and reduced
glutathione and NADPH levels (149,150). Damage to the mitochondrial membrane and
the electron transport chain increases mitochondrial ROS production (151), which can
then further impair mitochondrial function. Finally, Aβ activates microglia in several
experimental models (153-155) which are capable of releasing of NO (155) and O2(156). NO and O2- combine together to produce significant amounts of a much more
reactive molecule, ONOO-, which has been implicated in AD because of the levels of
nitrotyrosine, a product of the reaction of ONOO- with tyrosine, are elevated in AD
(157). Consistent with this is the observation that ONOO- can be generated by microglia
activated by Aβ (158).

1.6 ROS cellular targets
ROS are highly reactive molecules that can react with a number of different targets in the
brain to initiate neuronal death and neurodegeneration through various different
pathways. ROS impair cellular function and cause cell death through the oxidation of
lipids, proteins and DNA, and through the formation of toxic molecules such as alcohols,
aldehydes, peroxides, ketones and cholesterol oxide. The products of membrane lipid
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peroxidation by ROS, such as HNE and acrolein, cause toxicity to cells by covalently
modifying proteins on cysteine, lysine and histidine residues by a process called Michael
addition. This can impair the function of membrane ion-motive ATPases, such as the
Na+/K+- and Ca2+- ATPases, as well as glucose and glutamate transporters, which can
cause membrane depolarization and a reduction in cellular ATP levels (159, 160). HNE
stimulates the apoptotic cascade through disruption of cellular calcium homeostasis (161)
by activating of c-Jun amino terminal kinases and mitogen-activated protein kinase-1
(MAPK) (162). The interaction of ROS with DNA can cause mutations and strand
breaks, and ROS modifications to proteins can alter protein function through reversible
post-translational modifications or impair protein activity. The perturbed calcium
homeostasis as a result of ROS overproduction can also lead to an excitotoxic response,
where excessive calcium influx results in the activation of glutamate receptors and
initiates events resulting in apoptosis (163, 164).

1.7 APP features and trafficking
A major pathological hallmark feature of AD is the accumulation of insoluble aggregates
of Aβ which is produced by the sequential proteolytic processing of its precursor, APP
(165, 166). APP is a large, 695-770 amino acid, type-1 transmembrane protein with an
extracellular amino terminus and an intracellular carboxyl terminus (167, 168). APP is
produced in large amounts in neurons and quickly metabolized (169) through multiple
different pathways of proteolysis by α, β and γ-secretase enzymes (170) at various
subcellular locations (171). Initially, APP is sorted in the endoplasmic reticulum (ER)
and the Golgi apparatus, where it is subject to post-translational modification such as Nand O-linked glycosylation, tyrosine sulfation and ectodomain and cytoplasmic
phosphorylation (172-175). APP is transported to the axon and dendrites in post-Golgi
transport vesicles (176) where it undergoes fast axonal transport to synaptic terminals
(177) and is either trafficked directly to the cell surface or to endosomal compartments
through clathrin-associated vesicles. At the cell surface, APP is internalized into clathrincoated pits mediated by the interaction of the intracellular YENPTY domain of APP
(178) with multiple binding partners. This requires the presence of a phosphotyrosine
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binding domain on the interacting protein, with the two best studied proteins being X11
and Fe65. Mutation of the YENPTY domain alters APP endocytosis (179) and
diminishes Aβ production (180). Following internalization, APP is transported to
endosomal compartments, where a small portion of endocytosed APP is recycled back to
the cell surface, while a considerable amount of APP is degraded in lysosomes (165).
Finally, APP retrograde trafficking occurs between endosomes and the trans-Golgi
network (TGN), which is mediated by retromer complexes. Sorting protein-related
receptor (sorLA) is an adaptor protein that affixes cargo to the retromer complex and
binds APP (181).

1.8 APP metabolism
APP undergoes proteolytic processing through one of two pathways: non-amyloidogenic
processing of APP, which leads to the generation of non-pathogenic peptide fragments
and prevents Aβ production, or amyloidogenic processing leading to the generation of Aβ
(Figure 1-4). The amyloidogenic processing of APP occurs when the β-secretase, β-site
APP cleaving enzyme-1 (BACE1), mediates the initial and rate-limiting step in the
processing of APP (182). BACE1 cleaves APP at a position located 99 amino acids from
the carboxyl terminus, resulting in release of the soluble amino-terminal ectodomain of
APP (sAPPβ) and a 99 amino acid membrane-bound intracellular carboxyl-terminal
fragment (C99 or βCTF). The carboxyl-terminal fragment is then processed within the
membrane by the γ-secretase multi-protein complex, which is composed of presenilin 1
(PS-1), presenilin 2 (PS-2), nicastrin, Aph-1 and Pen-2 (183). The γ-secretase complex
cleaves the βCTF at one of several sites between amino acids 38 and 34 to generate Aβ
and the APP intracellular domain (AICD). AICD is released into the cytosol and Aβ is
thought to accumulate intra-neuronally (184) or to be released into extracellular fluids,
such as plasma or cerebrospinal fluid through the recycling of endosomal compartments
to the cell surface. The γ-secretase cleavage produces Aβ that is 40 amino acids in length
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Figure 1-4 APP metabolism through the amyloidogenic and non-amyloidogenic
pathway.
Cleavage of APP in the amyloidogenic pathway involves processing by both β-secretase
(BACE1) and the γ-secretase complex that releases the soluble amino-terminal
ectodomain of APP (sAPPβ), the APP intracellular domain (AICD) and an Aβ peptide
that can be of varying length, with the 40 and 42 amino acid Aβ peptides being the most
abundant. Alternatively, APP processing can occur through the non-amyloidogenic
pathway where it is first cleaved by the α-secretase (ADAM10) then by the γ-secretase
complex, thereby preventing the generation of toxic Aβ peptides and leading to the
production of the soluble amino-terminal ectodomain of APP (sAPPα), the AICD and p3,
a truncated peptide that is pathologically irrelevant.
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(Aβ1-40), and the more toxic Aβ that is 42 amino acids in length (Aβ1-42) at a ratio of
10:1. The Aβ1-42 isoform is more hydrophobic, more prone to form fibrils, more
resistant to degradation and is the isoform most commonly found within cerebral amyloid
plaques (185). The non-amyloidogenic processing of APP is the more prevalent pathway,
and occurs when APP is cleaved within the Aβ domain at a position 83 amino acids away
from the carboxyl terminal domain. APP is cleaved by 3 enzymes with α-secretase
activity belonging to the ADAM family of proteases: ADAM9, ADAM10 and ADAM17
(186). This generates a truncated membrane-bound intracellular carboxyl-terminal
fragment (C83 or αCTF), lacking the amino-terminal portion of the Aβ domain. The
αCTF is then cleaved within the membrane by the γ-secretase protein complex to
generate AICD and p3, a truncated Aβ peptide, which is pathologically irrelevant (187).
Autosomal dominant forms of AD, which typically manifest with early-onset
pathogenesis (188), are often caused by mutations in the genes encoding APP, PS-1 and
PS-2, and cause changes in the stability and processing of Aβ. While most mutations in
APP are found close to the γ-secretase cleavage site, the Swedish mutation, which is the
most well-studied APP mutation, causes a double amino acid change next to the BACE1
cleavage site. This enhances cleavage of the mutant APP by BACE1 leading to increased
production of both Aβ1-40 and Aβ1-42 in the plasma of individuals carrying this
mutation (189). Mutations in PS-1 and PS-2 alter the amino acids within their nine TMD
and typically increase the production of the more toxic Aβ1-42 (190). Other mutations,
such as the Arctic mutation, increase the aggregation of Aβ (191). Increased number of
the APP gene locus (192) is also known to cause AD, an example of which is seen in
Down syndrome, in which trisomy of chromosome 21 occurs and causes early
accumulation of Aβ (193). In total there are 32 APP, 179 PSEN1 and 14 PSEN2 gene
mutations, most of which result in an increase in the production of the more toxic Aβ1-42
as compared to Aβ1-40 (194).

1.9 Intracellular sites of Aβ production
The precise subcellular location of APP processing and subsequent Aβ generation is
controversial. Aβ generation can occur wherever β and γ- secretase enzymes are located,
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and thus it is possible that this can occur in various subcellular compartments.
Accumulation of Aβ has been observed in the ER, the TGN, post-TGN secretory vesicles,
mitochondria, endosomes, lysosomes, multivesicular bodies, autophagic vacuoles and the
cytosol (195-204). While a consensus has not yet been reached, the identities of
organelles involved in APP processing and Aβ generation have been researched
extensively. Based on the results of biochemical and genetic studies, the importance of
APP endocytic trafficking in Aβ production is generally agreed upon. In vivo experiments
demonstrate that endocytosis is required for synaptic activity-dependent release of
approximately 70% of Aβ in neurons (205). According to the most accepted model, APP
that reaches the cell surface is predominantly processed by α-secretases (206); however,
some unprocessed APP is internalized into early endosomes, where the initial cleavage of
APP by BACE1 to form the βCTF occurs. This is supported by the observations that
early endosomes have the optimal pH for BACE1 activity, and fluorescence energy
resonance transfer analysis showing APP and BACE1 interact predominantly in these
compartments (207). The βCTF that is produced in this reaction is then processed further
within early endosomes by the γ-secretase complex resulting in the generation of Aβ,
which is subsequently released into the extracellular environment by the recycling of
endosomes to the cell surface. Alternatively, the βCTF could potentially be trafficked to
other downstream post-endocytic locations such as late endosomes, the multivesicular
body or the lysosome for processing. APP that is not cleaved by BACE1 in early
endosomes can be recycled back to the cell surface or back to the TGN by the
SorLA/retromer protein complex, which is thought to retain APP within the Golgi and
prevent its processing to Aβ. While the standard model indicates that very little Aβ is
generated outside of the endosomal pathways, several groups have identified the ER and
TGN as a major site for Aβ production (208-210), which is consistent with the
localization of β- and γ- secretases to this pathway (211, 212). Furthermore, some αsecretase activity has also been observed in the TGN (212).
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1.10 Assembly state of Aβ
Aβ is produced as a monomer, but can exist in several different assembly states including
monomers, dimers, trimers, tetramers, dodecamers, higher-order oligomers, protofibrils
and insoluble mature fibrils, which form microscopically visible amyloid plaques that
define AD pathology (213). Fibril formation of Aβ is a complex, nucleation dependent,
process of protein aggregation involving the misfolding of Aβ peptides into soluble and
insoluble fibrillar assemblies (214). Kinetic studies have shown that the misfolding of Aβ
monomers precedes the formation of oligomers, which then act as seeds for the formation
and elongation of Aβ fibrils (215). The mechanisms driving this process in the AD brain
are not fully understood. For many years, the insoluble fibrillar form of Aβ was thought
to be responsible for the neurodegeneration and cognitive decline associated with AD
(216). However, studies showed that accumulation of insoluble fibrillar forms of Aβ in
transgenic mice overexpressing APP was accompanied by minimal neuron loss (217),
and that the correlation between fibrillar forms of Aβ and cognitive impairment was weak
(218). Similarly, in humans, a weak correlation between fibrillar Aβ plaque level in the
brain and dementia was found, and cognitively intact individuals have been found to have
high levels of fibrillar Aβ in their brains (219, 220). These observations indicate that a
species other than the fibrillar Aβ could be responsible for the cognitive deficits in the
early stages of AD. The toxicity of the various molecular species of Aβ has been
confirmed by different experimental approaches, including using synthetic or endogenous
Aβ peptides, cell culture systems overexpressing APP and APP transgenic mice. Aβ
monomers may play a neuroprotective role by promoting neuronal survival through the
activation of the phosphoinosotide-3-kinase (PI3K) pathway (221, 222) and in vitro and
in vivo studies have established that oligomeric and protofibril forms of Aβ are potent
neurotoxins (223-225). Oligomeric species of Aβ are more potent than fibrils and plaques
in eliciting synaptic dysfunction and inhibiting long-term potentiation, a form of synaptic
plasticity (226, 227). Most importantly, synapse loss and cognitive impairment correlate
more with brain levels of soluble oligomeric Aβ levels than with the density of fibrillar
Aβ plaques (228-230) suggesting that oligomers are the primary toxic species in AD.
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1.11 Physiological roles of APP
While the mechanisms involving the production of Aβ have been well studied, the
physiological function of APP, and whether a loss of these functions plays a role in AD,
remains unknown. The analysis of APP function in vivo is complicated by two major
factors. First, APP belongs to an evolutionarily conserved protein family that includes the
amyloid precursor-like proteins (APLP1 and APLP2) in mammals, and functional
redundancy between these proteins may compensate for APP loss of function in animal
models of targeted gene inactvation. Second, the proteolytic processing of APP leads to
various extracellular and intracellular APP fragments with different functions.
The combined deletion of APP together with its homologs leads to early postnatal death
(231,232), while APP, APLP1 and APLP2 single knockout mice are viable and fertile.
However, many studies have shown that animal models of targetted APP inactivation
have several defects and abnormalities (233,234). In transfected cell lines and cultured
neurons, APP has been shown to modulate cell growth, neurite outgrowth (235), neuronal
survival (236), cell adhesion (237) and cell motility (238). These functions of can be
reproduced by the soluble ectodomain of APP, which has also been implicated in cellular
processes including neuroprotection, memory enhancing functions, regulation of gene
expression and regulation of neuronal excitability and synaptic plasticity (239,240). The
AICD is also known to have a functional role by acting as a transcription factor
controlling a wide variety of cell functions (241), including apoptosis (242), cell
signaling, calcium homeostasis (243) controlling neuronal networks (244), cellular
trafficking and cytoskeletal dynamics (245). During neuronal differentiation and
maturation APP expression is up-regulated (246), and its expression is also induced
during traumatic brain injury (247). APP is targeted to synaptic sites through rapid
anterograde transport and the level of APP is correlated to synaptogenesis (248). Taken
together, the results from studies using different in vivo transgene overexpression or
targetted allele animal models and cultured cells indicate that APP plays a key
neurotrophic role in early developmental events, including neuronal migration,
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synaptogenesis and cell adhesion, with the processing of APP leading to various peptide
fragments with several cellular functions.

1.12 Cholesterol as a risk factor for AD
A number of cardiovascular risk factors, such as hypertension, hypercholesterolemia and
diabetes mellitus, have been shown in observational and epidemiologic studies to be
associated with AD and dementia (249, 250). Studies show that cardiovascular disease
(CVD) and AD occur together more often than would be expected by chance (251) and
neuritic plaques have been observed in patients with myocardial infarctions without
having previously diagnosed dementia (252). Furthermore, vascular injury may lower the
threshold for cognitive manifestations of clinical dementia (253). These observations
have led to the hypothesis that AD and CVD may share a common risk factor. Data from
human epidemiological studies show that hypercholesterolemia, in particular elevated
low-density lipoprotein cholesterol (LDL-C), is one of the major risk factors for both AD
and CVD (254).
Mean cholesterol levels in individuals with AD are not higher than in those without;
however, the results of large epidemiologic studies and prospective population studies
suggest that an elevation in plasma cholesterol level in midlife increases the risk of
developing AD in older age (255). One study found that individuals with familial
hypercholesterolemia were more likely to develop MCI than those without (256), and
similarly, another found that a high cholesterol level at midlife was associated with an
increased risk of developing dementia later in life (257). In patients with AD, high levels
of total cholesterol or LDL-C contributes to faster cognitive decline (258), and in patients
without AD or dementia, a separate study reported that high levels of total cholesterol, or
LDL-C, were related to lower scores on the Modified Mini-Mental State Exam (259).

1.13 The role of cholesterol in the brain
The brain is the most cholesterol-rich organ in the body, containing approximately 20%
of the total body cholesterol, but accounting for only approximately 2% of the body mass
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(260). Cholesterol is tightly regulated between the major brain cells, neurons and glia,
and is required for normal brain development. Cholesterol forms an essential component
of cell membranes and plays a crucial role in development and maintenance of neuronal
plasticity and function (261), with depletion of cholesterol resulting in synaptic and
dendritic spine degeneration, failed neurotransmission, and decreased synaptic plasticity
(262). Cholesterol is synthesized through the isoprenoid biosynthetic pathway from
acetyl coenzyme-A by a complex series of reactions catalysed by over 20 enzymes; 3hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyses the rate-limiting
step of this process and is the target of statin pharmacotherapy (263). Enzymes involved
in cholesterol production, such as HMG-CoA, are expressed at high levels in cortical,
hippocampal and cholinergic neurons (264) and the expression of enzymes, cholesterol
transport proteins and lipoprotein receptors varies between brain regions (265), as does
cholesterol content (266). Cholesterol synthesis in the developing central nervous system
(CNS) is much higher than that in the adult state. In the mature CNS, most of the
cholesterol is found concentrated within the specialized membranes of myelin (267)
where it is immobilized due to its slow rate of turnover, with the rest of brain cholesterol
being found in the plasma membranes of neurons and glial cells, as well as extracellular
lipoproteins. The turnover rate of cholesterol in individual neurons and astrocytes is
likely higher than that of myelin bound cholesterol, and is thought to reach an estimated
20% turnover per day depending on the brain area and neuronal cell type (268).

1.14 Cholesterol metabolism in the brain
The majority of cholesterol in the brain is free, unesterified cholesterol and its
homoeostasis is tightly regulated through a series of processes that include synthesis,
storage, transport, and removal. In the periphery, cholesterol homeostasis is mediated by
a lipoprotein transport system between the liver, intestine and other organs through blood
circulation. Cholesterol levels in the brain do not respond to the homeostastic control
mechanisms regulating peripheral plasma cholesterol levels, indicating that there is a
distinct metabolism of cholesterol in the CNS. While some studies have demonstrated
that a small amount of cholesterol from the periphery can be transported into the CNS in
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humans and in mice (269, 270), the majority of experimental evidence indicates that the
CNS is isolated from the complex peripheral cholesterol transport system by the bloodbrain barrier (271). The endothelial cells that comprise the blood-brain barrier express
mRNA for the low-density lipoprotein receptor (LDLR), scavenger receptor class B type
I (SR-BI) and members of the ATP binding cassette (ABC) family of transporters and,
under in vitro conditions, are able to transport cholesterol across the endothelial cells,
indicating that these transporters may be involved in mediating cholesterol influx across
the blood brain barrier (272). However, in vivo studies show that only small amounts of
apolipoprotein B, the main apolipoprotein associated with LDL particles in the peripheral
cholesterol transport system, are found in the human brain, suggesting that full size
particles do not pass by the blood-brain barrier and very little clearance of
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I-labeled

homologous LDL into the CNS was observed in mice, rabbit and sheep (273-275).
Furthermore, in mice fed a high-cholesterol diet, plasma total cholesterol levels were
increased 7-fold, while no changes in cholesterol concentration or rate of synthesis were
demonstrated in any region of the CNS (276). Thus, it is commonly assumed that the
majority of CNS cholesterol (>95%) originates from de novo synthesis.
Neurons and glial cells, including astrocytes, microglia and oligodendrocytes, can
synthesize cholesterol. In vitro cell culture experiments show that the pathway of
cholesterol synthesis differs in the sequence of enzymatic steps and resulting precursors
between neurons and astrocytes (277). Astrocytes synthesize cholesterol at a higher rate
than do neurons, and oligodendrocytes, the cells that are responsible for myelinization,
have a higher capacity for cholesterol production than do astrocytes (278). In addition to
de novo synthesis, cholesterol can also be taken up from extracellular sources, and a
significant amount of cholesterol is transported between neurons and glial cells by
cholesterol-containing lipoproteins, which are mainly secreted by astrocytes (279, 280,
281). A subset of the apolipoproteins found in the plasma are present in the CNS,
including apolipoprotein E (APOE), apolipoprotein J/clusterin (APOJ/CLU), and
apolipoprotein D (APOD), and have been shown to be up-regulated in various different
types of injury and disease (282-284). One of the 3 isoforms of APOE, APOE4, is a wellknown risk factor for late-onset AD. Lipoproteins secreted by astrocytes differ in
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their chemical and physical properties from those present in plasma (285, 286) having
densities similar to those of high-density lipoproteins and containing only either APOE
and APOJ/CLU. The mechanisms involved in lipoprotein assembly and secretion by
astrocytes are not well understood. After secretion, the nascent lipoproteins may acquire
cholesterol in a process similar to high-density lipoproteins, or they could be taken up
directly by neurons (287, 288). A specific subtype of the ABC family of transporters,
ABCA1, mediates the lipidation of nascent particles and in adult rodents is mainly
expressed by neurons and expressed at low levels by glial cells (289). The uptake of
lipoproteins in the brain is thought to be mediated by the binding of APO proteins to two
specific receptors, the prototypic LDLR, which is expressed by neurons and glial cells
(290, 291), and the LDL-related protein 1 (LRP1), which is predominantly expressed by
neurons (292). It has been suggested that in the mature state, neurons rely on the delivery
of cholesterol-containing, astrocyte-derived lipoproteins and few studies have addressed
lipoprotein uptake by astrocytes as they are thought to export rather than import lipids
(268). Cholesterol acquired from lipoproteins transits through the endosomal and
lysosomal pathway and is mainly stored within subcellular recycling compartments and
internal vesicles of multi-vesicular bodies in the endocytic pathway (293). Excess
cholesterol is stored intracellularly in lipid droplets after esterification by the enzyme
acyl-coenzyme A: cholesterol acyltransferase 1 (ACAT) (294), which has been shown to
be present in neurons, but not glial cells (295). Finally, some cholesterol must be
exported into the circulation to maintain homeostasis in the brain. There are two methods
by which this is accomplished. The first is the excretion of small amounts of APOEbound cholesterol into the CSF, where 1-2 mg of cholesterol is eliminated daily (296).
The second, and the more quantitative method, is the elimination of cholesterol is by its
conversion to 24S-hydroxycholesterol (24OHC) (297). The hydroxylation of cholesterol
at carbon 24 is mediated by the cytochrome P-450 species CYP46A1, and allows its
translocation between lipophilic compartments and facilitates its movement through the
blood brain barrier (298). Interestingly, CYP46A1 is found localized to neurons,
indicating that cholesterol elimination in the brain begins in neurons and not in glial cells
(296).
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1.15 Statins in AD
There is an established link between elevated plasma cholesterol levels and the risk of
developing AD. Statins inhibit cholesterol synthesis, thereby reducing plasma cholesterol
levels, and are the first line pharmacological therapy for the treatment of
hypercholesterolemia (299). Taken together, these observations have led to the idea that
statins could be useful in treating or preventing AD. There are many ways that high
cholesterol could affect the progression of AD pathology. Cell culture studies show that
cholesterol can increase the activity of the β- and γ-secretases (300-302) and reduce the
movement of APP through the non-amyloidogenic pathway (303-306). Following the
generation of Aβ, cholesterol has been shown to influence its aggregation state, with high
cholesterol promoting its accumulation following secretion whereas low cholesterol
levels allow more internalization and degradation of Aβ (307, 308). Finally, cholesterol
may also affect different non-amyloid factors, such as inflammation, oxidative stress or
tau metabolism (309). Preclinical and human studies regarding the relevance of statins as
a potential treatment or preventative for AD have shown conflicting results, with
preclinical studies suggesting beneficial effects of statins, while human trials have
provided more inconsistent results.
The results of various preclinical cell culture experiments have shown that statins can
reduce the generation of Aβ (310, 311) and several in vivo studies in animal models of
AD have confirmed this finding (312, 313). Statins can also inhibit the production of O2by endothelial cells (314) and increase the expression of eNOS either through the
inhibition of Rho isoprenylation (315), or directly through activation of the PI3K/Akt
pathway (316). Furthermore, statins are protective against Aβ-induced oxidative stress in
mouse models of AD (317, 318). These preclinical observations indicate that statins
could provide beneﬁts as a potential treatment or preventative for AD, but it is unclear
whether this is due to lower cholesterol levels or to statin pleiotropy (319). Barone et al.
(320) found that atorvastatin reduced lipid peroxidation, protein nitration and protein
oxidation in the parietal cortex of elderly dogs in an Aβ and cholesterol-independent
manner. The neuroprotective effect observed in this study was suggested to be mediated
27

through the activation of the cell stress response, as expression of effectors of the
adaptive cell response increased and correlated with the reduction of oxidative and
nitrosative stress biomarkers in the parietal cortex of these animals (321, 322).
While the consensus from preclinical evidence regarding the neuroprotective effects of
statins is encouraging, human clinical trials have shown much more inconsistent results.
Several observational studies in humans support the hypothesis that statins may be a
potential treatment for dementia or AD or may act to decrease the risk of developing of it
(323-330). However, these findings have been challenged by other observational studies.
In one study, statins did not improve cognitive performance in non-demented elderly
individuals (331) and similar results were observed in a separate large cohort study that
assessed more than 2 million individuals, with approximately 11 percent taking statins
(332). Furthermore, Zandi et al. (333) found no correlation between statin use and
dementia or AD in elderly individuals assessed from 1995 to 1997, and again in 19982000. A separate study found that statin treatment did not alter the risk of developing
dementia or AD in individuals 65 years and older, which was not affected by the
lipophilicity of the statin used (334). The results of randomized control trials (RCT) have
yielded similar contradictory results. One large double blind RCT study demonstrated
that pravastatin treatment had no protective effect on cognitive function over a follow-up
period of 3 years (335), and another showed that atorvastatin treatment for 72 weeks had
no significant effect in delaying cognitive decline in patients with mild to moderate AD
(336). Similarly, Sano et al. (2011) found simvastatin treatment had no effect in
individuals with mild to moderate AD. In contrast to this, administering lovastatin to nondemented individuals reduced serum Aβ levels in a dose-dependent manner (338). In
another study, atorvastatin treatment for 1 year had a positive effect on cognitive
performance after 6 month of treatment, but this was restricted to individuals who met
specific criteria (339). Other groups have also assessed the effect of statin use in patients
diagnosed with AD. Li et al. (2007) examined neuropathological changes of AD and
found that statin users had lower Braak stages (a measure of neurofibrillary tangle
involvement), but not lower scores on a quantitative scale of amyloid plaque pathology,
than non-users. A meta-analysis of all statin RCT results suggests that there is insufficient
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evidence to recommend statins as a treatment or preventative for AD (341). This is likely
due to major differences in study design and data analysis, as well as the different
lipophilicity and chemical structure of different statins which influences their ability to
cross the BBB.

1.16 Hypotheses for my thesis research
1.16.1

Working hypothesis

My working hypothesis was that pathological conditions associated with
Alzheimer’s disease alter CHT function by changing the subcellular trafficking of
the transporter in a manner that reduces choline uptake activity and cholinergic
neurotransmission. Specifically, my research investigated the effect of peroxynitrite
(Chapter 2) and cholesterol manipulation (Chapter 3) on CHT activity and trafficking,
and whether CHT is differentially regulated by its interaction with either wild-type APP
or APP containing the Swedish mutation (Chapter 4).

1.16.2

Hypothesis for Chapter 2

Experiments in Chapter 2 were designed to determine the effect of the peroxynitrite
donor SIN-1 on CHT activity and trafficking. The hypothesis of this study was that
inhibition of CHT by SIN-1 is mediated via alterations in transporter trafficking, as
opposed to oxidative or nitrosative modification of CHT protein.

1.16.3

Hypothesis for Chapter 3

The experiments presented in Chapter 3 were carried out to assess how CHT activity and
trafficking is regulated by plasma membrane cholesterol and its association with
cholesterol-rich lipid rafts. For this study, my hypothesis was that CHT is localized to
lipid rafts and disruption of rafts alters CHT activity and trafficking, and causes a
decrease in choline uptake activity and cholinergic neurotransmission.
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1.16.4

Hypothesis for Chapter 4

The experiments presented in Chapter 4 were designed to assess whether CHT is
differentially regulated by its interaction with either the wild-type or Swedish mutant
APP. My hypothesis for this study was that the interaction of CHT with either wildtype APP or APP containing the Swedish mutation alters CHT function through
different mechanisms that alter CHT trafficking and choline uptake activity.

30

1.17 References
1.

Schliebs, R., and Arendt, T. (2006) J Neural Transm 11, 1625-1644

2.

Bigl, M., Apelt, J., Luschekina, E. A., Lange-Dohna, C., Robner, S., and Schliebs,
R. (2000) Neurosci Lett 292, 107-110

3.

Härtig, W., Bauer, K., Brauer, J., Gosche, T., Hortobagyi, P., and Penke, P.
(2002) Rev Neurosci 13, 95-165

4.

Schliebs, R., and Arendt, T. (2010) Behav Brain Res 2, 555-563

5.

Woolf, N. J., and Butcher, L. L. (2011) Behav Brain Res 221, 488-498

6.

Dutar, P., Bassant, M., Senut, M., and Lamour, Y. (1995) Physiol Rev 75, 393427

7.

Frotscher, M., and Leranth, C. (1985) J Comp Neurol 239, 237-246

8.

Leranth, C., and Frotscher, M. (1987) J Comp Neurol 261, 33-47

9.

Vizi, E. S., and Kiss, J. P. (1998) Hippocampus 8, 566-607

10.

Nathanson, N. M. (2008) Pharmacol Ther 119, 33-43

11.

Gotti, C., Clementi, F., Fornari, A., Gaimarri, A., Guiducci, S., Manfredi, I.,
Moretti, M., Pedrazzi, P., Pucci, L., and Zoli, M. (2009) Biochem Pharmacol 78,
703-711

12.

Yakel, M. (2013) Eur J Physiol 465, 441-450

13.

Chang, K. T., and Berg, D. K. (2001) Neuron 32, 855-865

14.

Sharma, G., and Vijayaraghavan, S. (2001) Proc Natl Acad Sci U S A 98, 41484158

15.

Sharma, G., and Vijayaraghavan, S. (2003) Neuron 38, 929-939
31

16.

Wess, J. (2006) Crit Rev Neurobiol 10, 66-99

17.

Caulfield, M. P., and Birdsall, N. J. M. (1998) Pharmacol Rev 50, 279-290

18.

Wess, J., Eglen, R. M., and Guatam, D. (2007) Nat Rev Drug Discov 6, 721-733

19.

Haga, T. (1971) J Neurochem 18, 781-798

20.

Kuhar, M.J., and Murrin, L.C. (1978) J Neurochem 30, 15-21

21.

Ferguson, S. M., Bazalakova, M., Savchenko, V., Tapia, J. C., Wright, J., and
Blakely, R. D. (2004) Proc Natl Acad Sci U S A 101, 8762-8767

22.

Yamamura, H. I., and Snyder, S. H. (1972) J Neurochem 21, 1355-1374

23.

Haga, T., and Noda, H. (1973) Biochem Biophys Acta 291, 564-575

24.

Kuhar, M. J. (1973) Life Sci 13, 1623-1634

25.

Okuda, T., Haga, T., Kanai, Y., Endou, H., Ishihara, T., and Katsura, I. (2000)
Nat Neurosci 3, 120-125

26.

Apparsundaram, S., Ferguson, S,M., and Blakely, R.D. (2001) Biochem Soc Trans
29, 711-716

27.

Apparsundaram, S., Ferguson, S.M., George, A.L. jr., and Blakely, R.D. (2000)
Biochem Biophys Res Commun 276, 862-867

28.

Okuda, T., and Haga, T. (2000) FEBS Lett 484, 92-97

29.

Wright, E.M., and Turk, E. (2004) Pflugers Arch 447, 510-518

30.

Ribeiro, F.M., Black, S.A., Cregan, S.P., Prado, V.F., Prado, M.A., Rylett, R.J.,
and Ferguson, S.S. (2005) J Neurochem 94, 86-96

32

31.

Ferguson, S.M., Savchenko, V., Apparsundaram, S., Zwick, M., Wright, J.,
Heilman, C.J., Yi, H., Levey, A.I., and Blakely, R.D. (2003) J Neurosci 23, 96979709

32.

Okuda, T., Osawa, C., Yamada, H., Hayashi, K., Nishikawa, S., Ushio, T., Kubo,
Y., Satou, M., Ogawa, H., and Haga, T. (2012) J Biol Chem 287, 42826-42834

33.

Sitte, H.H., Farhan, H., and Javitch, J.A. (2004) Mol Interv 4, 38-47

34.

Cuddy, L.K., Winick-Ng, W., and Rylett, R.J. (2014) J Neurochem 128, 725-740

35.

Berse, B., Szczecinska, W., Lopez-Coviella, I., Madziar, B., Zemelko, V.,
Kaminski, R., Kozar, K., Lips, K.S., Pfeil, U., and Blusztajn, J.K. (2005) Dev
Brain Res 157, 132-140

36.

Nakata, K., Okuda, T., and Misawa, H. (2004) Synapse 53, 53-56

37.

Haerberger, R.V., Pfeil, U., Lips, K.S., and Kummer, W. (2002) J Invest
Dermatol 119, 943-948

38.

Lips, K.S., Pfeil, U., Haberberger, R.V., and Kummer, W. (2002) Cell Tissue Res
307, 275-280

39.

Lips, K.S., Pfeil, U., Reiners, K., Rimasch, C., Kuchelmeister, K., BraunDullaeus, R.C., Haberberger, R.V., Schmidt, R., and Kummer, W. (2003) J
Histochem Cytochem 51, 1645-1654

40.

Pfeil, U., Haberberger, R.V., Lips, K.S., Eberling, L., Grau, V., and Kummer, W.
(2003a) Life Sci 72, 2087-2090

41.

Pfeil, U., Lips, K.S., Eberling, L., Grau, V., Haberberger, R.V., Kummer, W.
(2003b) Am J Respir Cell Mol Biol 28, 473-477

42.

Brock, M., Nickel, A.C., Madziar, B., Blusztajn, J.K., and Berse, B. (2007) Brain
Res 1145, 1-10
33

43.

Madziar, B., Shah, S., Brock, M., Burke, R., Lopez-Coviella, I., Nickel, A.C.,
Cakal, E.B., Blusztajn, J.K., and Berse, B. (2008) J Neurochem 107, 1284-1293

44.

Krishnaswamy, A., and Cooper, E. (2009) Neuron 61, 272-286

45.

Schnitzler, A.C., Lopez-Coviella, I., and Blusztajn, J.K. (2008) Brain Res 1246,
19-28

46.

Schnitzler, A.C., Mellot, T.J., Lopez-Coviella, I., Tallini, Y.N., Kotlikoff, M.I.,
Follettie, M.T., and Blusztajn, J.K. (2010) J Neurosci 30, 8221-8228

47.

Ribeiro, F.M., Alves-Silva, J., Volknandt, W., Martins-Silva, C., Mahmud, H.,
Wilhelm, A., Gomez, M.V., Rylett, R.J., Ferguson, S.S., Prado, V.F., and Prado,
M.A. (2003) J Neurochem 87, 136-146

48.

Collier, B., and Katz, H.S. (1974) J Physiol 238, 639-655

49.

Simon, J.R., and Kuhar, M.G. (1975) Nature 255, 162-163

50.

O’Regan, S., and Collier, B. (1981) Neurosci 6, 511-520

51.

Saltarelli, M.D., Lowenstein, P.R., and Coyle, J.T. (1987) Eur J Pharmacol 135,
35-40

52.

Ivy, M.T., Newkirk, R.F., Karim, M.R., Mtshali, C.M., and Townsel, J.G. (2001)
Neuroscience 102, 969-978

53.

Ribeiro, F.M., Black, S.A., Prado, V.F., Rylett, R.J., Ferguson, S.S., and Prado,
M.A. (2006) J Neurochem 97, 1-12

54.

Apparsundaram, S., Martinez, V., Parikh, V., Kozak, R., and Sarter, M. (2005) J
Neurosci 25, 3851-3856

55.

Faundez, V., Horng, J.T., and Kelly, R.B. (1998) Cell 93, 423-432

56.

Misawa, H., Fujigaya, H., Nishimura, T., Moriwaki, Y., Okuda, T., Kawashima,
34

K., Nakata, K., Ruggiero, A.M., Blakely, R.D., Nakatsu, F., and Ohno, H. (2008)
Eur J Neurosci 27, 3109-3117
57.

Ivy, M.T., Newkirk, R.F., Wang, Y., and Townsel, J.G. (2010) J Neurochem 112,
1295-1304

58.

Ford, M.G., Pearse, B.M., Higgins, M.K., Vallis, Y., Owen, D.J., Gibson, A.,
Hopkins, C.R., Evans, P.R. and McMahon, H.T. (2001) Science 291, 1051-1055

59.

Nichols, B.J., and Lippincott-Schwartz, J. (2001) Trends Cell Biol 11, 406-412

60.

Prado, M.A.M., Alves-Silva, J., Magalhaes, A.C., Prado, V.F., Linden, R.,
Martins, V.R., and Brentani, R.R. (2004) J Neurochem 88, 769-781

61.

Ribeiro, F.M., Pinthong, M., Black, S.A., Gordon, A.C., Prado, V.F., Prado,
M.A., Rylett, R.J., and Ferguson, S.S. (2007a) Eur J Neurosci 26, 3437-3448

62.

Cuddy, L.K., Gordon, A.C., Black, S.A.G., Jaworski, E., Ferguson, S.S.G., and
Rylett, R.J. (2012) J Neurosci 32, 5573-5584

63.

Cancela, J,M., Bertrand, N., and Beley, A. (1995) Biochem Biophys Res Commun
213, 944-949

64.

Issa, A,M., Gauthier, S., and Collier, B. (1996) J Neurochem 66, 1924-1932

65.

Cooke, L.J., and Rylett, R.J. (1997) Brain Res 751, 232-238

66.

Vogelsberg, V., Neff, N.H., and Hadjiconstantinou, M. (1997) J Neurochem 68,
1062-1070

67.

Gates, J. jr., Ferguson, S.M., and Blakely, R.D. (2004) J Pharmacol Exp Ther
310, 536-545

68.

Black, S.A.G., Ribeiro, F.M., Ferguson, S.S.G., and Rylett, R.J. (2010)
Neuroscience 167, 765-773

35

69.

Meyer, E. M., West, C. M., and Chau, V. (1986) J Biol Chem 261, 14365-14368

70.

Meyer, E.M., West, C.M., Stevens, B.R., Chau, V., Nguyen, M., and Judkins, J.H.
(1987) J Neurochem 49, 1815-1819

71.

Yamada, H., Imajoh-Ohmi, S., and Haga, T. (2012) Biomed Res 33, 1-8

72.

Xie, J., and Guo, Q. (2004) J Biol Chem 279, 28266-28275

73.

Ribeiro, F.M., Ferreira, L.T., Marion, S., Fontes, S., Gomez, M., Ferguson, S.S.,
Prado, M.A., and Prado, V.F. (2007b) Neurochem Int 50, 356-364

74.

Wang, B., Yang, L., Wang, Z., and Zheng, H. (2007) Proc Natl Acad Sci U S A
104, 14140-14145

75.

Bales, K.R., Tzavara, E.T., Wu, S., Wade, M.R., Bymaster, F.P., Paul, S.M., and
Nomikos, G.G. (2006) J Clin Invest 116, 825-832

76.

Geula, C., and Mesulam, M.M. (1994) Alzheimer Disease. Raven Press, New
York, pp. 263–291

77.

Bartus, R.T. (2000) Exp Neurol 163, 495-529

78.

Sarter, M., Bruno, J.P., and Givens, B. (2003) Neurobiol Learn Mem 80, 245-56

79.

Woolf, N.J. (1998) Prog Neurobiol 55, 59-77

80.

Davies, P., and Maloney, A.J. (1976) Lancet 2, 1403

81.

Bowen, D.M., Smith, C.B., and White, P. (1976) Brain 99, 459-496

82.

Perry, E.K., Gibson, P.H., and Blessed, G. (1977) J Neurol Sci 34, 247-265

83.

Whitehouse, P.H., Price, D.L., and Strubel, R.G. (1982) Science 215, 1237-1239

84.

Nilsson, L., Nordberg, A., and Hardy, J.A. (1986) J Neural Transm 67, 275-285

85.

Bierer, L.M., Haroutunian, V., Gabriel, S., Knott, P.J., Carlin, L.S., Purohit, D.P.,
36

Perl, D.P., Schmeidler, J., Kanof, P., and Davis, K.L. (1995) J Neurochem 64,
749-760
86.

Gsell, W., Jungkunz, G., and Riederer, P. (2004) Curr Pharmacol Design 10,
265-293

87.

Nordberg, A. (2002) Cerebrovasc Brain Met Rev 4, 303-328

88.

Contestabile, A., Ciani, E., and Contestabile, A. (2008) Neurochem Res 33, 318327

89.

Mufson, E.J., Counts, S.E., Perez, S.E., and Ginsberg, S.D. (2008) Expert Rev
Neurother 8, 1703-1718

90.

Rinnne, T., de Kloet, E.R., and Wouters, L. (2002) Biol Psychiatry 52, 1102-1112

91.

Shinotoh, H., Namba, H., Fukushi, K., Nagatsuka, S., Tanaka, N., Aotsuka, A.,
Ota, T., Tanada, S., and Irie, T. (2000) Ann Neurol 48, 194-200

92.

Davies, K.L., Mohs, R.C., Marin, D., Purohit, D.P., Perl, D.P., Lantz, M., Austin,
G., and Haroutunian, V. (1999) JAMA 281, 1401-1406

93.

Tiraboschi, P., Hansen, L.A., Alford, B., Sabbagh, M.N., Schoos, B., Masliah, E.,
Thal, L.J., and Corey-Bloom, J. (2000) Neurology 54, 407

94.

DeKosky, S.T., Ikonomovic, M.D., Styren, S.D., Beckett, L., Wisniewski, S.,
Bennett, D.A., Cochran, E.J., Kordower, J.H., and Mufson, E.J. (2002) Ann
Neurol 51, 145-155

95.

Mufson, E.J., Ma, S.Y., Dills, J., Cochran, E.J., Leurgans, S., Wuu, J., Bennett,
D.A., Jaffar, S., Gilmor, M.L., Levey, A.I., Kordower, J.H. (2002) J Comp Neurol
443, 136-153

96.

Chu, Y., Cochran, E.J., Bennett, D.A., Mufson, E.J., and Kordower, J.H. (2001) J
Comp Neurol 437, 296-307
37

97.

Sofroniew, M.V., Pearson, R.C.A., Eckenstein, F., Cuello, A.C., and Powell,
T.P.S. (1983) Brain Res 289, 370-374

98.

Pearson, R.C.A., Sofroniew, M.V., Cuello, A.C., Powell, T.P.S., Eckenstein, F.,
Esiri, M.M., and Wilcock, G.K. (1983) Brain Res 289, 375-379

99.

Rinne, J.O., Paljarvi, L., and Rinne, U.K. (1987) J Neurol Sci 79, 67-76

100.

Slotkin, T.A., Seidler, F.J., Crain, B., Bell, J.M., Bissette, G., and

Nemeroff,

C.B. (1990) Proc Natl Acad Sci 87, 2452-2455
101.

Pascual, J., Fontan, A., Zarranz, J.J., Berciano, J., Florez, J., and Pazos, A. (1991)
Brain Research 552, 179-174

102.

Rodriguez-Puertas, R., Pazos, A., Zarranz, J.J., and Pasual J. (1994) J Neural
Transm Park Dis Dement Sect 8, 161-169

103.

Rylett, R.J., Goddard, S., Schmidt, B.M., and Williams, L.R. (1993) J Neurosci
13, 3956-3963

104.

Slotkin, T.A., Nemeroff, C.B., Bissette, G., and Seidler, F.J. (1994) J Clin Invest
94, 696-702

105.

Lovell, M.A., and Markesbery, W.R. (2007) J Neurosci Res 85, 3036-3040

106.

Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones,
P.K., Wataya, T., Shimohama, S., Chiba, S., Atwood, C.S., Petersen, R.B., and
Smith, M.A. (2001) J Neuropathol Exp Neurol 60, 759-767

107.

Halliwell, B. (1992) Free Radicals in the Brain pp 21-40

108.

Gilgun-Sherki, Y., Melamed, E., and Offen, D. (2001) Neuropharmacology 40,
959-975

38

109.

Esterbauer, H., Schaur, R.J., and Zollner, H. (1991). Free Radic Biol Med 11, 81128

110.

Markesbery, W.R., and Lovell, M.A. (1998) Neurobiol Aging 19, 33-36

111.

Selley, M. L., Close, D.R., and Stern, S.E. (2002) Neurobiol Aging 23, 383–388

112.

Arlt, S., Beisiegel, U., and Kontush, A. (2002) Curr Opin Lipidol 13, 289-294

113.

Montine, T.J., Markesbery, W.R., Morrow, J.D., and Roberts, L.J 2nd. (1998) Ann
Neurol 44, 410-430

114.

Praticò D., Lee, V.M-Y., Trojanowski, J.Q., Rokach, J., and FitzGerald, G.A.
(1998) FASEB J 12, 1777-1783

115.

Gabbita, S. P., Lovell, M. A., and Markesbery, W. R. (1998) J Neurochem 71,
2034-2040

116.

Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M.,
Aksenova, M., Gabbita, S.P., Wu, J.F., Carney, J.M., Lovell, M., Markesbery,
W.R. and Butterfield, D.A. (1995) J Neurochem 65, 2146-2156

117.

Good, P.F., Werner, P., Hsu, A., Olanow, C.W., and Perl, D.P. (1996) Am J
Pathol 149, 21-28

118.

Butterfield, D.A., Reed, T., Newman, S.F., and Sultana, R. (2007) Free Radical
Bio Med 43, 658-677

119.

Pappolla, M.A., Omar, R.A., Kim, K.S., and Robakis, N.K. (1992) Am J Pathol
140, 621-628

120.

Zemlan, F.P., Thienhaus, O.J., and Bosmann, H.B. (1989) Brain Res 476, 160162

121.

Lewen, A., Matz, P. and Chan, P.H. (2000) J Neurotrauma 17, 871-890

39

122.

Suzuki, Y.J., Forman, H.J. and Sevanian, A. (1997) Free Radic Biol Med 22, 269285

123.

Neill, S., Desikan, R., and Hancock, J. (2002) Curr Opin Plant Biol 5, 388-395

124.

Andreyev, A.Y., Kushnareva, Y.E., and Starkov, A.A. (2005) Biochemistry 70,
200-214

125.

Bush, A.I. (2000) Curr Opin Chem Biol 4, 184-191

126.

Deibel, M.A., Ehmann, W.D., and Markesbery, W.R. (1996) J Neurol Sci 143,
137-142

127.

Danscher, G., Jensen, K.B., Frederickson, C.J., Kemp, K., Andreasen, A., Juhl, S.,
Stoltenberg, M., and Ravid, R. (1997) J Neurosci 76, 53-59

128.

Donnelly, P.S., Xiao, Z., and Wedd, A.G. (2007) Curr Opin Chem Biol 11, 128133

129.

Butterfield, D.A., and Stadtman, E.R. (1997) Advantage of Cell Aging
Gerontology 2, 161-191

130.

Multhaup, G., Schlicksupp, A., Hesse, L., Beher, D. Ruppert, T., Masters, C.L.,
and Beyreuther, K. (1996) Science 271, 1406-1409

131.

Bush, A.I., Multhaup, G., Moir, R.D., Williamson, T.G., Small, D.H., Rumble, B.,
Pollwein, P., Beyreuther, K., and Masters, C.L. (1993) J Biol Chem 268, 1610916112

132.

Huang, X., Atwood, C,S., Hartshorn, M.A., Multhaup, G., Goldstein, L.E.,
Scarpa, R.C., Cuajungco, M,P., Gray, D,N., Lim, J., Moir, R.D., Tanzi, R.E., and
Bush, A.I. (1999a) Biochemistry 38, 7609-7616

133.

Huang, X., Cuajungco, M.P., Atwood, C.S., Hartshorn, M.A., Tyndall, J.D.,
Hanson, G.R., Stokes, K.C., Leopold, M., Multhaup, G., Goldstein, L.E., Scarpa,
40

R.C., Saunders, A.J., Lim, J., Moir, R.D., Glabe, C., Bowden, E.F., Masters, C.L.,
Fairlie, D.P., Tanzi, R.E., and Bush, A,I. (1999b) J Biol Chem 274, 37111-37116
134.

Opazo, C., Ruiz, F.H., and Inestrosa, N.C. (2000) Biol Res 33, 125-131

135.

Opazo, C., Huang, X., Cherny, R.A., Moir, R.D., Roher, A.E., White, A.R.,
Cappai, R., Masters, C.L., Tanzi, R.E., Inestrosa, N.C., and Bush, A.I. (2002) J
Biol Chem 277, 40302-40308

136.

Bush, A.I., Pettingell, W.H., Multhaup, G., de Paradis, M., Vonsattel, J.P.,
Gusella, J.F., Beyreuther, K., Masters, C.L., and Tanzi, R.E. (1994) Science 265,
1464-1467

137.

Atwood, C.S., Moir, R.D., Huang, X., Scarpa, R.C., Bacarra, N.M., Romano,
D.M., Hartshorn, M.A., Tanzi, R.E., and Bush, A.I. (1998) J Biol Chem 273,
12817-12826

138.

Huang, X., Atwood, C.S., Moir, R.D., Hartshorn, M.A., Vonsattel, J.P., Tanzi,
R.E., and Bush, A.I. (1997) J Biol Chem 272, 26464-26470

139.

Cherny, R.A., Legg, J.T., McLean, C.A., Fairlie, D.P., Huang, X., Atwood, C.S.,
Beyreuther, K., Tanzi, R.E., Masters, C.L., and Bush, A.I. (1999) J Biol Chem
274, 23223-23228

140.

Tabner, B.J., El-Agnaf, O.M.A., and Turnbull, S. (2005) J Biol Chem 280,
35789–35792

141.

Tabner, B.J., Mayes, J., and Allsop, D. (2010) Int J Alzheimers Dis 2011, 546380546386

142.

Mayes, J., Tinker-Mill, C., Kolosov, O., Zhang, H., Tabner, B.J., and Allsop, D.
(2014) J Biol Chem 289, 12052-12062

143.

Pike, C.J., and Cotman, C.W. (1993) Neuroscience 56, 269-274

144.

Pereira, C., Santos, M.S., and Oliveira, C. (1999) Neurobiol Dis 6, 209-219
41

145.

Blass, J.P., and Gibson, G.E. (1991) Revue Neurologique 147, 513-525

146.

Casley, C.S., Canevari, L., Land, J.M., Clark, J.B., Sharpe, M.A. (2002) J
Neurochem 80, 91-100

147.

Canevari, L., Clark, J.B., and Bates, T.E. (1999) FEBS Lett 457, 131-134

148.

Parks, J.K., Smith, T.S., Trimmer, P.A., Bennett, J.P., and Parker, W.D. (2001) J
Neurochem 76, 1050-1056

149.

Bernardi, P. (1992) J Biol Chem 267, 8834-8839

150.

Petronilli, V., Costantini, P., Scorrano, R., Passamonti, S., and Bernardi, P. (1994)
J Biol Chem 269, 16638-16642

151.

Sheehan, J.P., Swerdlow, R.H., Miller, S.W., Davis, R.E., Parks, J.K., Parker, D.,
and Tuttle, J.B. (1997) J Neurosci 17, 4612-4622

152.

Yankner, B.A., Duffy, L.K., and Kirschner, D.A. (1990) Science 250, 279-282

153.

Pike, C.J., Walencewicz, A.J., Glabe, C.G., and Cotman, C.W. (1991) Eur J
Pharmacol 207, 367-368

154.

Combs, C.K., Johnson, D.E., Cannady, S.B., Lehman, T.M., and Landreth, G.
(1999) J Neurosci 19, 929-938

155.

Meda, L., Cassatella, M.A., Szendrei, G.I., Otvos, Jr. L., Baron, P., Villalba, M.,
Ferrari, D., and Rossi, F. (1995) Nature 374, 647-650

156.

Tanaka, M., Sotomatsu, A., Yoshida, T., Hirai, S., and Nishida, A. (1994) J
Neurochem 63, 266-270

157.

Smith, M.A., Richey, Harris, P.L., Sayre, L.M., Beckman, J.S., and Perry, G.
(1997) J Neurosci 17, 2653-2657

42

158.

Xie, Z., Wei, M., Morgan, T.E., Fabrizio, P., Han, D., Finch, C.E., and Longo,
V.D. (2002) J Neurosci 22, 3484-3492

159.

Mark, R.J., Hensley, K., Butterfield, D.A., and Mattson, M.P. (1995) J Neurosci
15, 6239-6249

160.

Blanc, E. M., Keller, J. N., Fernandez, S., and Mattson, M. P. (1998) Glia 22,
149-160

161.

Mark, R.J., Lovell, M.A., Markesbery, W.R., Uchida, K., and Mattson, M.P.
(1997) J Neurochem 68, 255-264

162.

Tamagno, E., Robino, G., Obbili, A., Bardini, P., Aragno, M., Parola, M., and
Danni, O. (2003) Exp Neurol 180, 144-15

163.

Yamamoto, K., Ishikawa, T., Sakabe, T., Taguchi, T., Kawai, S., and Marsala, M.
(1998) Neuroreport 9, 1655-1659

164.

Mattson, M.P, and Chan, S.L. (2003) Cell Calcium 34, 385-397

165.

Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A.,
Ostaszewski, B.L., Lieberburg, I., Koo, E.H., Schenk, D., Teplow, D.B., and
Selkoe, D.J. (1992) Nature 359, 322-325

166.

Seubert, P., Oltersdorf, T., Lee, M.G., Barbour, R., Blomquist, C., Davis, D.L.,
Bryant, K., Fritz, L.C., Galasko, D., Thal, L.J., Lieberburg I., and Schenk, D.B.
(1993) Nature 361, 260-263

167.

Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik,
K.H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987) Nature 325, 733736

168.

Dyrks, T., Weidemann, A., Multhaup, G., Salbaum,J.M., Lemaire, H.G., Kang, J.,
Muller-Hill, B., Masters, C.L., and Beyreuther, K. (1988) EMBO J 7, 949-957

43

169.

Lee, J., Retamal, C., Cuitino, L., Caruano-Yzermans, A., and Shin, J.E. (2008) J
Biol Chem 283, 11501-11508

170.

Haass, C. (2004) EMBO J 23, 483-488

171.

Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J.M., Masters, C.L.,
and Beyreuther, K. (1989) Cell 57, 115-126

172.

Pahlsson, P., Shakin-Eshleman, S.H., and Spitalnik, S.L. (1992) Biochem Biophys
Res Commun 189, 1667-1673

173.

Knops, J., Gandy, S., Greengard, P., Lieberburg, .I, and Sinha, S. (1993) Biochem
Biophys Res Commun 197,380-385

174.

Hung, A.Y., and Selkoe, D.J. (1994) EMBO J 13, 534-542

175.

Graebert, K.S., Popp, G.M., Kehle, T., and Herzog, V. (1995) Eur J Cell Biol 66,
39-46

176.

Kins, S., Lauther, N., Szodorai, A., and Beyreuther, K. (2006) Neurodegener
Dis 3, 218-226

177.

Koo, E.H., Sisodia, S.S., Archer, D.R., Martin, L.J., Weidemann, A., Beyreuther,
K., Fischer, P., Masters, C.L., and Price, D.L. (1990) Proc Natl Acad Sci 87,
1561-1565

178.

Chen, W.J., Goldstein, J.L., and Brown, M.S. (1990) J Biol Chem 265, 3116-3123

179.

Perez, R.G., Soriano, S., Hayes, J.D., Ostaszewski, B., Xia, W., Selkoe, D.J.,
Chen, X., Stokin, G.B., and Koo, E.H. (1999) J Biol Chem 274, 18851-18856

180.

Ring, S., Weyer, S.W., Kilian, S.B., Waldron, E., Pietrzik, C.U., Filippov, M.A.,
Herms, J., Buchholz, C., Eckman, C.B., Korte, M., Wolfer, D.P., and Muller, U.C.
(2007) J Neurosci 27, 7817-7826

44

181.

Andersen, O.M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J.,
von Arnim, C.A., Breiderhoff, T., Jansen, P., Wu, X., Bales, K.R., Cappai, R.,
Masters, C.L., Gliemann, J., Mufson, E.J., Hyman, B.T., Paul, S.M., Nykjaer, A.,
and Willnow, T.E. (2005) Proc Natl Acad Sci 102, 13461-13466

182.

Vassar, R., Bennett, B. D., Babu-Kahn, S., Mendiaz, E. A., Denis, P., Teplow,D.
B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S.,
Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., and Louis, J. C.
(1999) Science 286, 735-741

183.

Bergmans, B.A., and De Strooper, B. (2010) Lancet Neurol 9, 215-226

184.

Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F.,
Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard, P., and
Relkin, N.R. (2000) Am J Pathol 156, 15-20

185.

Younkin, S.G., Eckman, C.B., Ertekin Taner, N., Kawarabayashi, T., Yager, D.,
Baker, M., Perez-tur, J., Houlden, H., Hutton, M., Younkin, L.H, and GraffRadford, N.R. (1998) Soc Neurosci Abstr 24, 263

186.

Asai, M., Hattori, C., Szabo, B., Sasagawa, N., Maruyama, K., Tanuma, S., and
Ishiura, S. (2003) Biochem Biophys Res Commun 301, 231-235

187.

Haass, C., Hung, A.Y., Schlossmacher, M.G., Teplow, D.B., and Selkoe, D.J.
(1993) J Biol Chem 268, 3021-3024

188.

St. George-Hyslop, P.H., and Petit, A. (2005) C R Biol 328, 119-130

189.

Citron, M. (2004) Trends Pharmacol Sci 25, 92-97

190.

Guo, Q., Fu, W., Sopher, B.L., Miller, M.W., Ware, C.B., Martin, G.M and
Mattson, M.P. (1999) Nat Med 5, 101-106

45

191.

Nilsberth, C., Westlind-Denielsson, A., Eckman, C.B., Condron, M.M., Axelman,
K., Forsell, C., Stenh, C., Luthman, J., Teplow, D.B., Younkin, S.G., Naslund, J.,
and Lannfelt, L. (2001) Nat Neurosci 4, 887-893

192.

Rovelet-Lecrux, A., Hannequin, D., Raux, G., La Meur, N., Laquerriere, A.,
Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., Dubas, F.,
Frebourg, T., and Campion D. (2006) Nat Genet 38, 24-26

193.

Gyure, K.A., Durham, R., Stewart, W.F., Smialek, J.E., and Troncoso, J.C. (2001)
Arch Pathol Lab Med 125, 489-492

194.

Shen, J., and Kelleher, R.J. 3rd. (2007) Proc Natl Acad Sci U S A 104, 403-409

195.

Busciglio, J., Gabuzda, D.H., and Yankner, B.A. (1993) Proc Natl Acad Sci 90,
2092-2096

196.

Cook, D.G., Forman, M.S., Sung, J.C., Leight, S., Kolson, D.L., Iwatsubo, T.,
Lee, V. M.-Y., and Doms, R.W. (1997) Nat Med 3, 1021-1023

197.

Manczak, M., Anekonda, T.S., Henson, E., Park, B.S., Quinn, J., and Reddy, P.H.
(2006) Hum Mol Genet 15, 1437-1449

198.

Greenfield, J.P., Tsai, J., Gouras, G.K., Hai, B., Thinakaran, G., Checler, F.,
Sisodia, S.S., Greengard, P., and Xu, H. (1999) Proc Natl Acad U S A 96, 742747

199.

Cataldo, A.M., Petanceska, S., Terio, N.B., Peterhoff, C.M., Durham, R.,
Mercken, M., Mehta, P.D., Buxbaum, J., Haroutunian, V., and Nixon, R.A.
(2004) Neurobiol Aging 25, 1263-1272

200.

Petersen, C.A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov, P.F.,
Alafuzoff, I., Leinonen, V., Ito, V., Winblad, B., Glaser, E., and Ankarcrona, M.
(2008) Proc Natl Acad U S A 105, 13145-13150

46

201.

Pasternak, S.H., Callahan, J.W., and Mahuran, D.J. (2004) J Alzheimers D 6, 5365

202.

Takashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H.,
Beal, M.F., Xu, H., Greengard, P., and Gouras, G.K. (2002) Am J Pathol 161,
1869-1879

203.

Buckig, A., Tikkanen, R., Herzog, V. and Schmitz, A. (2002) Histochem Cell
Biol 118, 353-360

204.

Yu, W.H., Cuervo, A.M., Kumar, A., Peterhoff, C.M., Schmidt, S.D., Lee, J-H.,
Mohan, P.S., Mercken, M., Farmery, M.R., Tjernberg, L.O., Jiang, Y., Duff, K.,
Uchiyama, Y., Naslund, J., Mathews, P.M., Cataldo, A.M., and Nixon, R.A.
(2005) J Cell Biol 171, 87-98

205.

Cirrito, J.R., Kang, J.E., Lee, J., Stewart, F.R., Verges, D.K., Silverio, L.M.,Bu, G
., Mennerick, S., and Holtzman, D.M. (2008) Neuron 58, 42-51

206.

Kojro, E., and Fahrenholz, F. (2005) 38, 105-127

207.

Kinoshita, A., Fukumoto, H., Shah, T., Whelan, C.M., Irizarry, M.C., and Hyman,
B.T. (2003) J Cell Sci 116, 3339-3346

208.

Xu, H., Sweeney, D., Wang, R., Thinakaran, G., Lo, A.C., Sisodia, S.S.,
Greengard, P., and Gandy, S. (1997) Proc Natl Acad Sci U S A 94, 3748-3752

209.

Siman, R., and Velji, J. (2003) J Neurochem 84, 1143-1153

210.

Burgos, P.V., Mardones, G.A., Rojas, A.L., DaSilva, L.L., Prabhu, Y., Hurley,
J.H., Bonifacino, J.S. (2010) Dev Cell 18, 425-436

211.

Baulac, S., LaVoie, M.J., Kimberly, T., Strahle, J., Wolfe, M.S., Selkoe, D.J., and
Xia, W. (2003) Neurobiol Dis 14, 194-204

212.

Skovronsky, D.M., Moore, D.B., Milla, M.E., Doms, R.W., Lee, V.M. (2000) J
Biol Chem 275, 2568-2575
47

213.

Glabe, C.G. (2008) J Biol Chem 283, 29639-29643

214.

Yoshiike, Y., Minai, R., Matsuo, Y., Chen, Y-R., Kimura, T., and Takashima, A.
(2008) PLoS ONE 3, 3235

215.

Ni, C.L., Shi, H.P., Yu, H.M., Chang, Y.C., and Chen, Y.R. (2011) FASEB J 25,
1390-1401

216.

Lorenzo, A., and Yankner, B.A. (1994) Proc Natl Acad Sci U S A 91, 1224312247

217.

Irizarry, M.C., Soriano, F., McNamara, M., Page, K.J., Schenk, D., Games, D.,
and Hyman, B.T. (1997) J Neurosci 17, 7053-7059

218.

Westerman,

M.A.,

Cooper-Blacketer,

D.,

Mariash,

A.,

Kotilinek,

L.,

Kawarabayashi, T., Younkin, L.H., Carlson, G.A., Younkin, S.G., and Ashe, K.H.
(2002) J Neurosci 22, 1858-1867
219.

Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R.,
Hansen, L.A., and Katzman, R. (1991) Ann Neurol 30, 572-580

220.

Dickson, D.W., Crystal, H.A., Bevona, C., Honer, W., Vincent, I., and Davies, P.
(1995) Neurobiol Aging 16, 285-298

221.

Giuffrida, M.L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V.,
Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., Garozzo, D.,
Nicoletti, F., Rizzarelli, E., and Copani, A. (2009) J Neurosci 29, 10582-10587

222.

Shoji, M. (2002) Front Biosci 7, 997-1006

223.

Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos,
M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhang, C.,
Finch, C.E., Krafft, G.A., and Klein, W.L. (1998) Proc Natl Acad Sci U S A 95,
6448-6453

48

224.

Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M., and Selkoe, D.J. (2006) J
Physiol 572, 477-492

225.

Klein, W.L., Krafft, G.A., and Finch, C.E. (2001) Trends Neurosci 24, 219-224

226.

Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith,
I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh,
D.M., Sabatini, B.L., and Selkoe, D.J. (2008) Nat Med 14, 837-842

227.

Selkoe, D.J. (2008) Behav Brain Res 192, 106-113

228.

Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T.,
Kurth, J.H., Rydel, R.E., and Rogers J. (1999) Am J Pathol 155, 853–862

229.

Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P.,
and Buxbaum, J.D. (2000) JAMA 283, 1571-1577

230.

Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood,
M., Viola, K.L., and Klein, W.L. (2007) J Neurosci 27, 796–807

231.

Ivon Koch, C.S., Zheng, H., Chen, H., Trumbauer, M., Thinakaran, G., van der
Ploeg, L.H.T., Price, D.L., and Sisodia, S.S. (1997) Neurobiol Aging 18, 661-669

232.

Heber, S., Herms, J., Gajic, V., Hainfellner, J., Aguzzi, A., Rulicke, T.,
Kretzschmar, H., von Koch, C., Sisodia, S., Tremml, P., Lipp, H-P., Wolfer, D.P.,
and Müller, U. (2000) J Neurosci 20, 7951-7963

233.

Müller, U., Cristina, N., Li, Z.W., Wolfer, D.P., Lipp, H.P., Rulicke, T., Brandner,
S., Aguzzi, A., and Weissmann, C. (1994) Cell 79, 755–765

234.

Zheng, H., Jiang, M., Trumbauer, M.E., Sirinathsinghji D.J., Hopkins, R., Smith,
D.W., Heavens, R.P., Dawson, G.R., Boyce, S., Conner, M.W., Stevens, K.A.,
Slunt, H.H., Sisodia, S.S., Chen, H.Y., and Van der Ploeg, L.H. (1995) Cell 81,
525-531

49

235.

Qiu, W.Q., Ferreira, A., Miller, C., Koo, E.H., and Selkoe, D.J. (1995) J Neurosci
15, 2157-2167

236.

Perez, R.G., Zheng, H., Van der Ploeg, L.H., and Koo, E.H. (1997) J Neurosci 17,
9407-9414

237.

Soba, P., Eggert, S., Wagner, K., Zentgraf, H., Siehl, K., Kreger, S., Lower, A.,
Langer, A., Merdes, G., Paro R, Masters, C.L., Müller, U., Kin, S., and
Beyreuther, K. (2005) EMBO J 24, 3624-3634

238.

Chen, M., and Yankner, B.A. (1991) Neurosci Lett 125, 223-226

239.

Li, H., Wang, B., Wang, Z., Guo, Q., Tabuchi, K., Hammer, R.E., Südhof, T.C.,
Wang, R., and Zheng, H. (2010) Proc Natl Acad Sci 107, 17362–17367

240.

Zheng, H., and Koo, E.H. (2006) Mol Neurodegener 1, 5

241.

Müller, T., Concannon, C.G., Ward, M.W., Walsh, C.M., Tirniceriu, A.L., Tribl,
F., Kogel, D., Prehn, J.H., and Egensperger, R. (2007) Mol Biol Cell 18, 201-210

242.

Nakayama, K., Ohkawara, T., Hiratochi, M., Koh, C.S., Nagase, H. (2008)
Neurosci Lett 444, 127-131

243.

Hamid, R., Kilger, E., Willem, M., Vassallo, N., Kostka, M., Bornho, C.,
Reichert, A.S., Kretzschmar, H.A., Haass, C., and Herms, J. (2007) J Neurochem
102, 1264-1275

244.

Vogt, D.L., Thomas, D., Galvan, V., Bredesen, D.E., Lamb, B.T., and Pimplikar,
S.W. (2011) Neurobiol. Aging 32, 1725-1729

245.

Ghosal, K., Vogt, D.L., Liang, M., Shen, Y., Lamb, B.T., and Pimplikar, S.W
(2009) Proc Natl Acad Sci 43, 18367-18377

246.

Bibel, M., Richter, J., Schrenk, K., Tucker, K.L., Staiger, V., Korte, M., Goetz,
M., and Barde, Y.A. (2004) Nat Neurosci 7, 1003-1009
50

247.

Murakami, N., Yamaki, T., Iwamoto, Y., Sakakibara, T., Kobori, N., Fushiki, S.,
and Ueda, S. (1998) J Neurotrauma 15, 993-1003

248.

Moya, K.L., Benowitz, L.I., Schneider, E., and Allinquant, B. (1994) Dev Biol
161, 597-603

249.

Ravona-Springer, R., Davidson, M., and Noy, S. (2003) CNS Spectr 8, 824-833

250.

Samuels, S.C., and Grossman, H. (2003) CNS Spectr 8, 834-845

251.

Skoog, I., Nilsson, B., Palmertz, L.A., Andreasson, A., and Svanborg, A. (1993)
N Engl J Med 328, 153-158

252.

Sparks, D.L., Gross, D.R., and Hunsaker, J.C. (2000) Neurobiol Aging 21, 363372

253.

Sadowski, M., Pankiewicz, J., and Scholtzova, H. (2004) Neurochem Res 29,
1257-1266

254.

De Backer, G., Ambrosioni, E., and Borch-Johnsen, K. (2003) Eur Heart J 24,
1601-1610

255.

Panza, F., D’lntrono, A., Colacicco, A.M., Capurso, C., Pichichero, G., Capurso,
S.A., Capurso, A., and Solfrizzi, V. (2006) Brain Res Rev 51, 275-292

256.

Zambón, D., Quintana, M., Mata, P., Alonso, R., Benavent, J., Cruz-Sánchez, F.,
Gich, J., Pocoví, M., Civeira, F., Capurro, S., Bachman, D., Sambamurti, K.,
Nicholas, J., and Pappolla, M.A. (2010) Am J Med 123, 267-274

257.

Whitmer, R.A., Sidney, S., Selby, J., Johnston, S.C., and Yaffe, K. (2005)
Neurology 62, 277-281

258.

Helzner, E.P., Luchsinger, J.A., Scarmeas, N., Cosentino, S., Brickman, A.M.,
Glymour, M.M., and Stern, Y. (2009) Arch Neurol 66, 343-348

51

259.

Yaffe, K., Barrett-Connor, E., Lin, F., and Grady, D. (2002) Arch Neurol 59, 378384

260.

Dietschy, J.M., and Turley, S.D. (2001) Curr Opin Lipidol 12, 105-112

261.

Pfrieger, F.W. (2003) Cell Mol Life Sci 60, 1158-1171

262.

Koudinov, A.R., and Koudinova, N.V. (2005) J Neurol Sci 229-230,233-240

263.

Gaylor, J.L. (2002) Biochem Biophys Res Commun 292, 1139-1146

264.

Korade, Z., Mi, Z., Portugal, C., and Schor, N.F. (2007) Neurobiol Aging 28,
1522-1531

265.

Ong, W.Y., Kim, J.H., He, X., Chen , P., Farooqui, A.A., and Jenner, A.M. (2010)
Mol Neurobiol 41, 299-313

266.

Zhang, Y., Appelkvist, E.L., Kristensson, K., and Dallner, G. (1996) Neurobiol
Aging 17, 869-875

267.

Snipes, G.J., and Suter, U. (1997) Sub-Cell Biochem 28, 173-204

268.

Dietschy, J.M., and Turley, S.D. (2004) J Lipid Res 45, 1375-1397

269.

Meaney, S., Lütjohann, D., Diczfalusy, U., and Björkhem, I. (2000) Biochim
Biophys 1486, 293-298

270.

Accad, M., Smith, S.J., Newland, D.L., Sanan, D.A., King, L.E.Jr., Linton, M.F.,
Fazio, S., and Farese, R.V.Jr. (2000) J Clin Invest 105, 711-719

271.

Linton, M.F., Gish, R., Hubl, S.T., Butler, E., Esquivel, C., Bry, W.I., Boyles,
J.K., Wardell, M.R., and Young, S.G. (1991) J Clin Invest 88, 270-281

272.

Dehouck, B., Dehouck, M.P., Fruchart, J.C., and Cecchelli, R. (1994) J Cell Biol
126, 465-473

52

273.

Turley, S.D., Burns, D.K., Rosenfeld, C.R., and Dietschy, J.M (1996) J Lipid Res
37, 1953-1961

274.

Spady, D.K., Huettinger, M., Bilheimer, D.W., and Dietschy, J.M. (1987) J Lipid
Res 28, 32-41

275.

Osono, Y., Woollett, L.A., Herz, J., and Dietschy, J.M. (1995) J Clin Invest 95,
1124-1132

276.

Quan, G., Xie, C., Dietschy, J.M., and Turley, S.D. (2003) Dev Brain Res 146,
87-98

277.

Suzuki, S., Kiyosue, K., Hazama, S., Ogura, A., Kashihara, M., Hara, T.,
Koshimizu, H., and Kojima, M. (2007) J Neurosci 27, 6417-6427

278.

Nieweg, K., Schaller, H., and Pfrieger, F.W. (2009) J Neurochem 109, 125-134

279.

Boyles, J.K., Notterpek, L.M., Wardell, M.R., and Rall, Jr. S.C. (1990) J Lipid
Res 31, 2243-56

280.

May, P.C., Lampert-Etchells, M., Johnson, S.A., Poirier, J., Masters, J.N., and
Finch, C.E. (1990) Neuron 5, 831-839

281.

Lorent, K., Overbergh, L., Moechars, D., De Strooper, B., van Leuven, F., Van
den Berghe, H. (1995) Neuroscience 65, 1009-1025

282.

Ong, W.Y., Lau, C.P., Leong, S.K., Kumar, U., Suresh, S., and Patel, S.C. (1999)
Neuroscience 90, 913-922

283.

Thomas, E.A., Dean, B., Pavey, G., and Sutcliffe, J.G. (2001) Proc Natl Acad Sci
USA 98, 4066-4071

284.

Iwata, A., Browne, K.D., Chen, X.H., Yuguchi, T., and Smith, D.H. (2005) J
Neurosci Res 82, 103-14

53

285.

LaDu, M.J., Gilligan, S.M., Lukens, S.R., Cabana, V.G., Reardon, C.A., Van
Eldik, L.J., and Holtzman, D.M. (1998) J Neurochem 70, 2070-2081

286.

Gong, J.S., Kobayashi, M., Hayashi, H., Zou, K., Sawamura, N., Fujita, S.C.,
Yanagisawa,K., and Michikawa, M. (2002) J Biol Chem 277, 29919-29926

287.

Pfrieger, F.W., and Ungerer, N. (2011) Prog Lipid Res 50, 357-371

288.

Krimbou, L., Marcil, M., and Genest, J. (2006) Curr Opin Lipidol 17, 258-267

289.

Fukumoto, H., Deng, A., Irizarry, M.C., Fitzgerald, M.L., and Rebeck, G.W.
(2002) J Biol Chem 277, 48508-48513

290.

Pitas, R.E., Boyles, J.K., Lee, S.H., Foss, D., and Mahley, R.W. (1987) Biophys
Acta 917, 148-161

291.

Swanson, L.W., Simmons, D.M., Hoffmann, S.L., Goldstein, J.L., and Brown,
M.S. (1988) Proc Natl Acad Sci USA 85, 9821-9825

292.

Moestrup, S.K., Gliemann, J., and Pallensen, G. (1992) Cell Tissue Res 269, 375382

293.

Möbius, W., Van Donselaar, E., Ohno-Iwashita, Y., Shimada, Y., Heijnen,
H.F.G., Slot, J.W., and Geuze, H.J. (2003) Traffic 4, 222-231

294.

Chang, T-Y., Bo-Liang, L., Chang, C.C.Y., and Urano, Y. (2009) Am J Physiol
Endocrinol Metab 297, 1-9

295.

Sakashita, N., Miyazaki, M., Takeya, M., Horiuchi, S., Chang, C.C.Y., Chang,
T.Y., and Takahashi, K. (2000) Am J Pathol 156, 227-236

296.

Björkhem, I., and Meaney, S. (2004) Arterioscler Thromb Vasc Biol 24, 806-881

297.

Russell, D.W., Halford, R.W., Ramirez, D.M., Shah, R., and Kotti, T. (2009)
Annu Rev Biochem 78, 1017-1040

54

298.

Meaney, S., Bodin, K., Diczfalusy, U., and Björkhem, I. (2002) J Lipid Res 43,
2130-2135

299.

Grundy, S.M., Hansen, B., Smith, S.C. Jr., Cleeman, J.I., and Kahn, R.A. (2004)
Circulation 109, 551-556

300.

Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C.G., and Simons,
K. (1998) Proc Natl Acad Sci U S A 95, 6460-6464

301.

Frears, E.R., Stephens, D.J., Walters, C.E., Davies, H., and Austen, B.M. (1999)
Neuroreport 10, 1699-1705

302.

Wahrle, S., Das, P., Nyborg, A.C., McLendon, C., Shoji, M., Kawarabayashi, T.,
Younkin, L.H., Younkin, S.G., and Golde, T.E. (2002) Neurobiol Dis 9, 11-23

303.

Refolo, L.M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint,
G.S., Duff, K., and Pappolla, M.A. (2000) Neurobiol Dis 7, 321-331

304.

Bodovitz, S., and Klein, W.L. (1996) J Biol Chem 271, 4436-4440

305.

Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. (2001) Proc
Natl Acad Sci U S A 98, 5815-5820

306.

Racchi, M., Baetta, R., Salvietti, N., Ianna, P., Franceschini, G., Paoletti, R.,
Fumagalli, R., Govoni, S., Trabucchi, M., and Soma, M. (1997) Biochem J 322,
893-898

307.

Yip, C.M., Elton, E.A., Darabie, A.A., Morrison, M.R., and McLaurin, J. (2001) J
Mol Bio 311, 723-734

308.

Mizuno, T., Nakata, M., Naiki, H., Michikawa, M., Wang, R., Haass, C., and
Yanagisawa, K. (1999) J Biol Chem 274, 15110-15114

309.

Shepardson, N.E., Shankar, G.M., and Selkoe, D.J. (2011) Arch Neurol 68, 12391244
55

310.

Buxbaum, J.D., Geoghagen, N.S., and Friedhoff, L.T. (2001) J Alzheimers Dis 3,
221-229

311.

Paris, D., Townsend, K.P., Humphrey, J., Obregon, D.R., Yokota, K., and Mullan,
M. (2002) Atherosclerosis 161, 293-299

312.

Chauhan, N.B., Siegel, G.J., and Feinstein, D.L. (2004) Neurochem Res 29, 18971911

313.

Li, L., Cao, D., Kim, H., Lester, R., and Fukuchi, K.I. (2006) Ann Neurol 60, 729739

314.

Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., and
Förstermann, U. (2002) Circulation 106, 1652-1658

315.

Laufs, U., La Fata, V., Plutzky, J., and Liao, J.K. (1998) Circulation 97, 11291135

316.

Kureishi, Y., Lou, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D.J., Sessa, W.C.,
and Walsh, K. (2001) Nat Med 6, 1004-1010

317.

Kurinami, H., Sato, N., Shinohara, M., Takeuchi, D., Takeda, S., Shimamura, M.,
Ogihara, T., and Morishita, R. (2008) Int J Mol Med 21, 531-537

318.

Tong, X.K., Nicolakakis, N., Fernandes, P., Ongali, B., Brouillette, J., Quirion,
R., and Hamel, E. (2009) Neurobiol Dis 35, 406-414

319.

Mancuso, C., Head, E., Barone, E., Perluigi, M., Preziosi, P., and Butterfield,
D.A. (2014) Handbook of Neurotoxicity 2339-2354

320.

Barone, E., Cenini, G., Di Domenico, F., Martin, S., Sultana, R., Mancuso, C.,
Murphy, M.P., Head, E., and Butterfield, D.A. (2011) Pharmacol Res 63, 172-180

321.

Butterfield, D.A., Barone, E., Di Domenico, F., Cenini, G., Sultana, R., Murphy,
M.P., and Head, E. (2012) Int J Neuropsychopharmacol 15, 981-987
56

322.

Mancuso, C., and Barone, E. (2009) Curr Drug Metab 10, 579-594

323.

Beydoun, M.A., Beason-Held, L.L., Kitner-Triolo, M.H., Beydoun, H.A.,
Ferrucci, L., Resnick, S.M., and Zonderman, A.B. (2011) J Epidemiol Community
Health 65, 949-957

324.

Haag, M.D., Hofman, A., Koudstaal, P.J., Stricker, B.H., and Breteler, M.M.
(2009) J Neurol Neurosurg Pscyhiatry 80, 13-17

325.

Li, G., Shofer, J.B., Rhew, I.C., Kukull, W.A., Peskind, E.R., McCormick, W.,
Bowen, J.D., Schellenberg, G.D., Crane, P.K., Breitner, J.C., and Larson, E.B.
(2010) J Am Geriatr Soc 58, 1311-1317

326.

Rosenberg, H., and Allard, D. (2008) Scand Cardiovasc J 42, 268-273

327.

Sparks, D.L., Kryscio, R.J., Sabbagh, M.N., Connor, D.J., Sparks, L.M., and
Liebsack, C. (2008) Curr Alzheimer Res 5, 416-421

328.

Cramer, C., Haan, M.N., Galea, S., Langa, K.M., and Kalbfleisch, J.D. (2008)
Neurology 71, 344-350

329.

Jick, H., Zornberg, G.L., Jick, S.S., Seshadri, S., and Drachman, D.A. (2000)
Lancet 356, 1627-1631

330.

Yaffe, J., Barrett-Connor, E., Lin, F., and Grady, D. (2002) Arch Neurol 59, 378384

331.

Benito-León, J., Louis, E.D., Vega, S., and Bermejo-Pareja, F. (2010) J
Alzheimer's Dis 21, 95-102

332.

Hippisley-Cox, J., and Coupland, C. (2010) BMJ 340, c2197

333.

Zandi, P.P., Sparks, D.L., Khachaturian, A.S., Tschanz, J., Norton, M., Steinberg,
M., Welsh-Bohmer, K.A., Breitner, J.C., and Cache County Study investigators.
(2005) Arch Gen Psychiatry 62, 217-224
57

334.

Rea, T.D., Breitner, J.C., Psaty, B.M., Fitzpatrick, A.L., Lopez, O.L., Newman,
A.B., Hazzard, W.R., Zandi, P.P., Burke, G.L., Lyketsos, C.G., Bernick, C., and
Kuller, L.H. (2005) Arch Neurol 62, 1047-1051

335.

Trompet, S., van Vliet, P., de Craen, A.J., Jolles, J., Buckley, B.M., Murphy,
M.B., Ford, I., Macfarlane, P.W., Sattar, N., Packard, C.J., Stott, D.J., Shepherd,
J., Bollen, E.L., Blauw, G.J., Jukema, J.W., and Westendorp, R.G. (2010) J
Neurol 257, 85-90

336.

Feldman, H.H., Doody, R.S., Kivipelto, M., Sparks, D.L., Waters, D.D., Jones,
R.W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D.A., Breazna, A.,
and LEADe Investigators. (2010) Neurology 74, 956-964

337.

Sano, M., Bell, K.L., Galasko, D., Galvin, J.E., Thomas, R.G., van Dyck, C.H.,
and Aisen, P.S. (2011) Neurology 77, 556-563

338.

Friedhoff, L.T., Cullen, E.I., Geoghagen, N.S.M., and Buxbaum, J.D. (2001) Int J
Neuropsychopharmacol 4, 127-130

339.

Sparks, D.L., Sabbagh, M.N., Connor, D.J., Lopez, J., Launer, L.J., Browne, P.,
Wasser, D., Johnson-Traver, S., Lochhead, J., and Ziolwolski, C. (2005) Arch
Neurol 62, 753-757

340.

Li, G., Larson, E.B., Sonnen, J.A., Shofer, J.B., Petrie, E.C., Schantz, A., Peskind,
E.R., Raskind, M.A., Breitner, J.C., and Montine, T.J. (2007) Neurology 69, 878885

341.

McGuinness, B., O’Hare, J., Craig, D., Bullock, R., Malouf, R., and Passmore, P.
(2010) Cochrane Database Syst Rev CD007514

58

Chapter 2

2

Peroxynitrite donor SIN-1 modifies high-affinity choline
transporter activity by altering its intracellular trafficking1

1

A version of this work has been published in the following manuscript:


Cuddy LK, Gordon AC, Black SA, Jaworski E, Ferguson SSG, Rylett RJ. Peroxynitrite donor
SIN-1 modifies high-affinity choline transporter activity by modifying its intracellular trafficking.
J Neurosci 18 April 2012 32 (16):5573-5584
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2.1 Introduction
CHT is an integral component of cholinergic neurons that moves choline from the
synaptic cleft into cholinergic nerve endings where it is used as substrate for ACh
synthesis. This choline uptake is HC-3 sensitive and can be the rate-limiting step for ACh
synthesis (1, 2). Importantly, CHT is sensitive to oxidative stress (3,4), and a critical
target for disruption of neuronal communication.
Increasing evidence suggests a role for reactive oxygen and nitrogen moieties in
progression of neurodegenerative disorders such as Alzheimer’s disease (5). ONOOforms by combination of O2- and NO, with these reactive species occurring in response to
tissue injury (6-9). ONOO- has multiple fates within cells, including contributing to
membrane lipid peroxidation and protein oxidation and nitration. ONOO- inhibits the
function of some neurotransmitter transporters, including the dopamine (10) and 5hydroxytryptamine transporters (11). Also, ONOO- decreases CHT activity in
synaptosomes from T. marmorata (3). Our laboratory found that SIN-1, which generates
ONOO- and other reactive oxidants, causes rapid, dose-dependent inhibition of CHT and
this is attenuated by ONOO- scavengers (4). Importantly, oxidants such as H2O2 did not
alter CHT activity (3, 4).
CHT proteins internalize constitutively by clathrin-mediated endocytosis, residing
predominantly in intracellular organelles including synaptic vesicles rather than at the
cell surface (12-17). Recruitment of CHT to the plasma membrane is a critical
mechanism regulating solute transport (12, 15, 17, 18). CHT interaction with the
endocytic machinery is mediated by a dileucine-like motif located in its intracellular
carboxyl-terminus, and we showed that mutation of a single leucine in this motif
(L531A) substantially reduces constitutive trafficking of CHT with L531A-CHT proteins
retained at the cell surface (14).
Here, I found that inhibition of choline uptake in SIN-1 treated cells is due to decreased
cell surface CHT levels rather than altered solute binding affinity, and that SIN-1
modulates CHT activity by increasing its internalization and this correlates with
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decreased plasma membrane CHT (4). However, the mechanisms by which SIN-1
modulates CHT trafficking between plasma membrane and subcellular organelles are
unknown. Thus, the aim of this study was to characterize mechanisms by which SIN-1
modulates CHT function. The endocytosis-defective mutant L531A-CHT was used to
test my prediction that it would be resistant to SIN-1 inhibition if the mechanism by
which SIN-1 decreases CHT activity involves enhancing CHT internalization. I tracked
CHT movement in endosomal-lysosomal compartments and found that acute SIN-1
treatment does not alter these events, but importantly, blocking proteasome, but not
lysosome, function attenuated SIN-1-mediated inhibition of CHT.

2.2 Materials and methods
2.2.1

Materials

SIN-1 [3-morpholinosydnonimine] was from Biomol Research Labs (Plymouth Meeting,
PA), lactacystin and MG-132 were from Calbiochem, chloroquine was from SigmaAldrich (St. Louis, MO), bafilomycin A1 was from Santa Cruz Biotechnology (Santa
Cruz,
3

CA),

and

[methyl-3H]choline

chloride

(128

Ci/mmol)

and

[methyl-

H]hemicholinium-3 diacetate ([3H]HC-3) (144.5 Ci/mmol) were from Perkin-Elmer Life

Sciences (Boston, MA). Other chemicals were purchased from Sigma-Aldrich at the
highest purity available. SH-SY5Y human neuroblastoma cells were from the American
Type Culture Collection (Manassus, VA), and Invitrogen (Burlington, ON, Canada)
supplied HEK 293 Flp-In cells, fetal bovine serum (FBS), and culture media and
reagents. Zenon-Alexa Fluor 488 and 555 mouse IgG labelling kits were from Molecular
Probes (Eugene, OR). Enhanced ChemiLuminescence immunoblot reagent (ECL) was
from GE Healthcare Life Sciences (Baie d’Urfé, QC, Canada) and Biodegradable
Scintillant was from Amersham Canada Ltd. (Oakville, ON, Canada). Polyclonal CHT
antibody was raised in rabbits to the antigenic peptide DVDSSPEGSGTEDNLQ that is
conserved at the carboxyl-terminus of human and rat CHT (Genemed Synthesis, San
Antonio, TX); this peptide was conjugated to KLH carrier protein by an amino-terminal
cysteine residue. CHT-specific IgG was affinity-purified in our laboratory from the crude
anti-serum on NHS-Sepharose (Amersham) to which antigenic peptide had been coupled
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as the binding element. The specificity of this antibody for detection of CHT was
described previously (4). Peroxidase-conjugated goat anti-rabbit IgG was from Jackson
ImmunoResearch Laboratories (West Grove PA).

2.2.2

Stable transfection and selection of cell lines

Full-length rat CHT cDNA ligated to pSPORT was a gift from Dr. T. Okuda (19); a
FLAG epitope tag (DYKDDDDK) was added to the amino-terminus by PCR and the
resulting cDNA ligated to pcDNA3.1 or pcDNA5 (4). Mutant L531A-CHT was produced
by site-directed mutagenesis using a QuikChange kit (Stratagene). SH-SY5Y cells were
transfected with plasmids [FLAG-CHT or FLAG-L531A-CHT cDNA ligated to
pcDNA3.1] by Lipofectamine 2000. Stable transformants (SY5Y-CHT and SY5YL531A-CHT, respectively) were selected using 500 μg/ml geneticin (G418) for 4 weeks,
then grown in Dulbecco’s modified Eagle medium (DMEM), 10% fetal bovine serum
(FBS), 100 U/ml penicillin, 100 μg/ml each of streptomycin and G418. SH-SY5Y cell
differentiation was induced by addition of 10 μM all-trans-retinoic acid (RA) for 3 days.
HEK 293 cell lines stably-expressing either FLAG-CHT were created by introducing
plasmids in pcDNA5 into the Flp Recombinase Target site in HEK-Flp-In cells by
Lipofectamine 2000 transfection (HEK-CHT cells). Stable transformants were selected
and expanded in DMEM containing 10% FBS, 10 μg/ml gentamicin and 50 μg/ml
hygromycin-B.
To inhibit clathrin-mediated constitutive trafficking of CHT proteins, we used AP180C, a
DN protein of the carboxyl-terminal portion of adaptin AP180, which can bind to and
sequester clathrin to effectively interfere with clathrin-mediated endocytosis (20).
Interruption of dynamin-mediated protein trafficking was achieved using Dyn-K44A as a
DN dynamin protein which has a point mutation that ablates dynamin GTPase activity
that is required for membrane scission (21).

2.2.3

SIN-1 treatment

The use of ONOO- donors such as SIN-1 allows continuous production of a low level of
ONOO- by a substance that is relatively stable over a longer period of time (22). As the
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half-life of ONOO- radical is less than 1 sec, bolus administration of this agent does not
produce either consistent or sustained concentrations of ONOO- under experimental
conditions. The donor efficiency of SIN-1 may be altered by changes in pH and buffer
composition; previous studies that used a Krebs buffer similar to that employed in the
present study estimated that 1 μmol ONOO- is formed per min in a solution of 1 mM
SIN-1. This suggests that the SIN-1 treatments used here could generate ONOO- levels
representative of those seen in brain under some conditions (23). The estimated half-life
for SIN-1 in these buffer conditions is 14-26 min, suggesting that donor activity would be
sustained throughout the treatment periods used in our study. Total ONOO- production
capacity under these buffer conditions has been estimated to be 30 μM, although the
ONOO- concentration in solution at a given time will be lower than this due to its much
shorter half-life.

2.2.4

Confocal cell imaging

Digital images of live and fixed cells were acquired with a Zeiss LSM510-Meta laser
scanning confocal microscope using a 63X magnification oil-immersion objective.
Fluorescent labelling of FLAG-tagged CHT proteins in live cells was accomplished using
rabbit anti-FLAG antibody complexed to either Zenon-555 dye (for Rab5a-GFP, Rab7GFP and Rab9-YFP) or Zenon-488 dye (for Lamp-1 staining or when no co-stain was
used). This fluorescently-tagged antibody was added to the medium bathing cells where it
could bind to the FLAG-epitope on the extracellularly-oriented amino-terminus of CHT
proteins inserted at the plasma membrane. Imaging of live cells allowed real-time
tracking of internalization of CHT into cells and movement of these proteins between
subcellular organelles. In some experiments, cells were transfected with fluorescentlylabelled subcellular compartment markers including Rab5a-GFP (early endosomes),
Rab7-GFP (early to late endosomes) or Rab9-YFP (late endosomes). Also in some
experiments, cells were formaldehyde-fixed after allowing the internalization of Zenonlabelled CHT proteins as this facilitated imaging and was required for counter-staining
cells to visualize lysosomes using an anti-human antibody directed to LAMP-1.
Formalin-fixation of GFP or YFP-fusion protein expressing cells did not alter the image
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quality of these fluorophores compared to images that were captured from live cells
expressing these fusion proteins.
Colocalization analysis was performed on confocal images using Imaris 7.0 with the
Imaris Colocalization module (bit-plane) to examine the colocalization of the brightest
2% of pixels in each channel. Graphing and statistical analysis was performed using
Prism GraphPad using one-way ANOVA with Tukey’s post-hoc test.

2.2.5

[3H]Choline uptake assay

Monolayers of cells were washed, then incubated at 37oC in Krebs-Ringer HEPES
solution (KRH) [mM: NaCl, 124; KCl, 5; MgSO4, 1.3; CaCl2, 1.5; glucose, 10; HEPESNaOH, 20, pH 7.4]. Either vehicle or SIN-1 was added to cells for specified times,
followed by incubation for 5 min with 0.5 μM [3H]-choline (0.5 μCi/ml) in the absence or
presence of 1 μM HC-3. Cells were placed on ice and washed with cold KRH, then lysed
in 0.1 M NaOH. After 30 min incubation, aliquots of samples were analyzed for tritium
by liquid scintillation spectrometry and protein concentration using Biorad protein dye.
Each independent experiment consisted of triplicate plates of cells per treatment group,
with results normalized to sample protein content and averaged. Specific choline uptake
was calculated as the difference between total choline uptake and non-specific uptake in
the presence of HC-3, with the resulting [3H]choline uptake data expressed as pmol / mg
protein per 5 min ± SEM.

2.2.6

[3H]HC-3 binding assay

Monolayers of cells were washed and incubated in KRH at 37oC with the addition of
either vehicle or 1 mM SIN-1 for specified times, then washed with ice-cold KRH and
kept on ice for 10 min to stop protein trafficking activity. Cells were then incubated with
[3H]HC-3 (10 nM; 0.23 Ci/mmol) in the presence or absence of 1 μM unlabelled HC-3
for 1 h on ice. For kinetic analysis, HC-3 binding was measured over the range of 0.5 - 10
nM HC-3 with the specific activity of [3H]HC-3 held constant at 0.23 Ci/mmol.
Following incubation, cells were washed rapidly with cold KRH to remove unbound HC3 and then lysed using 0.1 M NaOH for 30 min. Aliquots of cell lysates were used for
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quantification of tritium and protein content. Each independent experiment had triplicate
determinations with HC-3 binding normalized to sample protein content and then
averaged. Specific HC-3 binding was calculated as the difference between total and nonspecific HC-3 binding, and values were expressed as fmol / mg protein ± SEM.

2.2.7

Cell surface protein biotinylation assay

Cells plated on 60 mm dishes were washed with HEPES-buffered saline solution
(HBSS), then treated at 37oC with either vehicle (HBSS) or HBSS containing 1 mM SIN1 for the times indicated. After treatment, cells were placed on ice under cold HBSS to
stop protein trafficking. Plasma membrane proteins were biotinylated on ice by
incubating with 1 mg/ml sulfo-NHS-SS-biotin in HBSS for 1 h (4, 24). Unbound biotin
was quenched by washing and incubating cells in cold 100 mM glycine in HBSS. After
two further washes with HBSS, cells were lysed on ice for 30 min in Triton X-100 lysis
buffer [1% w/v Triton-X-100, 150 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM AEBSF,
10 μg/ml each of leupeptin and aprotinin, and 25 μg/ml pepstatin A, 700 U/ml DNase].
Neutravidin beads were incubated with cell lysates for 1 h at 4oC with gentle mixing to
bind biotin-labelled proteins to allow separation from the non-biotinylated proteins.
Beads were then washed with lysis buffer three times, PBS twice, and bound proteins
were eluted by incubation for 10 min at 55˚C with Laemmli sample buffer [2% SDS,
10% glycerol, 62.5 mM Tris-HCl pH 6.8, 2.5% β-mercaptoethanol and 0.001% bromophenol blue]. Aliquots of biotinylated proteins and total cell lysates were separated on a
7.5% SDS-PAGE gel and transferred to polyvinylidene difluoride (PVDF) membrane.
Membranes were blocked in 8% non-fat dry milk in wash buffer (PBS, 0.1% Tween-20)
for 1 h, then incubated for 2 h with rabbit anti-CHT antibody (1:1,000) in wash buffer
with 8% milk. After washing, membranes were incubated for 1 h with peroxidaseconjugated goat anti-rabbit IgG secondary antibody (1:10,000) in wash buffer containing
8% milk, and again washed. Immunoreactive proteins on membranes were detected by
chemiluminescence using the enhanced chemiluminescence (ECL) kit (GE Healthcare).
Immunopositive bands (at approximately 50-kDa for CHT protein) were quantified by
densitometry using Scion Image software (NIH). Bands for cell surface CHT were
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normalized by comparison to vehicle-treated control cells in each experiment which
represented basal cell surface CHT levels.

2.2.8

Data analysis

Data are presented as the mean ± SEM with n values representing the number of
independent experiments performed on separate populations of cells; each n value was
obtained from the average of multiple sample replicates in each experiment. GraphPad
Prism 5 and InStat software were used for data analysis. Sigmoid and Michaelis-Menten
equations were used to calculate kinetic parameters (Bmax and KD) of HC-3 binding.
Statistical significance was assessed by paired Student’s t-test, or between groups using
one-way ANOVA with either Dunnett’s or Tukey’s post-hoc multiple comparison test, as
appropriate (asterisks denote p < 0.05).
Replicate experiments were performed on cells cultured in successive passages as much
as possible to minimize inter-experiment variability; intra-experiment variability between
replicate samples was minimal thus facilitating comparisons of treatment effects.

2.3 Results
2.3.1

SIN-1 decreases activity of wild-type CHT, but not mutant
L531A-CHT

Initial experiments in this chapter characterized SIN-1 effects on choline uptake in SHSY5Y cells stably expressing wild-type CHT or the endocytosis-deficient mutant L531ACHT. My lab showed previously that SIN-1 treatment of cells decreases choline uptake
activity and reduces cell surface CHT levels due to accelerated endocytosis (4). Also,
CHT undergoes clathrin-mediated endocytosis and L531A-CHT, which lacks the
dileucine trafficking motif, is defective in this internalization (14). Thus, I predicted that
if SIN-1 reduces cell surface levels of CHT by increasing its clathrin-mediated
endocytosis, then L531A-CHT activity would be resistant to this SIN-1 mediated effect.
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Laser scanning confocal images of live cells confirmed that a large proportion of CHT is
located in subcellular organelles, whereas L531A-CHT resides at the cell surface (data
not shown) (14). Also, consistent with the increased levels of plasma membrane CHT,
choline uptake activity in SY5Y-L531A-CHT cells is significantly greater than in SY5YCHT cells (1673±151 and 816±106 pmol/mg protein/5 min, respectively). A critical
observation made in the this study in support of my prediction is that acute SIN-1
exposure caused a dose-dependent decrease in choline uptake by wild-type CHT, but did
not alter activity of SY5Y-L531A-CHT. Consistent with our previous findings (4),
choline uptake was 49±14% of control in SY5Y-CHT cells treated with 1 mM SIN-1, but
L531A-CHT was resistant to inhibition by 1 mM SIN-1, retaining 95±11% of control
uptake activity. Figure 2-1 illustrates dose-response relationships for choline uptake in
SIN-1-treated retinoic acid-differentiated SY5Y-CHT and SY5Y-L531A-CHT cells. A
statistically significant difference was seen between SY5Y-CHT and SY5Y-L531A-CHT
dose-response curves at 1 mM SIN-1. It is important to note that as 1 mM SIN-1 did not
alter activity of L531A-CHT, it is unlikely that inhibition of CHT is due to oxidative or
nitrosative modification of CHT proteins.
At higher doses of SIN-1 (5 mM), inhibition of the two transporters did not differ
significantly (49% and 33% of control uptake for L531A-CHT and CHT) (data not
shown), but this is likely due to non-specific effects of SIN-1 such as the collapse of ionic
gradients required for active uptake of choline or compromised membrane integrity,
rather than to an effect of the drug on CHT. We showed previously that the decrease in
CHT activity mediated by acute exposure of cells to 1 mM SIN-1 is not due to damage to
cell integrity or toxicity monitored by LDH release and the MTT assay (4). Also, the
SIN-1-mediated inhibition of choline uptake occurs rapidly; choline uptake activity
assayed at 5 min of SIN-1 exposure reveals a significant decrease in CHT activity (data
not shown).
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Figure 2-1 SIN-1 inhibits choline uptake activity of wild-type CHT but not L531ACHT in SH-SY5Y cells.
Retinoic acid-differentiated SH-SY5Y cells stably expressing either wild-type CHT or
L531A-CHT were treated for 30 min with either vehicle or varying concentrations of
SIN-1, and then HC-3-sensitive choline uptake activity was measured. Baseline uptake
was found to be 816 ± 106 and 1673 ± 151 pmol of choline per milligram of protein over
5 min for CHT and L531A-CHT, respectively. Data (percentage of control uptake in the
absence of SIN-1) are expressed as mean ± SEM of four or five independent experiments,
each with triplicate measurements. Statistical analysis was performed on the data before
it being normalized to vehicle-treated control uptake for each group; asterisks denote
statistically significant differences at p ≤ 0.05.
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2.3.2

SIN-1 decreases cell surface levels of wild-type CHT, but not
L531A-CHT

Two approaches, equilibrium binding of the CHT antagonist [3H]HC-3 and plasma
membrane protein biotinylation, were used to measure the SIN-1 effects on the amount of
CHT protein at the cell surface. Plasma membrane levels of wild-type and L531A-CHT
were assayed in SH-SY5Y cells after 15 min incubation with either vehicle or 1
mM SIN-1. Consistent with the data shown in Figure 2-1 on the effects of SIN-1 on
choline uptake activity, CHT and L531A-CHT responded differentially to exposure to
this ONOO− donor. In the first approach, specific binding of [3H]HC-3 was significantly
decreased in SIN-1-treated SY5Y-CHT cells to 69.0 ± 3.7% of vehicle-treated cells (n =
3 independent experiments; p = 0.004). By comparison, there were no differences in
specific binding of [3H]HC-3 between vehicle- and SIN-1-treated SY5Y-L531A-CHT
cells (111.4 ± 15.6% of vehicle-treated cells; n = 4 independent experiments; p= 0.64).
With the second approach, immunoblots of biotinylated cell surface proteins were used to
assess the plasma membrane levels of CHT in vehicle- and SIN-1-treated SY5Y-CHT
and SY5Y-L531A-CHT cells. Cell surface levels of wild-type CHT are significantly
reduced in SIN-1-treated SY5Y-CHT cells to 61.5 ± 13.7% when compared with vehicletreated cells (n = 4 independent experiments; p = 0.005). By comparison, cell surface
levels of mutant L531A-CHT do not differ between control and SIN-1 treatment groups
in SY5Y-L531A-CHT cells (108.5 ± 14.9% of vehicle-treated cells; n = 4 independent
experiments; p = 0.42). Statistical analysis was by paired Student's t test. Thus, based on
both [3H]HC-3 binding and protein biotinylation data, cell surface levels of CHT were
significantly decreased by SIN-1. Neither method revealed a significant change in the
plasma membrane levels of L531A-CHT protein in SIN-1-treated SH-SY5Y cells when
compared with controls.
For kinetic analysis of the effects of SIN-1 on [3H]HC-3 binding to wild-type CHT
protein, HEK-CHT cells were used as they express higher levels of CHT, thereby
facilitating quantification of ligand binding. Analysis of [3H]HC-3 (0.5–10 nM) binding
to CHT was performed following treatment with or without 1 mM SIN-1 (Figure 2-2) to
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Figure 2-2 SIN-1 decreases CHT activity by changing the number of transporter
proteins at the cell surface, but not altering binding of solute to transporters.
Kinetic parameters for cell surface [3H]HC-3 binding in HEK-CHT cells were estimated
using between 0.5 and 10 nM HC-3. Data were calculated as fentomoles of HC-3 bound
per milligram of protein, and expressed as mean ± SEM (n = 4). Data were fit by
Michaelis-Menten nonlinear regression analysis of individual experiments, and
differences between vehicle and SIN-1 treatments were examined by comparison of the
apparent binding affinity for ligand (KD) and the number of CHT sites (Bmax) values of
the two curves. While the apparent KD for HC-3 binding to CHT did not differ between
vehicle- and SIN-1-treated cells, the Bmax for [3H]HC-3 binding decreased to ~50% of the
control value in cells treated with 1mM SIN-1 (p<0.05, Student’s t test).
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establish whether the observed decrease in cell surface binding of HC-3 was due to a
change in binding affinity (KD) of HC-3 for its target on CHT or only to a change in the
plasma membrane level of CHT (Bmax). The apparent KD for HC-3 binding to CHT did
not differ between vehicle- and SIN-1-treated cells (4 ± 0.9 and 4 ± 0.7 nM,
respectively). However, SIN-1 did reduce the cell surface CHT levels with the Bmax for
[3H]HC-3 binding decreased by ∼50% from 473 ± 82 in control cells to 226 ± 71 fmol of
[3H]HC-3 bound/mg protein by SIN-1 (p < 0.05; Student's t test).

2.3.3

Blockade

of

clathrin-mediated

endocytosis

attenuates

inhibition of CHT by SIN-1
Major endocytic pathways for cell surface proteins can be selectively down-regulated by
expression in the cells of DN proteins that block the function of critical proteins. In these
experiments, I inhibited clathrin-mediated endocytosis with AP180C (20) and used DynK44A as a blocker of both dynamin- and clathrin-dependent endocytosis (21) to examine
routes by which CHT internalizes from the plasma membrane during acute SIN-1
exposure. SY5Y-CHT cells were transiently-transfected with plasmids encoding either
GFP as a negative control protein or DN proteins, then choline uptake activity was
assayed in the absence and presence of SIN-1.
Figure 2-3A reveals that the expression of AP180C blocked the SIN-1 effect indicating
that clathrin-mediated endocytosis is involved in the response of CHT to SIN-1 in these
cells. Dyn-K44A also attenuated ONOO--mediated inhibition of CHT. To verify that
these DN proteins functioned to block CHT internalization, we imaged cells coexpressing CHT and either AP180C or Dyn-K44A; control cells were transfected with
empty vector pcDNA3.1. Figure 2-4B illustrates that cells that were transfected to
express either of these DN proteins displayed increased CHT localization at the plasma
membrane and had substantially reduced subcellular levels of the transporter protein
when compared to cells not expressing either of the DN proteins (denoted by arrows) or
that were transfected with empty vector.
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Figure 2-3
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Figure 2-3 Inhibition of CHT activity by SIN-1 is attenuated by AP180C and DynK44A.
Selected endocytic pathways were inhibited in SY5Y-CHT cells using DN proteins. A,
SY5Y-CHT cells were transiently transfected to express either empty vector pcDNA3.1
as a control, AP180C to block the clathrin-dependent pathway, or Dyn-K44A to block
dynamin-dependent pathways. HC-3-sensitive choline uptake was assayed in transfected
cells after 20 min of either vehicle or 1 mm SIN-1 treatment; HC-3-sensitive choline
uptake was determined as the difference between uptake in the absence and presence of 1
μm HC-3, and expressed as picomoles/milligrams of protein per 5 min. Data were
analyzed using a repeated-measures one-way ANOVA with Tukey's post hoc multiplecomparisons test. Data are expressed as the mean ± SEM of five independent
experiments. A single asterisk (*) denotes when SIN-1 treatment is significantly different
from vehicle treatment (p ≤ 0.05), and a double asterisk (**) indicates when SIN-1treated groups are significantly different from each other (p ≤ 0.05). B, Live cells
transfected with plasmids encoding either AP180C or Dyn-K44A had visible
accumulation of Zenon 488-labeled CHT at the cell surface, whereas cells that were
either transfected with the empty vector pcDNA3.1 as the control or that did not become
transfected in the DN-transfected plates had substantial internalization of fluorescently
labeled CHT into subcellular compartments (these latter cells are identified by white
arrows in the AP180C and Dyn-K44A samples). Scale bars: Vector and Dyn-K44A, 5
μm; AP180C, 10 μm.
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2.3.4

CHT internalizes into Rab5a-positive organelles in control
and SIN-1 treated cells

We found previously that acute exposure of cells to the ONOO--donor SIN-1 alters
choline uptake activity by increasing the rate at which CHT proteins undergo
endocytosis, potentially accounting for the reduction of CHT at the plasma membrane
(4). The mechanism by which this occurs is not known, but it could be due to modified
interaction of CHT with other proteins and/or internalization machinery such as
endocytic and trafficking adaptor or Rab proteins. To address this, I assessed the
distribution of CHT internalized from the cell surface to subcellular organelles in live
vehicle- and SIN-1-treated SY5Y-CHT and SY5Y-L531A-CHT cells that coexpress
GFP-tagged Rab5a as a marker of early endosomes. As shown in Figure 2-4 Panels A-C,
wild-type CHT entered Rab5a-positive vesicles in vehicle-treated cells, showing a high
level of colocalization with this marker in punctate structures. Acute exposure of SY5YCHT cells to SIN-1 did not appear to substantially change the level of internalized CHT
colocalizing with Rab5a (Panels D-F). It is interesting to note that the Rab5a-positive
vesicles appeared to be larger in SIN-1-treated cells. By comparison, there was negligible
internalization of mutant CHT to Rab5a-positive endosomes in either vehicle- or SIN-1treated SY5Y-L531A-CHT cells during the experimental observation period (Panels GL).

2.3.5

CHT is present in the late endosome/lysosome system under
both vehicle and SIN-1 treatment

Confocal imaging of live cells in which CHT trafficking was followed was used to
further address the movement of CHT into late endosomes and lysosomes and to assess if
this was altered by SIN-1 treatment. Co-localization was seen between CHT and Rab7GFP (Figure 2-5), Rab9-YFP (Figure 2-6) and endogenous Lamp-1 (Figure 2-7) in both
vehicle-treated control cells and cells that were acutely exposed to 1 mM SIN-1.
As illustrated in Figure 2-5, CHT co-localizes with the late endosomal marker Rab7, but
the amount of this co-localization was not substantially altered by SIN-1 treatment. To
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Figure 2-4 Wild-type CHT but not L531A-CHT traffics to Rab5a-positive
subcellular compartments in live cells.
Confocal images showing Zenon 555-labeled CHT (red) and GFP-tagged Rab5a (green)
distribution in vehicle-treated cells and cells treated with 1 mm SIN-1 for 15 min.
Colocalized CHT and Rab5a appear as yellow. Zenon 555 dye conjugated with rabbit
anti-FLAG antibody was added to the medium bathing the cells for 10 min at 37°C where
it could bind to the extracellular FLAG epitope on CHT, and then the movement of
fluorescently labeled proteins into cells was tracked at 10 min after the addition of
treatment. Similar levels of colocalization of CHT with Rab5a-GFP were observed in
both vehicle (Panels A–C)- and SIN-1 (Panels D–F)-treated cells expressing wild-type
CHT. Interestingly, the subcellular organelles containing CHT-Rab5a in SIN-1-treated
cells were larger than those observed in the vehicle-treated cells. In support of my
hypothesis, L531A-CHT does not appear to internalize in either vehicle (Panels G–I)- or
SIN-1 (Panels J–L)-treated cells, and the accumulation of Zenon-labeled L531A-CHT
can be observed at the cell surface. Scale bars, 5 μm.
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Figure 2-5 CHT colocalization with Rab7-GFP is seen in vehicle-treated (A) and
SIN-1-treated (B) SY5Y-CHT cells.
Confocal images show Zenon 555-labeled CHT (red) and GFP-tagged Rab7 (green)
distribution in vehicle- and 1 mm SIN-1-treated SY5Y-CHT cells. Colocalized CHT and
Rab7 appear as yellow. Zenon 555 dye conjugated to rabbit anti-FLAG antibody was
added to the medium bathing the cells for 10 min at 37°C where it could bind to the
FLAG epitope on the N terminus of CHT located at the cell surface. This facilitated
tracking of the internalization and distribution of CHT proteins in cells after 15 min of
either vehicle or SIN-1 treatment. Scale bar, 3 μm.
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Figure 2-6
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Figure 2-6 CHT colocalization with Rab9-YFP in SY5Y-CHT cells is not changed by
SIN-1 treatment.
Confocal images show Zenon 555-labeled CHT (red) and YFP-tagged Rab9 (green)
distribution in vehicle- and 1 mm SIN-1-treated SY5Y-CHT cells. Zenon 555 dye
conjugated to rabbit anti-FLAG antibody was added to the medium bathing the cells for
15 min where it could bind to the FLAG epitope of the extracellular N terminus of CHT
proteins that were located at the cell surface. This facilitated tracking of the
internalization and distribution of CHT proteins in cells at 0, 30, and 60 min under either
vehicle (Panels A–C) or SIN-1 (Panels D–F) treatment. Colocalized CHT and Rab9YFP appear as yellow in the Overlay images, and the histograms resulting from analysis
of these images are shown (G). CHT and Rab9-YFP pixels that were determined to be
colocalized in the colocalization channel are shown as white in the Colocalized Pixels
images. To quantify colocalization, the brightest 2% of the red pixels (to the right of the
vertical yellow line on the histograms) and green pixels (above the horizontal yellow line
on the histograms) were selected. Imaris software was used to quantify the colocalization
of CHT with Rab9-YFP. Data were analyzed by one-way ANOVA followed by Tukey's
posttest and are expressed as mean ± SEM for a minimum of 40 cells per treatment group
from four independent experiments (a single asterisk denotes p ≤ 0.01). Scale bar, 3 μm.
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Figure 2-7
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Figure 2-7 CHT colocalization with Lamp-1 is seen in vehicle- and SIN-1-treated
SY5Y-CHT cells.
Confocal images show Zenon 488-labeled CHT (green) and Alexa Fluor 555-labeled
Lamp-1 (red) distribution in vehicle-treated and 1 mm SIN-1-treated SY5Y-CHT cells.
Zenon 488 dye conjugated to rabbit anti-FLAG antibody was added to the medium
bathing the cells for 15 min where it could bind to the FLAG epitope of the N terminus of
CHT located at the cell surface. This facilitated tracking of the internalization and
distribution of CHT proteins in cells at 0, 30, and 60 min of either vehicle (Panels A–C)
or SIN-1 (Panels D–F) treatment. The colocalization of CHT and LAMP-1 can be seen
as yellow in the Overlay panels. Images were analyzed as described in Figure 2-6 and in
Materials and Methods. CHT and Lamp-1 that were determined to be colocalized in the
colocalization channel are shown as white in the Colocalized Pixels images.
Quantification of colocalized CHT and LAMP-1 is shown (G). Data were analyzed with a
one-way ANOVA followed by Tukey's posttest and are expressed as the mean ± SEM for
a minimum of 40 cells per treatment from four independent experiments. Scale bar, 3 μm.
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assess the amount of CHT in late endosomes and lysosomes further under SIN-1 and
vehicle treatment, I used a quantitative approach to determine the relative amount of CHT
co-localization with Rab9-YFP or endogenous Lamp-1 using a method described
previously by Lorenzen et al (2010). An example of this analysis is shown in Figure 2-6
for CHT and Rab7-YFP. The brightest 2% of pixels of CHT (red), indicated to the right
of the vertical yellow line on the histogram, that fall within the brightest 2% of pixels of
Rab9-YFP (green), indicated above the horizontal line on the histogram, was selected as
the threshold intensity. The percentage of pixels that were both red and green were then
determined as the percent of the two proteins that are colocalized. In these experiments, I
found that CHT is extensively colocalized with both the late endosomal marker Rab9 and
the lysosomal marker Lamp-1 under both vehicle and SIN-1 treatments. Further analysis
to quantify these images revealed that in vehicle treated cells at 0, 30 and 60 min
colocalization of CHT with Lamp-1 was 39.9 2.3, 30.9 1.6 and 37.6 1.3, respectively,
and under SIN-1 conditions at 0, 30, 60 min was 35.7 1.9, 30.7 1.7 and 35.5 1.6,
respectively. The high levels of colocalization of CHT with both Rab9-YFP and Lamp-1
suggests that CHT transits through the late endosomal/lysosomal pathway. Moreover, this
data also suggests that SIN-1 does not alter the trafficking of CHT in this protein
degradative pathway.

2.3.6

Inhibition of the proteasome, but not the lysosome, blocks
the SIN-1 effect on choline uptake

To further determine if SIN-1 alters CHT trafficking through the late endosome/lysosome
pathway and to investigate if SIN-1 targets CHT into an alternate route for degradation
by the proteasome, the proteolytic activities of the lysosome and proteasome were
blocked using a pharmacological approach. In this experiment, separate sets of cells were
treated with either the lysosome inhibitors chloroquine or bafilomycin A1 or the
proteasome inhibitors lactacystin or MG132, then choline uptake activity was assayed in
the absence and presence of 1 mM SIN-1. Figure 2-8 (A and B) showed that neither
chloroquine nor bafilomycin A1 modified the inhibition of CHT activity by SIN-1. This
is a further indication that the movement of CHT to the lysosome for degradation is not
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altered by SIN-1 treatment. An interesting observation in this experiment is that that
chloroquine caused a significant increase in choline uptake activity compared to control
in vehicle-treated cells (Figure 2-8A). This is consistent with the idea that CHT is
normally trafficked to and degraded by the lysosome, and suggests that inhibition of this
degradative process allows more CHT to be available for recycling back to the cell
surface. Importantly, both of the proteasome inhibitors lactacystin and MG132 attenuated
the SIN-1 mediated inhibition of CHT (Figure 2-8C and 2-8D) indicating that the
proteasome may play a role in the inhibition of choline uptake activity observed in SIN-1
treated cells.

2.3.7

Ubiquitination of CHT is enhanced in SIN-1 treated cells

Finally, I investigated whether CHT is ubiquitinated and whether this is modified by
acute SIN-1 treatment of SH-SY5Y-CHT cells. Ubiquitination is a reversible
posttranslational modification of cellular proteins that can alter their subcellular
trafficking or may target them to either lysosomes or proteasomes for degradation. In
these experiments, I used either SH-SY5Y cells stably expressing the empty vector
pcDNA3.1 and not CHT to serve as a negative control or SY5Y-CHT stably expressing
FLAG-tagged CHT protein. Cells were treated with vehicle or 1 mM SIN-1 for 20 min,
and FLAG-CHT was recovered from lysates using anti-FLAG affinity resin. Figure 29 (bottom two panels) shows a representative immunoblot that was probed for ubiquitin
using anti-ubiquitin antibody, stripped, and reprobed for FLAG-CHT using anti-CHT
antibody. The anti-ubiquitin immunoblot reveals faint protein bands positive for ubiquitin
in both the vehicle- and SIN-1-treated cells. The most robust ubiquitin-positive band
appears in the SIN-1-treated cells at an apparent molecular mass of ∼80 kDa; a
corresponding band is evident in the anti-CHT blot (denoted by the arrows). No
ubiquitinated or CHT-positive bands were detected in negative control “vector” cells.
Despite CHT having a molecular weight of ∼62 kDa, this protein generally appears on
SDS-PAGE as a diffuse band with an apparent molecular mass of ∼50 kDa. Based on a
shift in the mass of FLAG-CHT of ∼30 kDa, this suggests that SIN-1 treatment may lead
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Figure 2-8
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Figure 2-8 Inhibition of CHT activity by SIN-1 is attenuated by proteasome
inhibitors lactacystin and MG-132, but not by lysosome inhibitors chloroquine and
Baf-A.
Proteolytic activity of the lysosome and proteasome were blocked using a
pharmacological approach. A, Cells were treated with either DMSO or 20 nm Baf-A
dissolved in complete medium for 24 h at 37°C. HC-3-sensitive choline uptake was
assayed in cells after 20 min of either vehicle or 1 mm SIN-1 treatment. HC-3-sensitive
choline uptake was determined as the difference between uptake in the absence and
presence of 1 μm HC-3, and expressed as picomoles/milligram of protein per 5 min. Data
are expressed as mean ± SEM of five independent experiments. B, Cells were treated
with either double-distilled H2O or 50 μm chloroquine dissolved in complete medium for
2 h at 37°C. HC-3-sensitive choline uptake was assayed in cells after 20 min of either
vehicle or 1 mm SIN-1 treatment. Data are expressed as mean ± SEM of five independent
experiments. C, Cells were treated with either double-distilled H2O or 0.5 μm lactacystin
dissolved in complete medium for 1 h at 37°C. HC-3-sensitive choline uptake was
assayed in cells after 20 min of either vehicle or 1 mm SIN-1 treatment. Data are
expressed as mean ± SEM of five independent experiments. D, Cells were treated with
either DMSO or 5 μm MG-132 in complete medium for 30 min at 37°C. Data were
analyzed using a repeated-measures one-way ANOVA with Tukey's post hoc multiplecomparisons test. Data are expressed as mean ± SEM of four independent experiments.
*SIN-1 treatment is significantly different from vehicle treatment (p < 0.05). **Drug
treatment is significantly different from vehicle treatment (p < 0.05). ***SIN-1-treated
groups are significantly different from each other (p < 0.05).
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Figure 2-9 SIN-1 treatment causes CHT ubiquitination in SY5Y-CHT cells.
FLAG-CHT was recovered from lysates prepared from SY5Y-CHT cells that were
treated with either vehicle or 1 mm SIN-1 for 20 min using anti-FLAG M2 affinity resin.
Proteins were resolved by SDS-PAGE, transferred to PVDF membranes, and probed with
either anti-ubiquitin or anti-CHT antibodies. Lysates prepared from SH-SY5Y cells that
stably express the empty vector pcDNA3.1, and not CHT protein, were used as a negative
control (“Vector” lane). Representative immunoblots show total FLAG-CHT and actin
proteins in total cell lysates (top two panels). The bottom two panels illustrate FLAGCHT proteins recovered on anti-FLAG affinity resin probed first with anti-ubiquitin
antibody (1:5000), and then with anti-CHT antibody (1:10,000) following stripping. The
arrows show ubiquitin and CHT-positive bands that appear at ∼80 kDa. The
immunoblots shown are representative of data obtained in three independent experiments.
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to the addition of approximately four ubiquitin molecules to CHT, indicating that this
could be due to multiple mono-ubiquitin or di-ubiquitin molecules or a short
polyubiquitin chain.

2.4 Discussion
The mechanisms by which SIN-1 could alter CHT activity include structural modification
of the protein by nitration of tyrosine residues or S-nitrosylation or oxidation of cysteine
residues, changes in cell surface levels of CHT proteins due to altered subcellular
trafficking or localization or degradation, dissipation of transmembrane electrochemical
gradients, or loss of cell viability. I made novel findings in the present study that support
my prediction that CHT inhibition by SIN-1 is mediated by changes to protein trafficking
events, since the activity of a CHT mutant that does not undergo clathrin-mediated
endocytosis is not affected by SIN-1. I also found that with SIN-1 treatment CHT
internalizes from the cell surface by a clathrin- and dynamin-mediated process, since DN
proteins that block either clathrin or dynamin function attenuate SIN-1-mediated
inhibition of CHT. Moreover, I show for the first time that CHT proteins move through
the endosomal–lysosomal pathway colocalizing with compartment markers, but that SIN1 does not alter this trafficking. Our studies reveal that CHT normally undergoes
lysosomal degradation, since lysosome inhibitors enhance choline uptake activity likely
by increasing CHT availability for recycling to the cell surface. Importantly, however,
proteasome, but not lysosome, inhibitors attenuate SIN-1-mediated inhibition of choline
uptake, indicating that proteasomal degradation has a role in CHT protein disposition in
cells exposed to SIN-1. Finally, I demonstrate for the first time that CHT protein
undergoes ubiquitination, and this is enhanced by SIN-1 treatment.
I made the critical observation that mutant L531A-CHT is resistant to the SIN-1mediated inhibition that is seen with wild-type CHT. Thus, inactivation of CHT function
by SIN-1 is not likely due to oxidative or nitrosative modification of essential amino
acids, thereby highlighting the importance of changes in intracellular trafficking of CHT
proteins in its response to SIN-1. These findings for CHT inhibition differ from
mechanisms by which hDAT activity is decreased in ONOO−-treated cells or hSERT is
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inhibited in cells exposed to NO and related compounds, including peroxynitrite. With
hDAT, inhibition by ONOO− is caused by modification of a cysteine residue that is
critical for transporter function (10). It is interesting, however, that ONOO− does not
block hDAT directly, as it was shown that inhibition is caused by a highly reactive
dopamine-quinone moiety formed by reaction of ONOO−with intracellular dopamine
(25). Similarly, hSERT inhibition may involve S-nitrosylation of cysteine residues since
inhibition was attenuated by addition of L-cysteine to the incubation buffer (11); Lcysteine acts as a “sink” by providing excess thiol groups to interact with reactive
compounds (26). CHT is relatively cysteine poor, having only five cysteine residues in
human CHT (17) compared with 13 in hDAT (27) and 18 in hSERT (28), but it is not
known whether any of these cysteines are critical for CHT function. With regard to
nitration of tyrosine residues in CHT, we did not detect this in SIN-1-treated cells by
immunoblot using nitrotyrosine antibodies (4).
We reported that SIN-1 enhances CHT endocytosis from plasma membrane, thereby
decreasing its cell surface levels and reducing choline uptake capacity (4). Now, my data
shows that CHT proteins internalize by clathrin- and dynamin-dependent mechanisms to
Rab5a-positive early endosomes in both control and SIN-1-treated cells. Moreover, CHT
levels in this compartment are not altered by SIN-1, suggesting that transporters are not
retained there and move to other endosomal compartments. In relation to the mechanism
underlying changes in CHT endocytosis, dynamin, which carries out endocytic budding
of vesicles and membrane scission (29, 30), undergoes S-nitrosylation at a critical
cysteine residue in NO-treated cells. Importantly, this modification of dynamin causes
accelerated endocytosis of plasma membrane proteins (30, 31). There are no data on the
effects of ONOO− on dynamin function, but since NO can be rapidly converted to
ONOO− and both of these highly reactive molecules can S-nitrosylate reactive cysteines,
enhanced endocytosis associated with dynamin modification might also be mediated by
ONOO−.
In addition to CHT proteins recycling back to the cell surface following endocytosis (32,
15), other potential destinations for CHT in the neuron include being directed into the late
endosomal pathway and/or lysosomes for degradation. This would effectively remove
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CHT proteins from the recycling pool that is important for supplying CHT to the cell
surface and regulating choline uptake activity. I now show that some CHT proteins in
both vehicle- and SIN-1-treated cells move to colocalize with late endosome pathway
small GTPases Rab7 and Rab9 and LAMP-1-positive lysosomes. The amount of CHT
colocalized with these markers did not differ between vehicle- and SIN-1-treated cells;
thus, SIN-1 does not promote CHT accumulation in these compartments. My data also
shows for the first time that the normal site for CHT degradation is the lysosome, since
the lysosome inhibitor chloroquine enhances choline uptake activity.
An unexpected finding is that the decreased CHT activity observed in SIN-1-treated cells
was attenuated by proteasome blockers, suggesting that proteasomal protein degradation
is involved in SIN-1-mediated loss of CHT function. Trafficking patterns for plasma
membrane proteins to lysosomes or proteasomes may be altered under diverse conditions,
including oxidative stress [glucose transporter GLUT1 (33)], single point mutations [lowdensity lipoprotein receptor (34)], and loss of intramolecular disulfide bonding [ATPbinding cassette transporter ABCG2 (35)]. While the mechanisms mediating these
changes likely differ, there are similarities between our observations with CHT and
effects of oxidative stress on GLUT1. Cell surface GLUT1 levels decrease during
oxidative stress due to enhanced internalization and altered subcellular trafficking, with
this linked to ubiquitination of GLUT1 and proteasome-dependent changes in protein
kinase B (Akt) activation. Under these conditions, GLUT1 also undergoes monoubiquitination or di-ubiquitination (33).
Trafficking of solute transporters is also regulated by phosphorylation, and this is
modulated by oxidative stress. Like CHT, GLUT4 glucose transporters are located
mostly in intracellular vesicles under basal conditions and its plasma membrane levels are
increased when solute is needed by the cell; insulin, ischemia, and hypoxia increase
GLUT4 translocation (36). Acute exposure of cardiomyocytes to H2O2 enhances plasma
membrane GLUT4 levels by a mechanism involving activation of AMP-activated protein
kinase and PI3-kinase/Akt (37). However, GLUT4 is not the substrate for these kinases,
with regulatory proteins including Rab GAP AS160 being phosphorylated and then
modulating GLUT4 disposition (38). CHT in neurons is phosphorylated, and PKC
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regulates its activity and cell surface levels (39, 40), although the underlying mechanisms
are unknown. Multiple kinases are altered by ONOO−, including activation of p38 kinase
and Src kinase (41, 43, 44), but there are no data on the effects of kinases that are
modulated by ONOO− on CHT disposition.
CHT interacts with amyloid precursor protein (APP) through its C-terminal tail, and APP
has a role in regulating CHT subcellular trafficking in cholinergic neurons (44); APP
serves as substrate for generation of β-amyloid, a critical feature in Alzheimer's disease
pathogenesis, which is involved in production of oxidative stress in brain. APP is
internalized from plasma membrane by endocytosis and moves through the endosomal
pathway to lysosomes where it is cleaved by secretases. However, APP can also enter a
novel, rapid transport pathway to move directly from the cell surface to lysosomes (45). It
is not known whether this trafficking is altered by oxidative–nitrosative stress or what
effect this could have on the function of its binding partner CHT, but this raises important
questions about the regulation of cholinergic presynaptic function by APP disposition and
trafficking in neuropathology.
In summary, plasma membrane CHT levels are determined by the balance between cell
surface recruitment of CHT-containing vesicles and retrieval of CHT proteins to
subcellular organelles. Events that alter the dynamics of either this constitutive or the
depolarization-regulated recycling of CHT will control the amount of choline that is
available for ACh synthesis and the ability of cholinergic neurons to communicate with
their target cells. It is not known whether the enhanced endocytosis and loss of cell
surface CHT proteins in SIN-1-treated cells is a mechanism to remove damaged proteins
from the neuron or a protective measure to prevent protein damage, but our previous
work examining transferrin receptor disposition in SIN-1-treated cells shows changes to
that receptor that parallel effects on CHT (4), suggesting that this is a more generalized
mechanism for the response of some cell surface proteins to cellular stress.
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3.1 Introduction
The activity and trafficking of membrane proteins can be regulated by the plasma
membrane lipid environment. Proteins can be segregated into cholesterol and
sphingolipid-rich microdomains in membranes termed lipid rafts (1, 2) that are involved
in cellular events, including membrane organization, protein–protein interactions, and
signal transduction (3, 4). Lipid rafts also have a role in trafficking of membrane proteins
by facilitating their endocytosis in clathrin-independent caveolae (5, 6). Cholesterol can
play a critical role in organization of membrane proteins, and influence their function or
activity either indirectly through changes in membrane fluidity or directly by cholesterol–
protein interactions (7, 8). The disruption of lipid rafts by removal of cholesterol can
significantly affect either the structure or function of some membrane proteins (9). In
relation to this study, several neurotransmitter transporters are localized to lipid rafts. One
mechanism by which this can regulate their solute uptake activity is by altering their
endocytosis and trafficking, thereby affecting the amount of cell surface transporter
protein (10-13). However, specific cholesterol–transporter interactions have also been
identified that are independent of association of the protein with lipid rafts. For example,
reconstitution of 5-HT transporter and GABA transporter activity is not observed when
cholesterol is replaced by other sterols that have similar effects on membrane fluidity (14,
15), and depletion of membrane cholesterol can decrease 5-HT transporter affinity for its
substrate (14).
CHT is active at the plasma membrane, but experimental evidence indicates that the
majority of CHT proteins form a subcellular reserve pool within endocytic and synaptic
vesicles (16, 17). Only a small proportion of total cellular CHT proteins are at the cell
surface, with a constitutive cycle of endocytosis by a clathrin/dynamin-dependent
mechanism and recycling back to the plasma membrane serving as a critical regulatory
mechanism that controls cell surface CHT density (16, 17). Plasma membrane CHT
levels are enhanced by depolarization-induced exocytosis of synaptic vesicles that deliver
additional CHT proteins to the cell surface during excitation of cholinergic nerve
terminals, thereby increasing the amount of choline transported into cholinergic nerve
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terminals to drive ACh synthesis (18). CHT trafficking is also regulated by
phosphorylation (19), extracellular ligand concentration (21), and by interaction with
other proteins, such as amyloid precursor protein (22).
To-date, there have been only limited, and conflicting, reports regarding the influence of
cholesterol or cholesterol-rich lipid rafts on high-affinity choline uptake; one study shows
that cholesterol reduction in isolated nerve endings (synaptosomes) decreased choline
uptake (23), whereas another study reports that depletion of membrane cholesterol in
synaptosomes did not significantly influence choline uptake (24). A recent study suggests
that depleting membrane cholesterol by treating synaptosomes with high concentrations
of methyl-β-cyclodextrin (MβC) reduced high-affinity choline uptake (25). Although
these observations suggest that cholesterol has a role in regulation of CHT, the
underlying mechanisms were not investigated and there has been no assessment of
whether CHT proteins are partitioned in membrane lipid rafts. Thus, the goal of this study
was to address these points and provide data on cholesterol-related changes to CHT
activity. I used pharmacological approaches to modulate membrane cholesterol levels in
neural cells, and found that treatments that reduced cholesterol caused a reduction in
CHT activity and addition of cholesterol to cells resulted in enhanced CHT activity. I
showed for the first time that CHT proteins are enriched in lipid rafts, and that disruption
of lipid rafts reduces cell surface CHT. These results suggest that membrane cholesterol
and lipid rafts serve as an important regulator of CHT trafficking and activity by retaining
functional CHT at the cell surface.

3.2 Materials and methods
3.2.1

Materials

Filipin, MβC, cholesterol–MβC complex (MβC–Chol), and cholesterol oxidase were
from Sigma-Aldrich (St. Louis, MO, USA) and [methyl-3H]choline chloride
(128 Ci/mmol) and [methyl-3H]hemicholinium-3 diacetate ([3H]HC-3) (169 Ci/mmol)
were from Perkin-Elmer Life Sciences (Boston, MA, USA). Other chemicals were from
Sigma-Aldrich at the highest purity available. SH-SY5Y human neuroblastoma cells
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were from American Type Culture Collection (Manassus, VA, USA), and Invitrogen
(Burlington, ON, Canada) supplied AlexaFluor 647 cholera toxin subunit B conjugate
(CTB), Zenon AlexaFluor 555 rabbit IgG and Zenon AlexaFluor 488 mouse IgG labeling
kits, Amplex Red Cholesterol Assay kit, and culture media and reagents. Enhanced
ChemiLuminescence immunoblot reagent was from GE Healthcare Life Sciences (Baie
d'Urfé, QC, Canada) and Biodegradable Scintillant was from Amersham Canada Ltd.
(Oakville, ON, Canada). Purified mouse anti-EEA1 antibody was from BD Biosciences
(Mississauga, ON, Canada) and rabbit polyclonal flotillin-1 antibody from Santa Cruz
Biotechnology, Santa Cruz, CA, USA. Polyclonal CHT antibody was raised in rabbits to
the antigenic peptide DVDSSPEGSGTEDNLQ that is conserved at the carboxyl terminus
of human and rat CHT (Genemed Synthesis, San Antonio, TX, USA); this peptide was
conjugated to keyhole limpet hemocyanin carrier protein by an amino-terminal cysteine.
CHT-specific IgG was affinity purified in our laboratory from crude anti-serum on NHSSepharose (Amersham) to which antigenic peptide was coupled as the binding element.
Specificity of this antibody for detection of CHT was described previously (26).

3.2.2

Selection of cell line and cell culture

Full-length rat CHT cDNA ligated to pSPORT was a gift from Dr T. Okuda (21); a
FLAG epitope tag was added to the amino terminus by PCR and the resulting cDNA
ligated to pcDNA3.1 (26). SH-SY5Y cells were transfected with this FLAG-CHT
plasmid by Lipofectamine 2000. Stable transformants were selected using 500 μg/mL
G418 for 4 weeks, then grown in DMEM, 10% FBS U/mL penicillin, and 100 μg/mL
each of streptomycin and G418. SH-SY5Y cell differentiation was induced by addition of
10 μM RA for 3 days; substantial morphological and biochemical differentiation of cells
occurred during this time (data not shown).

3.2.3

[3H]Choline uptake assay

Monolayers of cells were washed, then incubated at 37°C in KRH. Vehicle or drug was
added to cells for specified times, followed by incubation for 5 min with 0.5 μM
[3H]choline (0.5 μCi/mL) in the absence or presence of 1 μM HC-3. Following this
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incubation, cells were placed on ice and washed with cold KRH, then lysed in 0.1 M
NaOH. After 30 min lysis, aliquots of samples were analyzed for tritium content by liquid
scintillation spectrometry and protein concentration using Bio-Rad protein dye (Bio-Rad
Laboratories, Hercules, CA, USA). Each independent experiment consisted of triplicate
plates of cells per treatment group, with results normalized to sample protein content and
averaged. Specific choline uptake was the difference between total choline uptake and
non-specific uptake in the presence of HC-3, with the resulting [3H]choline uptake data
expressed as pmol/mg protein per 5 min ± SEM.

3.2.4

[3H]HC-3 binding assay

Monolayers of cells were washed and incubated in KRH at 37°C with addition of vehicle
or drug for specified times, then washed with ice-cold KRH, and kept on ice for 10 min
to stop protein trafficking activity. Cells were incubated with [3H]HC-3 (10 nM;
1 Ci/mmol) in the presence or absence of 1 μM unlabeled HC-3 for 1 h on ice. For kinetic
analysis, HC-3 binding was measured over the range of 0.5–10 nM HC-3 with the
specific activity of [3H]HC-3 held constant at 1 Ci/mmol. Following incubation, cells
were washed rapidly with cold KRH to remove unbound HC-3 and lysed in 0.1 M NaOH
for 30 min. Aliquots of lysates were used for quantification of tritium and protein content.
Each independent experiment had triplicate determinations with HC-3 binding
normalized to sample protein content, then averaged. Specific HC-3 binding was
calculated as the difference between total and non-specific HC-3 binding, and values
were expressed as fmol/mg protein ± SEM.

3.2.5

Lipid raft preparation and sucrose flotation gradients

SH-SY5Y cells stably expressing CHT were grown to confluence on 100-mm dishes
prior to the preparation of membrane fractions. Cells were placed on ice and washed
twice with HBSS, then lysed for 30 min in sodium carbonate lysis buffer (0.5 M
Na2CO3 with 1 mM AEBSF, 10 μg/mL each of leupeptin and aprotinin, and 25 μg/mL
pepstatin A) or Triton X-100 lysis buffer (0.5% Triton X-100 with 1 mM AEBSF,
10 μg/mL each of leupeptin and aprotinin, and 25 μg/mL pepstatin A). Cell lysates were
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collected and homogenized three times for 10 s each using a Polytron tissue grinder.
Homogenates were next sonicated three times for 20 s using a Sonic Dismembrator.
Homogenates were adjusted to 40% sucrose, then added to ultracentrifuge tubes and
overlaid with 30% sucrose and 5% sucrose solutions. Samples were centrifuged at
120 000 g for 16 h at 4°C using a Beckman SW 41 (Beckman Coulter Canada LP,
Mississauga, ON, Canada) Ti rotor. Twelve or ten (for cells lysed in sodium carbonate or
Triton X-100, respectively) 1 mL fractions were collected from the top to bottom of each
sucrose gradient. Protein aliquots from each fraction were incubated for 10 min at 55°C
with Laemmli buffer (2% sodium dodecyl sulfate, 10% glycerol, 62.5 mM Tris-HCl, pH
6.8, 2.5% β-mercaptoethanol, and 0.001% bromophenol blue), then separated on 7.5%
SDS–PAGE gels and transferred to PVDF membranes. Membranes were blocked in 8%
non-fat dry milk in wash buffer (phosphate-buffered saline, 0.15% Triton X-100) and
incubated with either anti-CHT antibody, anti-EEA1 antibody or anti-flotillin antibody
overnight at 4°C. After washing, membranes were incubated for 1 h with speciesmatched secondary antibodies in wash buffer containing 8% milk, and washed again.
Immunoreactive proteins on membranes were detected by chemiluminescence using the
ECL kit. Immunopositive bands were quantified by densitometry using Scion Image
software (NIH).

3.2.6

Synaptosome preparation

Purified nerve terminals [synaptosomes] were isolated from mouse forebrain using
established methods (27). Young adult (3–4 months of age) C57B6 mice of either sex
bred locally were used in these experiments in compliance with the Canadian Council on
Animal Care (CCAC) and the ARRIVE (www.nc3rs.org.uk/ARRIVE) guidelines, and a
protocol approved by the Animal Use Subcommittee at the University of Western
Ontario. Briefly, tissues were homogenized in 0.32 M sucrose buffered with 5 mM
HEPES, pH 7.4. Following differential centrifugation at 1000 g for 10 min and
12 000 g for 20 min to recover the crude P2 fraction, pellets were resuspended in
buffered 0.32 M sucrose and layered onto discontinuous gradients comprised of 8.5, 13,
and 20% Ficoll in buffered 0.32 M sucrose. Following centrifugation at 27 000 g for
45 min, fractions at the 8.5–13% and 13–20% interfaces were recovered as they
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contained purified synaptosomes; these were diluted 5-fold with 0.32 M sucrose, then
centrifuged at 12 000 x g for 30 min. Purified synaptosome pellets were lysed in sodium
carbonate lysis buffer and the resulting homogenates used directly to isolate lipid rafts, as
described above.

3.2.7

Cellular imaging

Digital images of fixed cells were acquired with a Zeiss LSM510-Meta laser-scanning
confocal microscope (Carl Zeiss Canada Ltd., Toronto, ON, Canada) using a 63X oilimmersion objective and magnified three times, unless specified otherwise. FLAG-tagged
CHT proteins were fluorescently labeled in live cells using rabbit anti-FLAG antibody
complexed to either Zenon 555 dye (for EEA1 staining) or Zenon 488 dye (for flotillin
staining). The fluorescently tagged antibody was added to medium bathing the cells
where it could bind to the FLAG epitope located on the extracellularly oriented amino
terminus of CHT proteins at the plasma membrane. After allowing internalization of
Zenon-labeled CHT proteins, cells were formaldehyde fixed then counter-stained with
AlexaFluor 647 CTB (0.2 ng/μL) and either anti-flotillin (1: 200) or anti-EEA1 (1: 100)
antibodies. Following immunostaining, images were acquired using 488-nm excitation
and 505- to 530-nm emission wavelengths for flotillin; 543-nm excitation and 560- to
615-nm emission for EEA1; and 647-nm excitation and 650-nm emission using a longpass filter for CTB. FLAG-CHT was visualized using 488-nm excitation and 505- to 530nm emission (for EEA1-labeled cells) or using 543-nm excitation and 560- to 615-nm
emission (for flotillin-labeled cells). Images were processed and colocalization was
analyzed in Imaris (version 7.0.0; Bitplane Scientific Software, South Windsor, CT,
USA), then formatted in Adobe Illustrator and Photoshop (Adobe Systems Inc, San Jose,
CA, USA).

3.2.8

Cholesterol quantification

SH-SY5Y cells expressing FLAG-tagged CHT were grown to confluence on 100-mm
dishes, then lysed in sodium carbonate lysis buffer and lipid rafts were isolated on
sucrose gradients, as described above. Total cholesterol levels were measured in pooled
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raft fractions (#4–6) and non-raft fractions (#9–12) using the Amplex Red Cholesterol
Assay, according to manufacturer's instructions. Briefly, 50 μL of cholesterol standards
(0–20 μM per well) or sample replicates was added to 96-well black plates. Fifty μL of
working solution (300 μM Amplex Red reagent, 2 unit/mL horseradish peroxidase,
2 unit/mL cholesterol oxidase, and 0.2 unit/mL cholesterol esterase) was added to each
well and plates were incubated in the dark for 30 min at 37°C. Fluorescence was
measured (excitation 544 nm, emission 590 nm, SpectraMax M5 Molecular Devices,
Palo Alto, CA, USA). Relative fluorescence units of samples were converted into μM
cholesterol per μg sample protein using the standard curve, and data were expressed as a
percentage of vehicle-treated controls

3.2.9

Cell surface protein biotinylation assay

Cells plated on 100-mm dishes were washed with HBSS, then treated at 37°C with either
vehicle or drug. After treatment, cells were placed on ice under cold HBSS to stop
protein trafficking. Plasma membrane proteins were biotinylated at 4°C by incubating
with 1 mg/mL sulfo-NHS-SS-biotin in HBSS for 1 h (26, 28) with gentle agitation.
Unbound biotin was quenched by washing and incubating cells in cold 100 mM glycine
in HBSS. After two further washes with HBSS, cells were lysed on ice for 30 min in
sodium carbonate lysis buffer and lipid rafts prepared on sucrose flotation gradients as
described above. Twelve 1-mL gradient fractions were collected and pooled as either raft
fractions (#4–6) or non-raft fractions (#9–12). Pooled fractions were diluted to 10 mL
with lysis buffer (1% w/v Triton X-100, 150 mM NaCl, 50 mM Tris-HCl, and pH 7.5)
and pH adjusted to 7.5. Protein concentrations were measured using Bio-Rad dye and
aliquots of cell lysates containing 30 μg protein subjected to SDS–PAGE to determine
total CHT, flotillin, and EEA1 levels. Biotinylated proteins in sucrose density gradient
fractions were separated from non-biotinylated proteins by Neutravidin bead pull-down
from 500 μg total cellular protein from each sample. Beads were washed three times with
lysis buffer to remove non-specifically bound proteins. Proteins were eluted for 10 min at
55°C with Laemmli buffer, then separated on 7.5% SDS–PAGE gels and transferred to
PVDF membranes. Immunoblots for CHT, flotillin, and EEA1 were carried out as
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described above and analyzed using a Chemidoc Imaging System (Bio-Rad
Laboratories).

3.2.10

Internalization cell surface biotinylation assay

Cells plated on 100-mm dishes were washed twice with cold HBSS and placed on ice
under cold HBSS to stop protein trafficking. Plasma membrane proteins were
biotinylated at 4°C by incubating with 1 mg/mL sulfo-NHS-SS-biotin in HBSS for 1 h
with gentle agitation, then unbound biotin was quenched by washing and incubating cells
in cold 100 mM glycine in HBSS. Dishes were washed with warm HBSS, then incubated
at 37°C with either vehicle or drug to allow constitutive internalization of CHT proteins.
CHT internalization was subsequently terminated by transferring dishes of cells to ice
and replacing medium with cold HBSS. Residual cell surface biotin was stripped by
incubating cells once for 15 min and twice for 30 min with freshly prepared 50 mM
mercaptoethanesulfonic acid (MesNa) in TE buffer (150 mm NaCl, 1 mm EDTA, 0.2%
bovine serum albumin, 20 mm Tris, and pH 8.6). Stripping efficiency was determined for
each experiment on parallel sets of biotinylated cells that were maintained on ice and
which did not undergo MesNa stripping to assess the amount of CHT at the plasma
membrane. Cells were lysed in lysis buffer (1% w/v Triton X-100, 150 mM NaCl,
50 mM Tris-HCl, pH 7.5, 1 mM AEBSF, 10 μg/mL each of leupeptin and aprotinin,
25 μg/mL pepstatin A, and 700 U/mL DNase) and protein concentration was measured
using Bio-Rad dye. Biotinylated proteins were separated from non-biotinylated proteins
by Neutravidin bead pull-down from 500 μg protein from each sample. Beads were
washed three times with lysis buffer to remove non-specifically bound proteins, then
proteins eluted for 10 min at 55°C with Laemmli buffer, separated on 7.5% SDS–PAGE
gels, and transferred to PVDF membranes. Immunoblots for CHT were carried out as
described above and analyzed using a Chemidoc Imaging System.

3.2.11

Data analysis

Data are presented as mean ± SEM with n values representing the number of independent
experiments performed on separate populations of cells. Each n value was obtained from
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the average of multiple sample replicates in each experiment. Replicate experiments were
performed on cells cultured in successive passages as much as possible to minimize
interexperiment variability; intraexperiment variability between replicate samples was
minimal thus facilitating comparison of treatment effects. GraphPad Prism 5 (GraphPad
Software, San Diego, CA, USA), InStat software (GraphPad Software) and Image Lab
4.1 (Bio-Rad Laboratories) were used for data analysis. Sigmoid and Michaelis–Menten
equations were used to calculate kinetic parameters (Bmax and KD) of HC-3 binding. Data
were assessed for statistically significant differences by unpaired Student's t-test, or
between groups using repeated measures one-way ANOVA with Tukey's post
hoc multiple comparison test as appropriate, with statistical significance defined
as p ≤ 0.05.

3.3 Results
3.3.1

Membrane

cholesterol

manipulation modulates

choline

uptake activity
The initial experiments were designed to determine the effect of manipulation of
membrane cholesterol content on HC-3-sensitive, high-affinity choline uptake activity in
SH-SY5Y cells that stably express FLAG-tagged CHT. Three separate pharmacological
approaches having different mechanisms of action were used to lower membrane
cholesterol levels, and one approach was used to increase the membrane cholesterol level.
Cells were treated with either filipin which binds to and sequesters free cholesterol within
both lipid raft and non-raft areas of membrane and disrupts lipid rafts (29), MβC which
extracts unesterified cholesterol from plasma membrane resulting in the disruption of
lipid rafts and direct cholesterol–protein interactions (30), or cholesterol oxidase which
converts cholesterol to the inactive sterol cholest-4-en-3-one and does not alter
membrane fluidity (31). Neither cell density of cultures nor cell morphology was visibly
altered after drug treatments, and the level of total CHT protein was unchanged (data not
shown). I predicted that if cholesterol is required for CHT function, then HC-3-sensitive
choline uptake activity would be altered by these drugs. Figure 3-1 illustrates dose–
response relationships for [3H]choline uptake in cells treated with filipin, MβC, and
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Figure 3-1
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Figure 3-1 Manipulation of membrane cholesterol modulates choline uptake in SHSY5Y cells.
A, Cells were treated with either vehicle (methanol) or 2.5 or 5 μg/mL of filipin for
60 min at 37°C. Hemicholinium-3 (HC-3)-sensitive [3H]choline uptake activity was
assayed in cells during a 5-min incubation at 37°C. B, Cells were treated with either
vehicle (H2O) or 0.1 or 0.3 mM methyl-β-cyclodextrin (MβC) for 30 min at 37°C, then
[3H]choline uptake activity was determined. C, Cells were treated with either 0, 0.5, or
1 U/mL cholesterol oxidase in a buffer containing 100 mM MES and 3 M NaCl in KrebsRinger-HEPES (KRH) solution at 37°C for 30 min, then [3H]choline uptake was
measured. D, To assess whether supplementing membranes with additional cholesterol
influenced choline uptake, cells were treated with either vehicle (H2O), 5, or 25 μM
cholesterol–methyl-β-cyclodextrin (MβC–Chol), then [3H]choline uptake was assayed. In
all experiments, [3H]choline uptake activity was determined as the difference between
uptake in the absence and presence of 1 μM HC-3, and expressed as pmol/mg of protein
per 5 min and transformed to % of the respective control values. Data are expressed as
mean ± SEM of four independent experiments. Non-transformed data were analyzed by
one-way anova followed by Tukey's post-test. Asterisks (*) denote when drug treatment
groups are significantly different from vehicle groups (p < 0.05).
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cholesterol oxidase. When cells were pre-treated with vehicle or filipin for 60 min,
[3H]choline uptake was significantly reduced at both doses of filipin (2.5 or 5 μg/mL)
(Figure 3-1A). Similarly, treating cells with MβC for 30 min (0.1 or 0.3 mM) resulted in
a statistically significant decrease in [3H]choline uptake at the higher concentration of the
drug (Figure 3-1B). Finally, when cells were treated with cholesterol oxidase for 30 min,
a statistically significant reduction in [3H]choline uptake activity was observed at both
concentrations of cholesterol oxidase (0.5 and 1 U/mL) compared to vehicle-treated
control cells (Figure 3-1C).
In the next set of experiments, I determined if CHT activity is altered by increasing the
level of membrane cholesterol. SH-SY5Y cells were incubated with a cholesterolsaturated form of MβC (MβC-Chol) for 30 min (MβC-Chol complex concentration was 5
or 25 μM, calculated by weight of cholesterol) or with vehicle, then [3H]choline uptake
was measured. Importantly, when cholesterol was added to cells, a statistically significant
increase in choline uptake was observed at 25 μM MβC-Chol when compared to vehicletreated cells (Figure 3-1D).

3.3.2

MβC decreases both the Bmax and KD for [3H]HC-3 binding to
CHT

Several studies suggest that membrane cholesterol and lipid rafts regulate
neurotransmitter transporter activity by controlling the number of transporters at the cell
surface (11, 32, 33). However, cholesterol can also regulate the function of
neurotransmitter transporters by modulating their solute binding activity (34, 14, 35). To
establish whether the observed decrease in choline uptake following cholesterol depletion
was owing to a change in ligand binding affinity (KD) or to a change in the number of cell
surface CHT proteins (Bmax), kinetic analysis of binding of the non-transported
competitive inhibitor [3H]HC-3 to CHT was performed following treatment of cells with
either vehicle or 0.3 mM MβC (Figure 3-2A). These data revealed that cell surface CHT
levels were reduced by approximately 50% by MβC treatment, with Bmax for [3H]HC-3
binding decreased from 470.5 ± 115 to 220.7 ± 77 fmol [3H]HC-3 bound/mg protein in
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Figure 3-2 MβC modifies the binding kinetics for [3H]HC-3 to high-affinity choline
transporters by decreasing Bmax and KD.
Cells were treated with either vehicle (H2O) or 0.3 mM MβC for 30 min at 37°C, then
kinetic parameters for cell surface [3H]HC-3 binding were estimated using 0.5–10 nM
hemicholinium-3 (HC-3). Data were calculated as pmol [3H]HC-3bound/mg protein, and
expressed as mean±SEM from five independent experiments. A, A representative
experiment is shown for equilibrium binding of [3H]HC-3 to SH-SY5Y cells expressing
CHT. Data were fit by Michaelis–Menten non-linear regression analysis of individual
experiments. Differences between vehicle and MβC treatments were examined by
comparison of the number of CHT sites (Bmax) B, and the apparent binding affinity for
ligand (KD), C. When compared to control cells, the KD for HC-3 binding to CHT was
decreased approximately 60% and Bmax was reduced by approximately 50% in MβCtreated cells (*p < 0.05, unpaired Student's t-test).
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control and MβC-treated cells, respectively (Figure 3-2B). This coincides with a small,
but significant, MβC-mediated increase in binding affinity with the KD for [3H]HC-3
binding reduced from 8.5 ± 1.1 to 4.0 ± 0.6 nM in control and MβC-treated cells,
respectively (Figure 3-2C).

3.3.3

CHT proteins are associated with lipid rafts

The observation that choline uptake activity is modulated by changes in membrane
cholesterol suggests that CHT proteins may be located in lipid rafts. Technically, lipid
rafts are defined as membrane domains that are insoluble in cold non-ionic detergents,
such as Triton X-100, and have a specific buoyant density during sucrose gradient
centrifugation (36). However, non-ionic detergents can also solubilize proteins that are
only weakly associated with lipid rafts, and also lipid and protein composition of rafts
can differ between different extraction methods (37-39). Therefore, I used a second
approach to isolate lipid rafts and validate our findings using a non-detergent procedure
that is based on pH and carbonate resistance of lipid raft domains (40).
Importantly, my data show for the first time that CHT proteins are highly concentrated in
lipid rafts prepared from SH-SY5Y cells that stably express the transporter (Figure 3-3).
Membrane lipid rafts from cells lysed in either 1 M Na2CO3 pH 11 or 0.5% Triton X-100
were isolated using sucrose density gradient ultracentrifugation (41, 42). Solubilized
proteins remain in the bottom fractions of the gradient (within 40% sucrose), whereas
proteins associated with lipid rafts float to the upper layers (between 5% and 30%
sucrose). To confirm isolation of lipid rafts, I also analyzed the distribution of flotillin-1,
a lipid raft protein (43), and EEA1, a non-raft protein (41), in gradient fractions. Thus,
CHT proteins are found predominantly in lipid raft fractions, and this distribution profile
is similar in cells lysed with either Na2CO3 (Figure 3-3A and 3-3C) or Triton X-100
(Figure 3-3B and 3-3D). Figure 3-3A and 3-3B show representative immunoblots for
CHT protein, with blotting membranes stripped and reprobed with anti-flotillin
antibodies and anti-EEA1 antibodies. The histograms displayed in Figure 3-3C and 3-3D
illustrate quantification of CHT protein distribution in sucrose density gradients by
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Figure 3-3
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Figure 3-3 CHT proteins are distributed between raft and non-raft membrane
domains.
Cells were lysed with either 1 M sodium carbonate pH 11 (A, C) or 0.5% Triton X-100
(B, D), then lipid rafts were isolated on sucrose gradients based on buoyant density. A,
Representative immunoblots of gradient fractions 1–12 obtained using the sodium
carbonate method showing CHT, non-raft marker EEA1 and raft-resident protein flotillin.
B, Representative immunoblots of gradient fractions 1–10 obtained using the Triton X100 method. (C, D) Densitometric analysis of CHT in raft and non-raft fractions
expressed as a percentage of total CHT for cells lysed in either sodium carbonate or
Triton X-100, respectively. To determine CHT protein distribution in membrane domains
in brain cholinergic neurons, lipid rafts were isolated from mouse forebrain
synaptosomes. E, Representative immunoblots of gradient fractions 1–12 obtained using
the sodium carbonate method, from data obtained in three independent experiments. F,
Densitometric analysis for CHT in raft and non-raft fractions prepared from
synaptosomes expressed as a percentage of total CHT. Data are mean ± SEM of three
independent experiments. G, Free cholesterol content was determined in raft (5) and nonraft (9–12) fractions from sucrose density gradients using the Amplex Red Cholesterol
Assay Kit (Invitrogen) and normalized to sample protein content. Raft fraction #5
contains the highest cholesterol content when compared to the non-raft fractions #9–12.
Data are expressed as the mean ± SEM of three independent experiments.
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densitometry. Enrichment of CHT proteins in lipid rafts is seen with 85 ± 10% and
85 ± 6% of total CHT present in pooled flotillin-positive raft fractions, compared to
15 ± 6% and 15 ± 5% of total CHT present in EEA1-positive non-raft fractions from cells
lysed with Na2CO3 and Triton X-100, respectively.
To confirm if CHT proteins are also present in lipid rafts in brain cholinergic nerve
terminals, I prepared purified synaptosomes from mouse forebrain. Synaptosomes were
lysed in 1 M Na2CO3, then membrane lipid rafts were isolated on sucrose density
gradients and immunoblots performed for CHT, EEA1, and flotillin. Figure 3-3E shows a
representative immunoblot of the distribution of these proteins in gradient fractions.
Importantly, in confirmation of my findings using cultured neural cells, a substantial
proportion of CHT protein was found in lipid raft fractions. Densitometric quantification
of CHT protein on immunoblots revealed that 47 ± 5% is present in fraction #5 that also
coincides with the greatest density of the lipid raft protein flotillin. This is compared to
53 ± 15% in EEA1 positive non-raft fractions #9-12 (Figure 3-3F). Interestingly, the
maximum CHT protein distribution in fractions #5 and 12 coincide with higher levels of
free cholesterol content (Figure 3-3G)

3.3.4

CHT colocalizes with the lipid raft makers flotillin and
ganglioside GM1

Confocal imaging experiments where cell surface CHT proteins were fluorescently
labeled in live SH-SY5Y cells allowed further assessment of distribution of the
transporter in raft and non-raft membrane domains. I assessed the colocalization of CHT
with CTB, which binds to ganglioside GM1 and is found concentrated in lipid rafts (44),
along with either flotillin (raft marker) or EEA1 (non-raft marker). To identify
colocalized proteins, a threshold fluorescence intensity was set that filters for the
brightest 2% of pixels of CHT (red channel) that also fall within the brightest 2% of
pixels of GM1 (blue channel) and either flotillin (green channel) or EEA1 (green
channel); this approach to visualize protein colocalization was validated previously (45).
The colocalized pixels are identified in a separate colocalization channel (shown as
‘Colocalized pixels’ images). I found that CHT colocalizes to a similar extent with both
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Figure 3-4
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Figure 3-4 CHT proteins colocalize with flotillin and cholera toxin-labeled GM1,
and to a lesser extent with EEA1.
Panel A, Confocal images show the distribution in SH-SY5Y cells of Zenon 488-labeled
CHT (red), AlexaFluor 555-labeled flotillin (green), and AlexaFluor 647-labeled cholera
toxin subunit B (CTB) binding to GM1. The Zenon 555 dye conjugated to rabbit antiFLAG antibody was added to medium bathing live cells for 15 min where it could bind to
the FLAG epitope of the amino terminus of CHT located at the cell surface. This
facilitated tracking of CHT proteins at the cell surface, and as they are internalized into
and traffic within cells. Cells were then formalin fixed and stained for endogenous
ganglioside GM1 and flotillin. Colocalization of CHT and flotillin is yellow in Overlay
panels and colocalization of CHT and GM1 is white in Overlay panels. Images were
analyzed as described in Methods. CHT and flotillin determined to be colocalized in the
colocalization channel are shown as yellow in the ‘Colocalized pixels’ image, and CHT
and GM1 determined to be colocalized in the colocalization channel are shown as purple
in the ‘Colocalized pixels’ image. Panel B, Confocal images show Zenon 555-labeled
CHT (red), AlexaFluor 488-labeled EEA1 (green), and AlexaFluor 647 CTB-labeled
GM1 distribution. Colocalization of CHT and EEA1 is yellow and colocalization of CHT
and GM1 is white in the Overlay panels. CHT and EEA1 determined to be colocalized in
the colocalization channel are shown as yellow in the ‘Colocalized pixels’ image and
CHT and GM1 determined to be colocalized in the colocalization channel are shown as
purple in the ‘Colocalized pixels’ image. Data are representative of 10 cells from four
independent experiments. Scale bar, 5 μm.
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GM1 (Figure 3-4A, colocalized pixels shown in purple) and flotillin (Figure 3-4A,
colocalized pixels shown in yellow), and that all three proteins are found together in a
punctate distribution pattern indicative of lipid rafts (triple colocalized pixels panel not
shown). In contrast, in cells stained for EEA1 and GM1, I found that CHT appears to be
found more in GM1-positive compartments (Figure 3-4B, colocalized pixels shown in
purple) than colocalized with EEA1 (Figure 3-4B, colocalized pixels shown in yellow).

3.3.5

Effect of cholesterol manipulating drugs on cholesterol level
in SH-SY5Y cell membranes

I analyzed the effect of treatment of SH-SY5Y cells with either MβC or filipin on free
and esterified cholesterol content in pooled lipid raft fractions (#4–6) and non-raft
fractions (#9–12) obtained from sucrose gradients (Figure 3-5). As expected, total
cholesterol levels were higher in lipid raft fractions when compared to non-raft fractions,
with about 65% of the cholesterol contained in rafts (data not shown). Filipin, which
functionally depletes cholesterol by forming filipin–cholesterol complexes within the
membrane, did not significantly alter cholesterol levels. In cells treated with 5 μg/mL
filipin, cholesterol levels were 7.2 ± 0.5 and 3.9 ± 0.5 μmol/μg protein in raft and non-raft
fractions, respectively, compared to vehicle-treated controls where cholesterol levels
were 7.2 ± 0.4 and 3.9 ± 0.3 μmol/μg protein in lipid raft and non-raft fractions,
respectively (Figure 3-5A). In contrast, treatment of cells with 0.3 mM MβC, which
extracts cholesterol from membranes, significantly reduced cholesterol content in raft
fractions but not in non-raft fractions; in MβC-treated cells, cholesterol levels were
6.8 ± 0.4 and 3.7 ± 0.5 μmol/μg protein in raft fractions and non-raft fractions,
respectively, compared to 7.7 ± 0.3 and 3.8 ± 0.4 μmol/μg protein in raft and non-raft
fractions, respectively, in vehicle-treated cells (Figure 3-5B). This corresponds to a
cholesterol reduction of approximately 10% in lipid raft fractions, which compares with
the findings of Foster et al. (2008) (46) who showed that treatment of cells with a much
higher concentration of MβC (5 mM) causing a 52% reduction in cholesterol in lipid raft
fractions.
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Figure 3-5 The effect of treatments that manipulate membrane cholesterol on
cholesterol levels in raft and non-raft fractions from SH-SY5Y cells.
Cholesterol content was determined using the Amplex Red Cholesterol Assay kit and
normalized to sample protein content. Methyl-β-cyclodextrin (MβC), but not filipin,
significantly decreased cholesterol levels in lipid raft fractions. A, No changes in
cholesterol content were observed in cells treated with filipin. B, MβC caused a
significant reduction in cholesterol content in lipid raft fractions, but not non-raft
fractions. Samples were measured from pooled raft fractions (#4–6) and non-raft
fractions (#9–12) and data are expressed as % of control. Data were analyzed by oneway anova followed by Tukey's post-test and are given as the mean ± SEM of four
independent experiments. *p < 0.05, paired Student's t-test.
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3.3.6

Lipid raft disruption decreases plasma membrane CHT
protein levels

Kinetic analysis of [3H]HC-3 binding to CHT (Figure 3-2) revealed that MβC treatment
of cells decreases Bmax, suggesting that the number of CHT proteins at the plasma
membrane is decreased. To confirm this and extend my studies on how lipid raft
disruption alters CHT localization at the plasma membrane, we undertook cell surface
protein biotinylation experiments. CHT proteins are located predominantly in subcellular
endocytic compartments and synaptic vesicles (16) that also contain lipid rafts. Since we
wanted to examine the relative distribution of CHT within lipid rafts only at the cell
surface, plasma membrane proteins were biotinylated using membrane impermeable
sulfo-NHS-biotin at 4°C to ensure that labeled CHT proteins did not undergo
endocytosis. Prior to protein biotinylation, cells were treated at 37°C with either 5 μg/mL
filipin, 0.3 mM MβC or vehicle. Na2CO3-insoluble lipid rafts were isolated, then
biotinylated proteins were recovered from the pooled raft and non-raft fractions for
analysis.
A critical finding is that modification in membrane cholesterol by either filipin or MβC
reduced the amount of CHT protein in plasma membrane lipid raft fractions, but not in
non-raft fractions (Figure 3-6). Representative immunoblots show the levels of cell
surface (biotinylated) CHT protein, and the amount of total CHT protein, flotillin-1, and
EEA1 in raft and non-raft fractions from cells treated with either filipin (Figure 3-6A) or
MβC (Figure 3-6B). In vehicle-treated cells, plasma membrane CHT proteins are
concentrated in lipid rafts with a distribution similar to that seen for total cellular CHT
protein. Cell surface CHT levels in raft fractions were significantly reduced by
approximately 50% in both filipin- and MβC-treated cells when compared to vehicletreated cells (p < 0.05) (Figure 3-6C and 3-6D). This does not reflect redistribution of
CHT to non-raft areas of plasma membrane, as changes were not observed in CHT levels
in non-raft fractions between vehicle- and drug-treated cells. Immunoblots for cell
surface CHT were reprobed with anti-flotillin and anti-EEA1 antibodies to confirm the
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Figure 3-6 Filipin and MβC decrease cell surface CHT proteins in lipid rafts.
Cells were treated at 37°C for 60 min with vehicle (methanol) or 5 μg/mL filipin (A, C,
E), or for 30 min with vehicle (H2O) or 0.3 mM MβC (B, D, F). Cells were washed and
placed on ice, then plasma membrane proteins were biotinylated. Sodium carbonateresistant lipid rafts were prepared and biotinylated proteins were isolated from the pooled
raft (#4–6) and non-raft (#9–12) fractions. (A and B) Representative immunoblots for
CHT dimer, cell surface (biotinylated) CHT, total CHT, lipid raft-resident protein flotillin
and non-raft marker EEA1. (C and D) Densitometric analysis of cell surface CHT in raft
and non-raft fractions from cells treated with vehicle or drug shows a statistically
significant reduction in cell surface CHT in lipid rafts in drug-treated cells compared with
control. Data were analyzed by repeated measures one-way ANOVA followed by
Tukey's post hoc test, and are expressed as mean ± SEM of four independent experiments
*p < 0.05. (E and F) Increased exposures of cell surface CHT immunoblots shown in (A
and B) reveal CHT-immunopositive bands that likely represent CHT dimers in lipid raft
fractions. Densitometric analysis of CHT dimers shows a statistically significant
reduction in lipid rafts from drug-treated cells compared with control. Data are expressed
as mean ± SEM of four independent experiments. (*p < 0.05, paired Student's t-test).
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isolation of lipid rafts. As predicted, flotillin-1 levels in raft fractions were reduced in
drug-treated cells confirming disruption of lipid rafts. No changes in EEA1 levels or
distribution were observed between samples from vehicle- and drug-treated cells. Taken
together, these results suggest that total cellular and cell surface CHT proteins are
partitioned similarly between lipid raft and non-raft membrane domains in SH-SY5Y
cells, with lipid raft disruption resulting in reduced cell surface CHT in lipid rafts.
It is important to note the presence of CHT-immunopositive bands with an apparent
molecular mass of about 100 kDa in lipid raft fractions at higher exposures of the
immunoblots for cell surface CHT proteins (Figure 3-6A and 3-6B). These bands, which
are not present in the non-raft fractions, likely represent CHT protein dimers. In both
filipin- and MβC-treated cells, levels of the putative CHT dimers at the cell surface are
significantly reduced by about 50% (p < 0.05) (Figure 3-6E and 3-6F)

3.3.7

Lipid raft disruption does not alter CHT internalization from
the cell surface

CHT proteins at the cell surface undergo constitutive internalization by a clathrinmediated mechanism into early endosomes, and these proteins can recycle back to the
cell surface (17). I tested the hypothesis that the decrease in plasma membrane CHT
protein in filipin- and MβC-treated cells is because of an increase in internalization of
CHT. SH-SY5Y cell plasma membrane proteins were biotinylated on ice, and then cells
were incubated at 37°C with either vehicle, 0.3 mM MβC or 5 μg/mL filipin to allow
endocytosis of proteins from the cell surface to subcellular organelles. Only internalized
biotinylated proteins were measured as, following drug treatments, cells were returned to
ice to terminate endocytosis and residual biotin remaining on cell surface proteins was
stripped by membrane-impermeant MesNa. Figure 3-7 illustrates that neither filipin nor
MβC significantly alters CHT internalization from the cell surface to subcellular
organelles. The amount of internalized biotinylated CHT protein was normalized to total
cell surface CHT levels from cells that were incubated on ice in the absence of either
filipin or MβC (Figure 3-7A and 3-7C, lane 2). A separate set of cells was incubated on
ice throughout the procedure to ensure that MesNa efficiently stripped biotin from cell
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Figure 3-7 Lipid raft disruption does not alter CHT internalization.
Cell surface proteins were biotinylated for 1 h at 4°C, then cells were warmed to 37°C
and CHT proteins allowed to internalize in the presence of vehicle or drug. A,
Representative immunoblots for total and surface CHT showing no change in CHT
internalization at 15, 30, and 60 min in cells treated with 5 μg/mL filipin compared with
control. C, Representative immunoblots for total and surface CHT showing no change in
CHT internalization at 15 and 30 min in cells treated with 0.3 mM methyl-β-cyclodextrin
(MβC) compared with control. (B and D) Histograms show quantification of
immunoblots for CHT internalization, with internalized CHT normalized to total cell
surface CHT in each experiment. Data were analyzed by repeated measures oneway ANOVA followed by Tukey's post hoc test and expressed as mean ± SEM of five
independent experiments. (* measurement at 60 min is statistically different from
15 min, p < 0.05).
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surface proteins (Figure 3-7A and 3-7C, lane 1). Immunoblots of cell lysates (Figure 37A and 3-7B, lower panels) show that there were no changes in total CHT levels in cells
as a consequence of the treatments. A statistically significant time-related increase in
internalized CHT was observed in cells treated with either vehicle or filipin at 60 min
when compared to 15 min, but no other statistically significant changes between groups
were found (Figure 3-7B and 3-7D).

3.3.8

Identification of putative cholesterol-binding motifs in CHT
protein

Transmembrane proteins may bind cholesterol molecules, with the two most common
sites for this interaction on the protein being the Cholesterol Recognition/interaction
Amino acid Consensus sequence (CRAC domain) and the CARC domain that comprised
an inverted CRAC domain sequence (47, 48). The definition of both of these motifs is
based on a triad of basic (K or R), aromatic (Y or F), and aliphatic (L or V) residues. The
CRAC domain sequence is defined as L/V-(X)1-5-Y-(X)1-5-R/K, where X can be one to
five residues of any amino acid. The CARC domain is the reverse sequence and the
residue Y may be substituted by F. Analysis of the primary sequence of rat CHT reveals
putative cholesterol-binding motifs, with these being conserved between rodent and
human proteins. As illustrated in Figure 3-8, candidate sequences for putative CRAC and
CARC domains are found in TMD 4, 11, 12, and 13 of CHT. TMD 4 contains the CARC
sequence R-X5-F-X3-L that could bind cholesterol in the plasma membrane cytoplasmic
leaflet. TM 13 contains a CRAC sequence V-X1-Y-X2-K, also on the bilayer cytoplasmic
side. CRAC-like motifs, bearing close similarity to CRAC sequences, that could
potentially bind cholesterol on the cytoplasmic leaflet are in TM 11 and 12 [TM 11, LX3-F-X1-K or L-X4-F-X1-K; TM 12, V-X2-Y-X6-R]. In addition to cholesterol binding to
CRAC and CARC motifs, transmembrane domains containing G-XXX-G motifs may
also be engaged in binding cholesterol molecules (48, 49). Importantly, as shown in
Figure 3-8, TMD 12 of CHT has a conserved G-XXX-G-XXX-G motif (G-AVA-GYVS-G) that could potentially serve as both a cholesterol-binding motif and as a
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Figure 3-8 Schematic representation of transmembrane topology of rat high-affinity
choline transporters showing putative cholesterol-binding motifs.
The positions of putative CRAC-like and CARC sequence motifs are shown in
transmembrane domains 4, 11, 12, and 13. The positioning of transmembrane domains
shown is based on data for human CHT [Q9GZV3] submitted recently to
UniProtKB/Swiss-Prot athttp://www.uniprot.org/uniprot/Q9GZV3 [Last modified July
24, 2013]; rat and human CHT share 93% sequence identity.
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dimerization motif. This sequence of the protein also coincides with a CRAC-like
domain.

3.4 Discussion
I made several novel findings in this study that indicate that partitioning of CHT proteins
into cholesterol-rich lipid rafts, and potentially direct interaction of CHT with cholesterol,
may play a critical role in CHT localization at the cell surface and activity. I showed for
the first time in both SH-SY5Y cells and mouse brain cholinergic nerve terminals that
CHT proteins are partitioned between membrane lipid raft and non-raft microdomains,
and tend to be concentrated in lipid rafts. Microscopically, CHT proteins colocalize with
the lipid raft-resident protein flotillin and the lipid raft marker ganglioside GM1, and to a
lesser extent with the non-raft protein EEA1. Second, I found that choline uptake activity
shows a dependence on membrane cholesterol levels. Thus, treatment of neural cells with
the cholesterol interfering drugs filipin, cholesterol oxidase, or MβC causes a significant
decrease in HC-3-sensitive choline uptake. Moreover, choline uptake is significantly
increased by adding exogenous cholesterol to cells. Third, I determined that reducing cell
membrane cholesterol levels and disrupting lipid rafts by extracting cholesterol with
MβC decreased the number of cell surface CHT proteins when measured by [ 3H]HC-3
binding to CHT (decreased Bmax) and enhanced ligand binding affinity (decreased KD).
Fourth, I observed that treatment of cells with filipin and MβC results in a decrease in
plasma membrane CHT protein levels from lipid rafts, but not non-raft areas, measured
by cell surface protein biotinylation. This is not related to an accelerated rate of CHT
protein internalization. Finally, I identified putative cholesterol-binding motifs in CHT
protein that are conserved between rodent and human.
I used four separate pharmacological approaches that alter membrane cholesterol by
different mechanisms to assess how cholesterol may regulate CHT function and activity.
Treatment of cells with cholesterol oxidase results in conversion of membrane cholesterol
to its functionally inactive analogue steroid 4-cholesten-3-one, but does not alter the
physical state of plasma membranes (31). This allowed me to test if the change in choline
uptake activity in choline oxidase-treated cells is owing to altered membrane fluidity,
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rather than a change in membrane cholesterol levels. Based on my findings, it is unlikely
that the decrease in choline uptake observed in these cells is because of an alteration of
membrane fluidity. In other experiments, I treated cells with MβC which extracts cellular
cholesterol and can disrupt lipid rafts and cholesterol–protein interactions in both raft and
non-raft areas (30). Low concentrations of MβC (0.3 mM) significantly decreased
cholesterol content measured in membrane lipid raft fractions and resulted in decreased
choline uptake activity. However, it is not possible to determine from these experiments
if the loss of CHT activity is caused by a direct or indirect effect of lowering cholesterol.
Filipin, which binds to and chelates free cholesterol within the membrane resulting in
disruption of lipid rafts, was not expected to lower cholesterol levels and our results are
in agreement with previous reports with filipin and the polyene antifungal agent nystatin
(29, 35). Filipin treatment did, however, reduce choline uptake activity, suggesting that
disruption of lipid rafts does impact CHT function. Finally, I incubated cells with MβC–
Chol to increase membrane cholesterol levels and this significantly enhanced choline
uptake. Based on these experimental manipulations, it appears that CHT function requires
the presence of membrane lipid rafts and may also be modulated by changes in
cholesterol levels, indicating a potential role for direct interaction between cholesterol
and CHT proteins.
Decreased choline uptake in cells treated with agents that reduce membrane cholesterol
could be because of a loss of functional transporters at the cell surface, or be the result of
conformational changes in CHT protein that alter solute binding affinity or impair solute
translocation subsequent to binding. Kinetic analysis of binding of the inhibitor [3H]HC-3
to CHT in MβC-treated cells and quantification of cell surface protein biotinylation
assays in cells treated with either filipin or MβC indicate that there is a reduction in CHT
levels at the plasma membrane. Interestingly, the decrease in CHT protein is seen in lipid
raft fractions prepared from either filipin- or MβC-treated cells and is not accompanied
by an increase in CHT levels in non-raft fractions, indicating that down-regulation of
choline uptake activity is not a result of CHT movement between these compartments.
Indeed, some proteins display redistribution between these membrane compartments in
response to lipid raft disrupting treatments, whereas other proteins do not (36). My results
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are in agreement with those found for the dopamine transporter (DAT) by Foster et al.
(2008) who showed that while MβC treatment reduced DAT cell surface levels, it did not
affect partitioning of DAT proteins between lipid raft and non-raft fractions. My finding
of increased binding affinity (KD) of CHT for HC-3 in MβC-treated SH-SY5Y cells is in
agreement with a report of increased HC-3 binding affinity to CHT observed in MβCtreated synaptosomes (25), and is similar to reports of increased ligand binding affinity
found for other neurotransmitter transporters, such as DAT in MβC-treated cells (29, 35).
The change in binding properties of CHT in MβC-treated cells could indicate that the
conformational state of CHT required for solute binding is modulated by either lipid raft
association or by cholesterol binding. Previous studies show that CHT proteins may exist
in more than one state or conformation and that binding sites in some states may be
occluded under some conditions (50, 51). Alternatively, changes to the physical
properties of lipid rafts may disrupt cholesterol-sensitive protein–protein interactions
involving CHT or affect the ability of CHT to undergo post-translational modifications
such as phosphorylation, both of which could affect solute binding or translocation (36,
45).
Membrane cholesterol and/or lipid rafts could have a role in regulating the amount of
CHT protein at the cell surface by altering its rate of internalization into endosomes
and/or its recycling back to the cell surface. Several reports suggest that proteins can
traffic to the plasma membrane and be selectively recruited to lipid raft microdomains
(52-54). We showed previously that alterations in CHT internalization critically affect
transporter function, while CHT recycling is required to maintain the level of transporter
at the cell surface thereby regulating CHT activity to deliver sufficient choline to
maintain ACh synthesis. CHT undergoes endocytosis by a clathrin- and dynamindependent mechanism, but there is no evidence that CHT internalizes by a clathrinindependent, caveolin-dependent process from lipid raft domains. In this study, we found
that CHT protein internalization was not significantly altered by disruption of membrane
cholesterol or rafts by either filipin or MβC, suggesting that the decrease in plasma
membrane CHT levels was not owing to increased endocytosis; while not measured in
my studies, reduced recycling of transporters to the cell surface could result in decreased
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cell surface levels of the protein. These experiments also reinforce that CHT proteins do
not likely undergo internalization by caveolae since, as lipid rafts were disrupted, an
increase in plasma membrane CHT protein would have been predicted. In the current
studies, cells were treated with a relatively low concentration of MβC (0.3 mM) since we
observed that higher concentrations of the drug (2 or 5 mM) used in other studies led to
accumulation of CHT proteins at the cell surface (data not shown). MβC can inhibit
clathrin-mediated endocytosis (55) and as CHT undergoes rapid constitutive endocytosis,
conditions that disrupt this process can result in substantial accumulation of the protein at
the cell surface. Thus, I chose to use an MβC concentration that significantly decreased
cholesterol levels in lipid rafts, and was less likely to perturb endocytosis.
Interestingly, we observed a CHT-immunopositive band with an apparent molecular mass
of about 100 kDa in lipid raft fractions. These bands could represent homo-oligomers of
CHT proteins, with recent work by Okuda et al. (2012) showing that CHT expressed in
cultured cells can form homo-oligomers at the cell surface. Here, my studies provide
evidence that these homo-dimers are located within lipid rafts, and that these are reduced
by lipid raft disrupting treatments. This suggests that oligomerization may result in
stabilization of CHT into the raft domain and be required for cell surface localization of
CHT. Detection of CHT in cell lysates often reveals multiple protein species and it has
been suggested that these represent varying glycosylated forms of CHT (57). CHT may
undergo differential post-translational modifications, such as phosphorylation, between
raft and non-raft areas of membrane, but it remains to be established if these impact either
CHT activity or plasma membrane trafficking. For example, activation of PKC enhances
internalization of the noradrenaline transporter through a dynamin- and clathrinindependent lipid raft-mediated process (32). In comparison, PKC-induced internalization
of DAT is dynamin and clathrin dependent, and is independent of lipid rafts (46).
Several lines of evidence support a connection between alterations in cholesterol levels
and its disposition in aging (58) and AD (59) and the organization of lipid rafts is
disrupted in AD brains (60). Here, my studies provide the first evidence that association
of CHT proteins with cholesterol-rich lipid rafts is critical for transporter function and
localization. These data are important for understanding the normal function of widely
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distributed cholinergic neurons, and how they are altered in disorders that involve
cognitive dysfunction owing to reduced cholinergic transmission. These studies will
allow us to analyze responses to changes in the cholinergic nerve endings and to assess
alterations in pathology to aide in the design of new therapies. Therapeutic strategies
directed at CHT function may be useful for enhancing cholinergic transmission, for
example, early in AD when ACh release is reduced but cholinergic neurons remain
viable. Given the projected increases in our aging population and the prevalence of
neurodegenerative disorders, these studies are both timely and critical.
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4.1 Introduction
Pathologically, two major features of AD are the processing of APP to Aβ, which are the
principal component of Aβ plaques, and the dysfunction and eventual loss of cholinergic
neurons. While these two features of AD pathology are well established, the connection
between them is not fully understood. APP is a type 1 transmembrane protein that exists
in three different isoforms (APP695, APP751 and APP770) as a result of differential
splicing of exons 7 and 8 (1), with APP695 being the main isoform expressed in neurons
(2). APPwt is trafficked to the cell surface where it undergoes two distinct pathways of
proteolytic processing. Amyloidogenic processing of APPwt is thought to occur within the
endosomal pathway, where it is cleaved first by BACE1, followed by the γ-secretase
complex, resulting in Aβ production (3). Non-amyloidogenic processing occurs mainly at
the cell surface, where APPwt is cleaved by α-secretases within the Aβ domain (4).
Inheritable mutations in the genes encoding APP can alter subcellular trafficking and
proteolytic processing of APP. For example, APP695 containing the Swedish mutation
(K595N/M596L) (APPSwe), which causes early-onset familial AD by increasing Aβ
production by 6- to 8-fold, undergoes high-efficiency BACE1 cleavage primarily within
the TGN and secretory pathway (5, 6), and exhibits differences in its trafficking from the
cell surface through the endosomal pathway compared to APPwt (7).
The relationship between APP and cholinergic dysfunction is not well understood.
Evidence suggests that cholinergic neurotransmission promotes α-cleavage of APP
through ACh stimulation of specific muscarinic AChR subtypes (8), while in turn Aβ
oligomers inhibit ACh synthesis and release (9-11). Importantly, high-affinity choline
uptake in rat brain hippocampal synaptosomes is impaired by exposure to picomolarnanomlar concentrations of Aβ (11, 12). An important link between APPwt and the
cholinergic system identified recently shows a direct physiological role for APP within
cholinergic neurons by demonstrating that APPwt interacts with CHT, mediating its
presynaptic localization and increasing its rate of internalization from the cell surface
(13).
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Altering CHT trafficking has a direct impact on choline uptake activity and cholinergic
neurotransmission (16). The purpose of this study was to further investigate how APP wt
regulates CHT trafficking and activity, and to determine whether this interaction is
altered by the Swedish mutation. Here, I observed that CHT protein interacts significantly
less with APPSwe than with APPwt. Interestingly however, the expression of either APPwt
or APPSwe decreased CHT cell surface levels and CHT activity, and increased CHT
colocalization to early endosomes, to the same extent. In these experiments, neural cells
expressing APPSwe secreted significantly more Aβ than did cells expressing APPwt.
Importantly, lowering the production of Aβ through BACE1 inhibition significantly
increased CHT cell surface level in cells expressing APPSwe, but not in cells expressing
APPwt compared to vehicle-treated control cells. I confirm here that APPwt interacts
directly with CHT and make the novel observation that the interaction of CHT with APP
is disrupted by the Swedish mutation. Furthermore, I propose that CHT function is
inhibited by both APPwt and APPSwe, but the underlying mechanisms by which this
occurs differ. My data reveal that APPwt facilitates CHT endocytosis, while APPSwemediated inhibition of CHT function could be caused by the susceptibility of the
transporter to Aβ found in the extracellular environment.

4.2 Materials and methods
4.2.1

Materials

BACE1 inhibitor IV was obtained from Calbiochem, anti-FLAG M2 affinity gel, mouse
IgG-agarose, Duolink in situ orange starter kit mouse/rabbit, protease inhibitor cocktail
and polyclonal rabbit anti-APP c-terminal antibody were from Sigma-Aldrich, β-amyloid
1-16 (6E10) mouse monoclonal antibody was from Covance, rabbit polyclonal anti-actin
antibody was from Santa Cruz Biotechnology, anti-amyloid precursor protein A4 (clone
22C11) was from Millipore and [methyl-3H]choline chloride (88.5 Ci/mmol) was
from PerkinElmer Life Sciences. Other chemicals were purchased from Sigma-Aldrich at
the highest purity available. SH-SY5Y human neuroblastoma cells were from the
American Type Culture Collection, and Invitrogen supplied FBS, Lipofectamine 2000,
OptiMEM, and culture media and reagents. AlexaFluor 555 donkey anti-mouse IgG and
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AlexaFluor 647 goat anti-rabbit IgG antibodies were from Invitrogen. ECL was from GE
Healthcare Life Sciences and Biodegradable Scintillant was from GE Healthcare.
Polyclonal

CHT

antibody was

raised

in

rabbits

to

the

antigenic

peptide

DVDSSPEGSGTEDNLQ, which is conserved at the carboxyl-terminus of human and rat
CHT (Genemed Synthesis); this peptide was conjugated to KLH carrier protein by an Nterminal cysteine residue. CHT-specific IgG was affinity-purified in our laboratory from
the crude antiserum on NHS-Sepharose (GE Healthcare) to which antigenic peptide had
been coupled as the binding element. Peroxidase-conjugated goat anti-rabbit IgG was
from Jackson ImmunoResearch Laboratories.

4.2.2

Cell transfection and selection of cell lines

Full-length rat CHT cDNA ligated to pSPORT was a gift from Dr. T. Okuda (14); a
FLAG epitope tag (DYKDDDDK) was added to the amino-terminus by PCR and the
resulting cDNA ligated to pcDNA3.1 or pcDNA5. SH-SY5Y cells were transfected with
FLAG-CHT cDNA ligated to pcDNA3.1 by Lipofectamine 2000. Stable transformants
(SY5Y-CHT) were selected using 500 μg/ml G418 for 4 weeks, and then grown in
DMEM containing 10% FBS, 100 U/ml penicillin, and 100 μg/ml each of streptomycin
and 100 μg/ml G418. SH-SY5Y cell differentiation was induced by the addition of 10
μM RA for 3 d; substantial morphological and biochemical differentiation of cells
occurred during this time frame.
For transient transfection, cells were plated and treated with retinoic acid for 3 d before
transfection, and immediately before transfection the culture medium was changed to
complete medium that did not contain antibiotics. At the time of transfection, 1 μg of
plasmid DNA in 100 μl of OptiMEM was added to 100 μl of OptiMEM containing 2.5 μl
of Lipofectamine 2000, and then incubated for 20 min at room temperature. This mixture
was added to monolayers of cells in antibiotic-free medium and incubated for 4-6 h. At
the end of the incubation with transfection reagents, culture medium was replaced with
complete medium containing RA and grown for an additional 24 h.
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4.2.3

DNA constructs

Full-length human wild-type APP695 (APPwt) and APP695 containing the Swedish
mutation K595N/M596L (APPSwe) cDNA plasmids were generated by Dr. Dennis Selkoe
(15) and obtained from Addgene (Addgene plasmid 30137 and Addgene plasmid 30145,
respectively). SY5Y-CHT cells were transiently transfected with a ratio of 1 μg APP wt
plasmid DNA : 1.5 μg APPSwe plasmid DNA in all experiments to obtain equal levels of
expression of these two proteins. Control cells were transiently transfected with the
empty vector pcDNA3.1. In some confocal imaging experiments, cells were transiently
transfected with plasmids encoding cDNA for either full-length human HA-labeled
APP750-YFP (APPwt-YFP) or HA-labeled APP750-YFP containing the Swedish
mutation (APPSwe-YFP) to mediate expression of these fusion proteins.

4.2.4

Co-immunoprecipitation of FLAG-CHT and wild-type or
Swedish mutant APP

Either SY5Y-CHT cells or SH-SY5Y cells stably-expressing pcDNA3.1 empty vector
were plated on 100 mm dishes, then transiently transfected with either 6 μg APP wt
plasmid DNA or 9 μg APPSwe plasmid DNA using Lipofectamine 2000, according to
manufacturer’s instructions. For a control, cells were transfected with 9 μg pcDNA3.1. In
experiments where BACE1 activity was to be inhibited, cells were incubated in complete
medium containing either vehicle (DMSO) or 25 µM BACE1 inhibitor IV immediately
following transfection. Twenty-four hours after transfection, cells were lysed with 1%
Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100,
700 Units/ml DNase I and 10µL/mL protease inhibitor cocktail), then sample protein
concentration was measured using a BioRad protein assay reagent. Aliquots of cell
lysates containing 500 μg lysate protein were pre-cleared for 60 min with 50 μl mouse
IgG-agarose, then incubated overnight with 100 μl of washed anti-FLAG M2 affinity
resin. Alternatively, following pre-clearing, lysates were incubated on ice for 30 min with
2µL of anti-APP A4 (22C11) antibody and then incubated overnight with 50 µL of
washed Protein-G Sepharose. Anti-FLAG affinity resin with bound proteins and ProteinG Sepharose with bound proteins were collected by centrifugation and washed 3 times
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with lysis buffer to remove non-specifically bound proteins. Proteins were eluted by
incubation for 10 min at 55°C with Laemmli sample buffer (0.125 M Tris-HCl, pH 6.8,
4% SDS, 20% glycerol, 0.01% bromophenol blue, 5% 2-mercaptoethanol), then
separated on 7.5% SDS-PAGE gels and transferred to PVDF membranes. Membranes
were blocked in 8% non-fat dry milk in wash buffer (PBS with 0.15% Triton X-100) for
1 h, then incubated overnight at 4°C with anti-CHT (1:1000) antibody or anti-APP terminal antibody (1:1000). After washing, membranes were incubated for 1 h in wash
buffer containing 8% milk and peroxidase-conjugated goat anti-rabbit IgG secondary
antibody. Immunoreactive proteins on membranes were detected by chemiluminescence
using a Chemidoc Imaging System (BioRad).

4.2.5

Proximity ligation assay

To evaluate the interaction between CHT and either APPwt or APPSwe in situ, we used a
proximity ligation assay (PLA) method using Duolink technology (Sigma). In these
experiments, SY5Y-CHT cells grown on 35 mm confocal dishes were transiently
transfected with 1 µg APPwt plasmid DNA or 1.5 µg APPSwe plasmid DNA and allowed
to express for 24 h. Cells were then washed twice with warm HBSS, formalin-fixed for
15 min at room temperature and then blocked for 30 min at room temperature in blocking
solution (HBSS containing 3% goat serum). Cells were then labeled with primary
antibodies against either CHT (anti-CHT 1:500) or APP (anti-APP 6E10 1:100) in
blocking solution. Cells were then washed twice in HBSS and incubated with Duolink
secondary antibodies (Duolink in situ PLA probe anti-rabbit PLUS and Duolink in situ
PLA probe anti-mouse MINUS). Following binding of probes to target CHT and either
APPwt or CHT and APPSwe, protein complexes cells were washed twice in Duolink Wash
Buffer A and then incubated in ligation solution (1 U/µL DNA ligase) for 30 min at
37°C. Cells were then washed twice in Duolink Wash Buffer A and the hybridized DNA
molecule was amplified by rolling-circle amplification by incubation of the cells in
amplification solution (10 U/µL DNA polymerase) containing fluorescently-labeled
oligonucleotides for 100 min in the dark at 37°C. Cells were then washed twice with
Duolink Wash Buffer B and allowed to dry. Dishes were then mounted with coverslips
using Duolink in situ mounting media containing DAPI, and images were acquired using
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a Zeiss LSM510-Meta laser scanning confocal microscope using a 63X magnification
oil-immersion objective. Imaris software version 7.7.0 was used to count the number of
spots per cell signifying an interaction between either APPwt and CHT or APPSwe and
CHT protein complexes. As a control, background spots per cell were counted in cells
that had not been transfected. Statistical analysis was performed using GraphPad Prism
using one-way ANOVA with Tukey’s post-hoc test.

4.2.6

Cell surface protein biotinylation assay

SY5Y-CHT cells plated on 100 mm dishes were transiently-transfected with either 6 μg
APPwt plasmid DNA or 9 μg APPSwe plasmid DNA using Lipofectamine 2000 and
allowed to express for 24 h. For a control, cells were transfected with 9 μg empty vector.
In experiments where BACE1 activity was to be inhibited, cells were incubated in
complete medium containing either vehicle (DMSO) or 25 µM BACE1 inhibitor IV
immediately following transfection. Cells were then washed twice with cold HBSS and
placed on ice under cold HBSS to stop protein trafficking. Plasma membrane proteins
were biotinylated on ice by incubating with 1 mg/ml sulfo-NHS-SS-biotin in HBSS for 1
h. Unbound biotin was quenched by washing and incubating cells in cold 100
mM glycine in HBSS. After two further washes with HBSS, cells were lysed on ice for
30 min in 1% Triton X-100 lysis buffer. Neutravidin beads were incubated with cell
lysates for 1 h at 4°C with gentle mixing to bind biotin-labeled proteins to allow their
separation from the non-biotinylated proteins. Beads were then washed with lysis buffer
3 times and bound proteins were eluted by incubation for 10 min at 55°C with Laemmli
sample buffer. Aliquots of biotinylated proteins and total cell lysates were separated on
7.5% SDS-PAGE gels and transferred to PVDF membranes. Membranes were blocked in
8% nonfat dry milk in wash buffer for 1 h, and then incubated overnight with either antiCHT antibody (1:1000) or anti-APP c-terminal antibody (1:1000) in wash buffer with 8%
non-fat milk. After washing, membranes were incubated for 1 h with peroxidaseconjugated goat anti-rabbit IgG secondary antibody (1:10,000) in wash buffer containing
8%

milk,

and

washed

again.

Immunoreactive

proteins

were

detected

by

chemiluminescence using a Chemidoc Imaging System (BioRad). Immunopositive bands
(at ∼50-kDa for CHT protein and at ~100-kDa for APP) were quantified by
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densitometry. Bands for cell surface CHT were compared to vector-transfected control
cells in each experiment, which represented the basal cell surface CHT levels.

4.2.7

[3H]Choline uptake assay

Choline uptake activity was evaluated in SY5Y-CHT cells transiently transfected with 1,
2 or 4 µg APPwt plasmid DNA or 1, 2 or 4 µg of APPSwe plasmid DNA. Control cells
were transfected with 4 µg pcDNA3.1 DNA. Monolayers of cells were rinsed with warm
KRH, then incubated in KRH at 37oC for 15 min. Medium was then aspirated from cells
and choline uptake initiated by addition of KRH buffer containing 0.5 µM [3H]choline
(0.5 Ci/mmol) either with or without 1 µM HC-3. Uptake was stopped after 5 min by
placing cells on ice and washing with ice-cold KRH buffer. Cells were solubilized in 0.1
M NaOH, then aliquots taken for tritium quantification by liquid scintillation counting
and protein measurement.

4.2.8

Confocal imaging

Digital images of fixed cells were acquired with a Zeiss LSM510-Meta laser-scanning
confocal microscope using a 63x magnification oil-immersion objective and magnified 3
times. SY5Y-CHT cells plated on 35 mm confocal dishes were transfected with either
wild-type HA-tagged APP 750-YFP or HA-tagged APP 750-YFP containing the Swedish
mutation. Cells were allowed to express for 24 h. Cells were then washed twice in warm
HBSS and formaldehyde-fixed. Fixed cells were incubated first with anti-CHT (1:1000)
or anti-EEA1 (1:100) primary antibodies, then incubated with secondary antibodies rabbit
AlexaFluor 647 (1:1000), to label CHT, and mouse AlexaFluor 555 (1:1000), to label
EEA1. Images were then acquired using 488 nm excitation and 505-530 nm emission
wavelengths for APP; 543 nm excitation and 560-615 nm emission for EEA1; and 647
nm excitation and 650 nm emission using a long pass filter for CHT. Colocalization
analysis was performed on confocal images using Imaris software version 7.7.0 with the
Imaris Colocalization module (bit-plane) to examine the colocalization of the brightest
2% of pixels in each channel, as described previously (16). Graphing and statistical
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analysis of the data were performed with GraphPad Prism using one-way ANOVA with
Tukey's post-hoc test.

4.2.9

Aβ1-42 ELISA assay

SY5Y-CHT cells plated on 100 mm dishes were transiently-transfected with either 6 μg
APPwt or 9 μg APPSwe plasmid DNA using Lipofectamine 2000 and allowed to express
for 24 h. As controls,, cells were transfected with 9 μg vector DNA. The human Aβ1-42
released by cells was measured in culture media at 24 h following transfection using the
human Aβ1-42 ELISA kit (Invitrogen), according to the manufacturer’s protocols.

4.2.10

Data analysis

Data are presented as the mean ± SEM with n values representing the number of
independent experiments performed on separate populations of cells; each n value was
obtained from the average of multiple sample replicates in each experiment. Replicate
experiments were performed on cells cultured in successive passages as much as possible
to minimize inter-experiment variability, and intra-experiment variability between
replicate samples was minimal. GraphPad Prism 5 was used for data analysis. Statistical
significance was determined by unpaired Student’s t-test, or between groups using
repeated measures one-way ANOVA with Tukey’s post-hoc multiple comparison test, as
appropriate.

4.3 Results
4.3.1

CHT interacts more with APPwt than with APPSwe in a neural
cell line

My initial experiments were designed to confirm the interaction between CHT and APPwt
in a neural cell line, and to determine if CHT interacts with APP Swe and how this
compares to its interaction with APPwt. I used SY5Y-CHT cells stably-expressing FLAGtagged CHT protein as a model, with SH-SY5Y cells stably-expressing the empty vector
DNA without CHT serving as a negative control. Cells were transiently transfected with
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either empty vector or APPwt or APPSwe plasmid DNA and allowed to express for 24 h,
then either FLAG-CHT or APP and interacting proteins were recovered from cell lysates
using anti-FLAG affinity resin or anti-APP antibody and Protein-G Sepharose,
respectively. Figures 4-1A and B show representative immunoblots that were probed for
CHT protein using anti-CHT antibody or APP using anti-APP c-terminal antibody.
Importantly, the anti-APP immunoblot for APP proteins interacting with FLAG-CHT
shown in Figure 4-1A (top panel) reveals strong APPwt-positive protein bands (at ~100kDa) in SY5Y-CHT cells transfected to express APPwt, but only weak APPSwe-positive
protein bands (at ~100-kDa) in SY5Y-CHT cells transfected to express APPSwe. No
interacting APP-positive bands were present in co-IPs of lysates from SH-SY5Y cells not
expressing FLAG-CHT (vector), suggesting that the interaction is specific to CHT. These
data were verified in a reverse protocol using anti-APP antibody to recover APP and
interacting proteins. Thus, Figure 4-1B (top panel) shows the anti-CHT immunoblot for
CHT proteins interacting with APP revealing strong CHT-positive protein bands (at ~50
kDa) from lysates of SY5Y-CHT cells transfected to express APPwt, but only faint CHTpositive protein bands (at ~50 kDa) from lysates of SY5Y-CHT cells transfected to
express APPSwe. Again, no interacting CHT-positive bands were present from lysates of
SH-SY5Y cells not expressing FLAG-CHT (vector).
Quantification of the interacting APP and CHT protein bands (Figures 4-1A and B, top
panels) by densitometry reveals 3-fold less APPSwe-positive protein interacting with
FLAG-CHT in SY5Y-CHT cells expressing APPSwe, when compared to APPwt-positive
protein interacting with FLAG-CHT in SY5Y-CHT cells expressing APPwt (Figure 4-1C)
(p < 0.05). The APP-positive protein bands were normalised to the amount of FLAGCHT recovered on the anti-FLAG affinity resin. In agreement with these findings,
significantly less CHT-positive protein was found interacting with APP in SY5Y-CHT
cells expressing APPSwe, when compared to CHT-positive proteins interacting with APP
in SY5Y-CHT cells expressing APPwt (Figure 4-1D) (p < 0.05). The CHT-positive
protein bands were normalised to the amount of APP recovered on Protein-G Sepharose.

142

Figure 4-1
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Figure 4-1 CHT interacts to a greater extent with APPwt than with APPSwe in SY5YCHT cells and cultured cortical neurons.
A, FLAG-tagged CHT was isolated from SY5Y-CHT or SH-SY5Y cells stably
expressing empty vector that had been transiently transfected with either the APP wt or
APPSwe plasmids using anti-FLAG M2 affinity resin. Proteins were solubilized, separated
by SDS-PAGE and transferred to PVDF membranes. Membranes were probed with antiAPP c-terminal and anti-CHT antibodies (top 2 panels). Representative immunoblots
show total APP, FLAG-CHT and actin proteins in total cell lysates (bottom 3 panels).
Lysates prepared from SH-SY5Y cells not expressing CHT protein (vector) were used as
a negative control (left 3 lanes). The immunoblots shown are representative of data
obtained from 5 independent experiments. B, APP was isolated from SY5Y-CHT or SHSY5Y cells stably expressing empty vector that had been transiently transfected with
either the APPwt or APPSwe plasmids using Protein-G Sepharose. Representative
immunoblots show total APP, FLAG-CHT and actin proteins in total cell lysates (bottom
3 panels). The top two panels illustrate APP proteins recovered on protein G Sepharose
probed with anti-CHT antibody and anti-APP antibody. The immunoblots shown are
representative of data obtained from 3 independent experiments. C, Analysis of the
interacting APP immunobands in A by densitometry revealed that significantly less
APPSwe interacts with CHT than does APPwt (*p < 0.05). Data were analysed by unpaired
Student’s t-test and are expressed as the mean ± SEM of 5 independent experiments. D,
Analysis of the interacting CHT immunobands in this Figure B by densitometry revealed
that significantly less CHT interacts with APPSwe than does APPwt (*p < 0.05). Data were
analysed by unpaired Student’s t-test and are expressed as the mean ± SEM of 3
independent experiments.
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4.3.2

In-situ proximity ligation assay (PLA) detection of the
interaction of CHT with APPwt and APPSwe

The FLAG pull-down assay and co-immunoprecipitation experiments shown in Figure 41 allowed me to observe stable protein interactions between either CHT and APPwt or
CHT and APPSwe, but they do not reveal more transient interactions or the distribution of
the interacting proteins within individual cells. To address this, and to confirm my
findings above, I used in situ PLA to examine protein-protein proximity between either
CHT and APPwt or CHT and APPSwe in formalin-fixed SY5Y-CHT cells.
Figure 4-2A shows representative confocal images of SY5Y-CHT cells transiently
expressing either APPwt (top panel) or APPSwe (lower panel). The interacting protein
complexes are visualized as bright fluorescent red spots and the cell nuclei are visualized
in blue. The numbers of discrete spots per cell were quantified and enumerated using
Imaris Software version 7.7.0, and are shown in white in Figure 4-2A, far right panels.
Interestingly, as shown in Figure 4-2A, I found that interacting CHT and APPwt protein
complexes appear to be distributed throughout both the cell body and neuritic projections,
whereas CHT and APPSwe appear to interact primarily within the cell body. Furthermore,
and consistent with the results of my anti-FLAG affinity pull-down assay and coimmunoprecipitation experiments, quantification of the number of spots per cell revealed
a significantly lower number of interacting CHT and APPSwe protein complexes in cells
expressing APPSwe (69 ± 5 puncta per cell) compared to interacting CHT and APPwt
protein complexes in cells expressing APPwt (108 ± 8 puncta per cell) (p<0.05) (Figure
2B). In some images, a small number of interacting endogenous APP and CHT punctate
spots were present in surrounding untransfected cells and these were subtracted from the
final number of spots counted per image. No bright fluorescent red spots were found to
be present in negative control cells where primary antibodies were omitted, and cells
labeled with secondary probes alone (data not shown). To confirm that this observation
was not related to differences in primary antibody immunostaining due to differences in
APP or CHT protein expression, SY5Y-CHT cells transiently-expressing
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Figure 4-2
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Figure 4-2 In-situ proximity ligation assay demonstrating the greater interaction of
CHT with APPwt than with APPSwe.
A, Confocal microscopy was used to image the interaction of APPwt (top panel) or
APPSwe (lower panel) with CHT proteins. SH-SY5Y cells stably expressing CHT were
transiently transfected with either APPwt or APPSwe, then labeled with primary antibodies
directed against CHT (rabbit anti-CHT) or APP (mouse anti-APP 6E10). The binding of
the probes (oligonucleotide-linked secondary antibodies) to CHT and APP proteins in
close proximity (~30-40 nm) allowed the hybridization of the DNA strands and ligation
into a circular DNA molecule. This DNA circle was then amplified using rolling circle
amplification and detected by the hybridization of fluorescently-labeled oligonucleotides.
The signal was imaged using confocal microscopy and Imaris Software was used to
quantify the number of interacting proteins shown as white spots (far right panels). The
interacting protein complexes are visualized as bright fluorescent red spots and the cell
nuclei are visualized in blue. Confocal images are representative of 3 independent
experiments. B, This histogram reports the quantification of the interacting protein
complexes (white spots) per cell. Significantly fewer white spots per cell were present in
cells expressing APPSwe than in cells expressing APPwt. Data are expressed as the mean ±
SEM for a minimum of 25 cells per transfection group from 3 independent experiments,
and were analysed using a repeated-measures one-way ANOVA with Tukey’s post hoc
multiple comparisons test (*p < 0.05). C, Confocal images show the distribution of
AlexaFluor 555-labeled APP (red) and AlexaFluor 488-labeled CHT (green) in SY5YCHT cells transiently transfected with either APPwt (top panel) or APPSwe (bottom panel).
The colocalization of CHT and APP can be seen as yellow in the Overlay panels.
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either APPwt or APPSwe were formalin-fixed and labeled with primary antibodies
recognizing either APP or CHT following the PLA experimental protocol, and then
incubated with AlexaFluor-labeled secondary antibodies. Representative confocal images
of SY5Y-CHT cells show similar immunostaining for APP (red) and CHT (green)
between cells expressing either APPwt or APPSwe (Figure 4-2C).

4.3.3

BACE1 inhibition does not alter the preferential interaction
between CHT and APPwt versus to APPSwe

The Swedish mutation dramatically accelerates the β-cleavage of APP by BACE1 and
thus increases the generation of Aβ (17, 18). To determine if my observation that CHT
interacts less with APPSwe than it does with APPwt is related to differences in the βcleavage rate of APPwt and APPSwe, I evaluated the interaction of either CHT with APPwt,
or CHT with APPSwe in the presence or absence of BACE1 inhibitor IV.
To test this, I used SY5Y-CHT cells stably expressing FLAG-tagged CHT protein. Cells
were transiently transfected with either empty vector or APPwt or APPSwe plasmid DNA.
Immediately following transfection, cells were treated with vehicle or BACE1 inhibitor
IV and allowed to express for 24 h. FLAG-CHT and interacting proteins were recovered
from cell lysates using anti-FLAG affinity resin. Figure 4-3A shows a representative
immunoblot that was probed for CHT using anti-CHT antibody or for interacting APP
proteins using anti-APP C-terminal antibody. These experiments showed that BACE1
inhibition did not alter the relative difference between the interaction of CHT with APP wt
compared to that with APPSwe. Thus, quantification of the intensity of the interacting APP
protein bands (Figure 4-3A, top panel) by densitometry reveals a greater level of
interaction of APPwt with FLAG-CHT when compared to that of APPSwe with FLAGCHT in SY5Y-CHT cells, regardless of whether the cells were treated with vehicle or
BACE1 inhibitor IV (Figure 4-3B). The APP protein bands were normalised to the
amount of FLAG-CHT recovered on the anti-FLAG affinity resin. Inhibition of BACE1
activity was confirmed by the observation that the steady-state levels of both total and
interacting full-length APP protein were greater, and the level of the βCTF was lower in
cells treated with BACE1 inhibitor IV compared to vehicle-treated control cells (Figure
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Figure 4-3 The proportion of CHT protein interacting with APPwt versus CHT
interacting with APPSwe is the same in cells treated with vehicle or BACE1 inhibitor
IV.
A, FLAG-tagged CHT was isolated from SY5Y-CHT or SY5Y cells stably expressing
empty vector that had been transiently transfected with either the APP wt or APPSwe
plasmids. Cells that were treated with vehicle (DMSO) were used as a negative control
(left 3 lanes) for comparison with cells that were treated for 24 h with 25 µM BACE
inhibitor IV (right 3 lanes). Representative immunoblots show total full-length APP,
FLAG-CHT and c-terminal APP protein fragments in total cell lysates (bottom 3 panels).
The top two panels illustrate FLAG-CHT proteins recovered on anti-FLAG affinity resin
probed with anti-APP antibody and anti-CHT antibody. The immunoblots shown are
representative of data obtained from 6 independent experiments. B, Analysis of the
interacting APP immunobands (top panel) by densitometry revealed that less APPSwe
interacts with CHT than does APPwt, regardless of whether cells were treated with vehicle
or BACE1 inhibitor IV. Data are expressed as the mean ± SEM of 6 independent
experiments, and were analysed using a repeated-measures one-way ANOVA with
Tukey’s post hoc multiple comparisons test (*p < 0.05).
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4-3A, lower panels). The expression of CHT was comparable in cells treated with either
vehicle or BACE1 inhibitor IV.

4.3.4

CHT cell surface levels and choline uptake activity are
decreased by expression of APPwt or APPSwe

To compare the effect of the interaction of CHT with either APP wt or APPSwe on CHT
function in SY5Y-CHT cells, I assessed high-affinity choline uptake activity and CHT
cell surface levels in SY5Y-CHT cells transiently expressing either APPwt or APPSwe by
performing 3[H]choline uptake assay and cell surface protein biotinylation experiments,
respectively. In the biotinylation experiments, SY5Y-CHT cells were transiently
transfected with either vector or the APPwt or APPSwe plasmid and allowed to express for
24 h. Plasma membrane proteins were then biotinylated using membrane impermeable
sulfo-NHS-biotin at 4°C to ensure that labeled CHT proteins did not undergo
endocytosis. Representative immunoblots in Figure 4-4A show the levels of cell surface
(biotinylated) CHT protein and APP protein, and the amount of total CHT and APP
protein. Total CHT protein levels are equal between cells expressing either vector, or
APPwt or APPSwe, and total APP levels are equal between cells expressing APPwt or
APPSwe, and greater than cells expressing vector. Analysis of cell surface (biotinylated)
CHT and APP protein immunoblots reveals that CHT cell surface levels were
significantly reduced by approximately 30% in SY5Y-CHT cells expressing either APPwt
or APPSwe when compared to vector-expressing control cells (Figure 4-4B) (p < 0.05).
Moreover, the APPSwe protein cell surface levels are approximately 50% lower in SY5YCHT cells expressing APPSwe when compared to the APPwt protein cell surface levels in
cells expressing APPwt (Figure 4-4C) (p < 0.05).
CHT proteins are active at the cell surface, where they mediate the transport of choline
into cholinergic nerve terminals. Since the expression of APPwt or APPSwe significantly
reduced the number of CHT proteins at the cell surface, I predicted that the expression of
either APPwt or APPSwe would inhibit the high-affinity choline uptake activity of CHT. To
test this prediction, we measured 3[H]-choline uptake activity in SY5Y-CHT cells
expressing different amounts of either empty vector, or APPwt or APPSwe plasmid DNA.
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Figure 4-4
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Figure 4-4 Both [3H]-choline uptake activity and CHT plasma membrane levels are
reduced in SY5Y-CHT cells transfected with either APPwt or APPSwe.
A, Cells were washed and placed on ice, and then plasma membrane proteins were
biotinylated. Biotinylated proteins were captured using NeutrAvidin agarose, then
proteins were solubilized and separated by SDS-PAGE. PVDF membranes were
processed by immunoblotting with antibodies recognizing APP and CHT. Representative
immunoblots show steady-state APP and FLAG-CHT protein levels in total cell lysates
(2 lower panels). The top two panels illustrate cell surface (biotinylated) FLAG-CHT and
APP proteins. The immunoblots shown are representative of data obtained from 4
independent experiments. B, Analysis of cell surface CHT protein bands by densitometry
reveals that the level of CHT protein at the cell surface is significantly reduced in cells
expressing either APPwt or APPSwe when compared to vector-expressing control cells.
Data are expressed as the mean ± SEM of 5 independent experiments, and were analysed
using a repeated-measures one-way ANOVA with Tukey’s post hoc multiple
comparisons test (*p < 0.05). C, Analysis of cell surface APP protein bands by
densitometry reveals that the level of APP at the cell surface is significantly less in cells
expressing APPSwe when compared to APPwt. Data were analysed using a paired
Student’s t-test with Tukey’s and are expressed as the mean ± SEM of 5 independent
experiments (*p < 0.05) D, Choline uptake was assayed in SY5Y-CHT cells transfected
with varying amounts of either vector, or APPwt or APPSwe plasmid DNA. CHT activity
was significantly reduced in cells transfected with either 4 µg of APPwt or 4 µg of APPSwe
plasmid DNA when compared to vector-transfected control cells. Data are expressed as
the mean ± SEM of 5 independent experiments, and were analysed using a repeatedmeasures one-way ANOVA with Tukey’s post hoc multiple comparisons test (*p < 0.05).
E, Representative immunoblots show steady-state total APP, βCTF and FLAG-CHT
protein levels in total cell lysates from a representative choline uptake experiment.
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Figure 4-4D shows that high-affinity choline uptake was significantly reduced in cells
expressing higher amounts of either the APPwt plasmid or the APPSwe plasmid, compared
to vector-expressing control cells (p < 0.05). As shown in Figure 4-4E, the steady-state
levels of full-length APPwt protein increased, corresponding to the increasing amount of
APPwt plasmid DNA transfected. In contrast, the steady-state levels of full-length APPSwe
protein did not show a corresponding increase related to the increasing amount of APP Swe
plasmid DNA transfected. Importantly, however, in the APPSwe transected cells, there
was an increase in the amount of the βCTF that corresponded to the increasing amount of
APPSwe plasmid DNA transfected. The steady-state levels of total CHT protein were
equal between all transfection groups. Thus, in cells expressing APPwt, CHT activity
appears to be inhibited in a manner that parallels the increase in full-length APPwt protein
levels, whereas in cells expressing APPSwe, the inhibition of CHT activity corresponds
more to the appearance and levels of βCTF than to the levels of full-length APPSwe
protein.

4.3.5

CHT colocalizes with EEA1-positive early endosomes to a
similar extent in APPwt or APPSwe expressing cells

Both CHT and APPwt colocalize with early endosome marker Rab5, and co-expression of
CHT and APPwt increases the rate at which CHT proteins undergo endocytosis (13). This
could potentially account for the observation of a significant reduction of CHT proteins at
the plasma membrane in cells expressing either APPwt or APPSwe when compared to
vector-expressing control cells (Figure 4-4B). To evaluate whether the interaction of
CHT with either APPwt, or APPSwe affects CHT colocalization with early endosomes, I
used confocal microscopy to evaluate the subcellular distributions of CHT in conjunction
with the early endosome marker EEA1 and either APPwt-YFP or APPSwe-YFP in SY5YCHT cells. Images illustrating the distribution of CHT and EEA1 are provided for SY5YCHT cells transiently expressing either APP wt-YFP or APPSwe-YFP in Figures 4-5A and
4-5B, respectively. To assess the extent of colocalization between either APP wt-YFP or
APPSwe-YFP, and CHT and EEA1, I used a quantitative approach where a threshold
fluorescence intensity is set that filters the brightest 2% of pixels of CHT (blue channel)
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that also fall within the brightest 2% of pixels of either APPwt-YFP or APPSwe-YFP
(green channel) or EEA1 (red channel). In separate analyses, I also evaluated the
brightest 2% pixels of either APPwt-YFP or APPSwe-YFP that fall within the brightest 2%
of pixels of EEA1, and the brightest 2% of pixels of EEA1 with the colocalized pixels of
either APPwt-YFP and CHT or APPSwe-YFP and CHT. The colocalized pixels are
identified in a separate colocalization channel and shown as white in the lower overlay
panels of Figures 4-5A and 4-5B.
As documented in Figure 4-5C, analysis of the quantified pixels revealed that 45±1.6% of
CHT colocalized with APPwt-YFP and 40±1.6% of CHT colocalized with APPwt-YFP.
The percentage colocalization of APPwt-YFP with EEA1 was significantly greater than
the percentage colocalization of APPSwe-YFP with EEA1 (48±2.1% and 36±1.8%
colocalization, respectively), which is consistent with the model that rapid cleavage of
APPSwe-YFP within the secretory pathway results in a smaller population available at the
cell surface for endocytosis to early endosomes. Also in these experiments, the
percentage of colocalized pixels of APPwt-YFP and CHT with EEA1 was significantly
greater than the percentage colocalization of APPSwe-YFP and CHT with EEA1
(60±1.9% and 48±2.1% colocalization, respectively) (Figure 4-5C) (p < 0.05). Finally, I
determined the effect of transiently expressing either APPwt-YFP or APPSwe-YFP in
SY5Y-CHT cells on the localization of CHT to early endosomes. To accomplish this, I
compared the colocalization of CHT with EEA1 in cells transiently-expressing either
APPwt-YFP or APPSwe-YFP to cells that were untransfected in the same culture dish.
Importantly, there were no statistically significant differences in the percentage of
colocalization of CHT with EEA1 found in cells expressing either APPwt-YFP or APPSweYFP (34±1.3% and 33±1.2% colocalization, respectively). However, both of these values
were significantly greater than the percentage colocalization found for CHT with EEA1
in untransfected cells in culture plates that were transfected with either APP wt-YFP or
APPSwe-YFP (24±1.7% and 24±1.3% colocalization, respectively) (p < 0.05) (Figure 45D).
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Figure 4-5
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Figure 4-5 Colocalization of CHT with EEA1 is increased in SY5Y-CHT cells
expressing either APPwt or APPSwe.
Panel A, Confocal images show the distribution of AlexaFluor 647-labeled CHT (blue),
AlexaFluor 555-labeled EEA1 (red) and APPwt-YFP (green). Colocalized pixels were
identified in the colocalization channel and are shown as white in the lower overlay
panels. Scale bar, 5 µM. Panel B. Confocal images show the distribution of AlexaFluor
647-labeled CHT (blue), AlexaFluor 555-labeled EEA1 (red) and APPSwe-YFP (green).
Colocalized pixels were identified in the colocalization channel and are shown as white
in the lower overlay panels. Scale bar, 5 µM. C, CHT and APPwt-YFP, CHT and
APPSwe-YFP, APPwt-YFP and EEA1, and APPSwe-YFP and EEA1 pixels that were
determined to be colocalized in the colocalization channel were quantified using Imaris
software. Data are expressed as the mean ± SEM for a minimum of 25 cells per
transfection group from 4 independent experiments, and were analysed by one-way
ANOVA followed by Tukey’s post-test (*p < 0.05). D, CHT and EEA1 pixels that were
determined to be colocalized in cells expressing either APPwt-YFP or APPSwe-YFP or
in untransfected control cells were quantified using Imaris software. Data are expressed
as the mean ± SEM for a minimum of 25 cells per transfection group from 4 independent
experiments, and were analysed by one-way ANOVA followed by Tukey’s post-test and
(*p < 0.05).
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4.3.6

BACE1 inhibition reduces Aβ generation and increases CHT
protein cell surface levels in SY5Y-CHT cells expressing
APPSwe

A critical finding in the present study indicates that CHT proteins interact significantly
less with APPSwe than with APPwt. Importantly, however, the expression of either APP wt
or APPSwe in SY5Y-CHT cells increases CHT colocalization to early endosomes to a
similar extent, and significantly decreases both CHT cell surface levels and CHT activity.
Since APPSwe interacts much less with CHT than does APP wt, I next investigated the
mechanism by which APPSwe mediates changes to CHT function. Our findings above
show that CHT activity is inhibited in a manner that is dependent on the level of fulllength APPwt protein, whereas in cells expressing APPSwe, inhibition of CHT activity
corresponds more to the processing of APP as shown by the increased production of the
βCTF. Thus, I hypothesized that decreases in the activity and cell surface levels of CHT
in SY5Y-CHT cells expressing APPSwe are related to the increased generation of βCTF or
Aβ in these cells as a result of enhanced BACE1 processing of APPSwe compared to
APPwt.
To test this hypothesis, I measured CHT protein cell surface levels in SY5Y-CHT cells
that transiently transfected to express either vector, APPwt or APPSwe and treated with
either vehicle or BACE1 inhibitor IV for 24 h. Plasma membrane proteins were then
biotinylated using membrane impermeable sulfo-NHS-biotin at 4°C. Representative
immunoblots in Figure 4-6A show the levels of cell surface (biotinylated) CHT and APP
proteins (top two panels), and the steady-state amount of total CHT, full-length APP,
αCTF and βCTF proteins (bottom three panels). Similar to findings above (Figure 44A,B), analysis of the cell surface (biotinylated) CHT and APP protein immunoblots
reveals that in vehicle-treated cells, CHT cell surface levels are reduced by approximately
30% in SY5Y-CHT cells expressing either APPwt or APPSwe when compared to vectorexpressing control cells (Figure 4-6A top panel, 4-6B white bars). Moreover, the cell
surface levels of APPSwe are approximately 50% lower when compared to that of APPwt
(Figure 4-6A second panel, 4-6C white bars). I next compared the effects of vehicle or
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BACE1 inhibitor IV treatment on CHT cell surface levels in groups of cells expressing
either vector, APPwt or APPSwe. No significant differences in CHT cell surface expression
are found between the vehicle or BACE1 inhibitor IV treated groups of cells expressing
either vector or APPwt. Interestingly however, CHT cell surface expression is
significantly greater in APPSwe-expressing cells that were treated with BACE1 inhibitor
IV when compared to the APPSwe-expressing cells treated with vehicle (Figure 4-6A top
panel, Figure 4-6B, p < 0.05). Moreover, the APPSwe protein cell surface levels are
significantly higher in BACE1 inhibitor IV-treated SY5Y-CHT cells expressing APPSwe
compared to that observed in vehicle-treated SY5Y-CHT cells expressing APPSwe (Figure
4-6A second panel, Figure 4-6C, p < 0.05). No significant differences in APPwt cell
surface protein expression level are observed between vehicle or BACE1 inhibitor IVtreated SY5Y-CHT cells expressing APPwt. Finally, I measured the amount of Aβ1-42
secreted into the culture medium by ELISA of SY5Y-CHT cells treated with vehicle or
BACE1 inhibitor IV transiently expressing either empty vector, APPwt or APPSwe plasmid
DNA for 24 h. As predicted, culture medium collected from vehicle-treated SY5Y-CHT
cells expressing APPSwe contains a significantly greater amount of Aβ1-42 than that
collected from vehicle-treated SY5Y-CHT cells expressing either APPwt or empty vector
(Figure 4-6D white bars, p < 0.01). Importantly, BACE1 inhibition significantly lowers
the amount of Aβ1-42 in culture medium collected from cells expressing APPSwe when
compared to that collected from vehicle-treated APPSwe-expressing cells (p < 0.01)
(Figure 4-6D).
Also shown in Figure 4-6A (middle panel), the total CHT protein levels are equal
between the vehicle and BACE1 inhibitor IV-treated cells expressing either empty vector,
APPwt or APPSwe. As anticipated, the steady-state levels of total full-length APP protein
are increased and the level of the βCTF is lower in cells treated with BACE1 inhibitor IV
when compared to vehicle-treated cells (Figure 4-6A, lower panels).
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Figure 4-6
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Figure 4-6 BACE1 inhibition reduces Aβ secretion and increases CHT cell surface
levels in SY5Y-CHT cells expressing APPSwe.
A, Cells were washed and placed on ice, and then plasma membrane proteins were
biotinylated. Biotinylated proteins were captured using NeutrAvidin agarose, then
proteins were solubilized and separated by SDS-PAGE. PVDF membranes were
processed by immunoblotting with antibodies recognizing APP and CHT. This
representative immunoblot shows cell surface (biotinylated) FLAG-CHT and APP
proteins (top two panels). Steady-state CHT, APP and βCTF protein levels in total cell
lysates are illustrated in the lower 3 panels. The immunoblots shown are representative of
data obtained from 6 independent experiments. B, Analysis of cell surface CHT protein
bands by densitometry reveals that the level of CHT protein at the cell surface is
significantly increased in cells expressing APPSwe when compared to vehicle-treated
APPSwe-expressing control cells. Data are expressed as the mean ± SEM of 5 independent
experiments, and were analysed using a repeated-measures one-way ANOVA with
Tukey’s post hoc multiple comparisons test (*p < 0.05). C, Analysis of cell surface APP
protein bands by densitometry reveals that the level of APPSwe at the cell surface is
significantly greater than that found in vehicle-treated APPSwe expressing control cells.
Data were analysed using a two-way ANOVA with Bonferonnis’s post-test and are
expressed as the mean ± SEM of 5 independent experiments (*p < 0.05). D, Conditioned
medium was collected from these cell groups, then the Aβ1-42 levels were measured by
ELISA and quantified. Vehicle-treated APPSwe-expressing cells produced significantly
higher levels of Aβ1-42 than did BACE1 inhibitor IV –treated APPSwe-expressing cells.
Data are expressed as the mean ± SEM of 5 independent experiments, and were analysed
using a repeated measures two-way ANOVA with Bonferonni’s post hoc multiple
comparisons test (*p < 0.01)
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4.3.7

Choline uptake activity is reduced by conditioned medium
from APPSwe-expressing SY5Y-CHT cells

My previous experiment shows that inhibition of BACE1 activity significantly reduces
the amount of Aβ present in the culture medium of APPSwe-expressing cells, and
significantly increases CHT cell surface levels in these cells when compared to that found
in vehicle-treated APPSwe-expressing SY5Y-CHT cells. Since Aβ can inhibit high-affinity
choline uptake (4), I next examined whether the decrease in CHT activity in SY5Y-CHT
cells expressing APPSwe is related to the increased amount Aβ released into the culture
medium of these cells. To accomplish this, I collected culture medium conditioned for 24
h by SY5Y-CHT cells transiently expressing empty vector, APP wt or APPSwe plasmid
DNA. Using an Aβ1-42 ELISA, I found that the amount of Aβ1-42 secreted into the
medium by APPSwe-expressing cells is significantly greater than that from cells
expressing either APPwt or empty vector (p < 0.05) (Figure 4-7A). The conditioned
medium was added to SY5Y-CHT cells stably-expressing CHT but not transfected with
other plasmids for 30 min, 4 h or 24 h, then [3H]choline uptake activity was measured. As
shown in Figure 4-7B, cells treated with conditioned culture medium collected from
APPSwe-expressing SY5Y-CHT cells for 24 h have a statistically-significant (32%)
decrease in choline uptake activity when compared to cells treated with conditioned
culture medium collected from either vector or APPwt -expressing cells. It is interesting to
note that this corresponds to the 35% decrease in choline uptake activity that I observed
in SY5Y-CHT cells at 24 h after transient transfection with APPSwe (Figure 4-4D).

4.4 Discussion
The subcellular trafficking of CHT maintains a steady level of this solute transporter at
the cell surface, thereby regulating choline uptake activity and maintaining cholinergic
neurotransmission. Thus, any protein-protein interaction that regulates CHT trafficking
will have a direct impact on choline uptake activity and ACh synthesis. Previous studies
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Figure 4-7 Treatment of SY5Y-CHT cells with conditioned medium containing Aβ
from cells expressing APPSwe inhibits choline uptake activity.
A, SY5Y-CHT cells were transfected with either vector, or APPwt or APPSwe plasmid
DNA and allowed to express for 24 h. APPSwe-expressing cells produced significantly
higher levels of Aβ1-42 than did either vector or APPwt-expressing cells. Data are
expressed as the mean ± SEM of 5 independent experiments, and were analysed using a
repeated-measures one-way ANOVA with Tukey’s post hoc multiple comparisons test
(*p < 0.05). B, SY5Y-CHT cells were treated with conditioned medium collected from
SY5Y-CHT cells transiently expressing either empty vector, or APPwt or APPSwe, 24 h,
then added to untransfected SY5Y-CHT for either 30 min, 4 h or 24 h prior to
[3H]choline uptake assays being performed. CHT activity was significantly reduced only
in cells treated for 24 h with conditioned medium collected from SY5Y-CHT cells
expressing APPSwe. Data are expressed as the mean ± SEM of 5 independent experiments,
and were analysed using a repeated-measures one-way ANOVA with Tukey’s post hoc
multiple comparisons test (*p < 0.05).
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identified APP as a binding partner for CHT involved in regulating CHT endocytosis and
subcellular localization (13). Because APP containing the Swedish mutation is cleaved
within the secretory pathway (19, 20) and is trafficked differently from the cell surface
through the endosomal pathway as compared to APPwt, (7) the purpose of my study was
to investigate further how APP regulates CHT trafficking and activity and whether this is
altered by the Swedish mutation.
Through experiments that used co-immunoprecipitation and proximity ligation assays, I
made the novel observation that CHT associates significantly less with APPSwe than with
APPwt in SY5Y-CHT cells and in cultured mouse brain cortical neurons, and that this was
not related to the enhanced BACE1-mediated cleavage of APPSwe. Interestingly, the
expression of either APPwt or APPSwe decreased CHT cell surface levels and choline
uptake activity to the same extent. Moreover, the proportion of total cellular CHT
proteins that colocalize with the early endosomal marker EEA1 was increased to a similar
level in cells expressing either APPwt-YFP or APPSwe-YFP when compared to
untransfected control cells. In these experiments, SY5Y-CHT cells expressing APPSwe
secreted significantly more Aβ1-42 into the culture medium than did cells expressing
APPwt, and lowering the production of Aβ by BACE1 inhibition significantly increased
CHT cell surface level in cells expressing APPSwe, but not in cells expressing either
vector or APPwt, when compared to vehicle-treated cells. Finally, I found that treating
untransfected SY5Y-CHT cells with the culture medium collected from SY5Y-CHT cells
transiently expressing APPSwe significantly inhibited choline uptake activity.
My co-immunoprecipitation data reveal that CHT interacts significantly less with APP Swe
than it does with APPwt in both SH-SY5Y cells and cultured cortical neurons from mouse
brain. One explanation for this finding is that the subcellular trafficking pathway and
processing location of APPSwe (in the TGN), compared to APPwt (in endosomes),
substantially reduces the potential for APPSwe to interact with CHT. Differences in the
regulation of APPwt and APPSwe as a result of their subcellular processing locations have
been observed. For example, the interaction of the cellular prion protein with BACE1
retains BACE1 in the TGN and therefore inhibits its activity towards APP wt, but not
towards APPSwe, which is explained by the differential subcellular sites of action of
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BACE1 on APPwt, compared with APPSwe (21). Therefore, it is possible that APPSwe and
APPwt in turn can regulate other cellular proteins differently as a result of their distinct
subcellular processing locations. APPwt is proposed to interact with CHT and facilitate its
endocytosis into Rab5-positive early endosomes (13). Retention and processing of
APPSwe within the TGN could result in a smaller pool of APPSwe present at the cell
surface and in endosomal compartments available to interact with CHT. My PLA
experiments provide support for this hypothesis showing that interacting CHT and APP wt
protein complexes were distributed throughout both the cell body and neuritic
projections, whereas CHT and APPSwe appeared to interact primarily within the cell body.
A second explanation for the reduced interaction of CHT with APPSwe compared to
APPwt is that the APP and CHT association involves the amino acid residues K595 or
M596 that are mutated in APPSwe. While previous studies showed that the carboxylterminal domain of APP is sufficient to immunoprecipitate CHT (13), protein-protein
interactions depend both on the protein sequence and conformation, so this possibility
cannot be completely ruled out. Lastly, the differential interaction between CHT and
APPSwe compared to APPwt appears to be unique to CHT, as the Swedish mutation does
not appear to alter the ability of APP to mediate protein trafficking in a general manner.
For example, APPwt interacts with assembled NMDA receptors and enhances their cell
surface trafficking (22, 23) and this is not altered by either the London or Swedish APP
mutations (23).
Because CHT associates significantly less with APPSwe than with APPwt, I predicted that
APPSwe and APPwt over-expression would have different effects on CHT function and
localization. Unexpectedly, CHT cell surface levels were significantly reduced to similar
extents in SY5Y-CHT cells expressing either APP wt or APPSwe when compared to vectorexpressing control cells, and this corresponds to a significant reduction in high-affinity
choline uptake in cells expressing APPwt as well as in cells expressing APPSwe. Consistent
with the findings of Yamakawa et al. (2010), I found significantly less APPSwe than
APPwt proteins at the cell surface, which could be explained by the greater level of
processing of APPSwe within the secretory pathway. Interestingly, in cells expressing
APPwt, there was a reciprocal relationship between CHT activity and APPwt levels with
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the reduction in CHT activity being greater as the APP wt protein level increased. In
contrast, the reduction of CHT activity in cells expressing APPSwe was related more to the
increased production and level of βCTF. Finally, CHT localization to early endosomes
was significantly increased in cells expressing either APPwt-YFP or APPSwe-YFP when
compared to untransfected control cells, suggesting that the internalization rate of CHT is
increased similarly in cells expressing either APPwt or APPSwe. The increased movement
of CHT from the plasma membrane to early endosomes could represent the mechanism
by which CHT activity and cell surface expression was reduced in cells expressing either
APPwt or APPSwe. My results indicate that APPwt regulates CHT cell surface expression
and activity through a direct interaction with the transporter. Since APPSwe interacts much
less with CHT than it does with APPwt, but expression of either APPwt or APPSwe causes a
similar inhibition of CHT function, I investigated the hypothesis that the decrease in CHT
activity and cell surface expression in SY5Y-CHT cells expressing APPSwe is related to
the increased release of Aβ from these cells. Support for this hypothesis comes from
previous observations that Aβ can interact directly with CHT (26) and impairs highaffinity choline uptake (11), and from my finding that SY5Y-CHT cells expressing
APPSwe secrete significantly more Aβ1-42 into culture media than do cells expressing
APPwt. Furthermore, BACE1 inhibition significantly reduced the amount of Aβ in culture
medium of cells expressing APPSwe and significantly increased CHT cell surface level in
these cells, but not in cells expressing either vector or APPwt, compared to vehicle-treated
cells. Finally, my data show that treating untransfected SY5Y-CHT cells with the culture
medium collected from SY5Y-CHT cells transiently expressing APPSwe significantly
inhibited choline uptake activity. Therefore, I propose that the inhibition to CHT function
observed in APPSwe expressing cells is due to the increased generation of Aβ in these
cells, and not a result of the interaction between CHT and APP Swe itself. In addition to
APP itself, APP metabolites including Aβ, βCTF, sAPPβ and AICD also been shown to
exert physiological effects. Since BACE1 inhibition not only blocks the production of
Aβ, but also inhibits the generation of sAPPβ and βCTF, we cannot rule out the
possibility that these fragments may be mediating some of the CHT impairment in
APPSwe-expressing SY5Y-CHT cells.

165

Several previous studies report cognitive impairment beginning in the early stages before
Aβ plaque development in the Tg2576 mouse model over-expressing human APP695 with
the Swedish mutation compared to non-transgenic controls (27-29). These early studies
were not able to determine that the high concentrations of Aβ were responsible for the
memory and learning deficits, and not the over-expression of APP (30); however, this
was clarified by a study showing that reduction of Aβ levels through genetic inactivation
of BACE1 in Tg2576 mice prevented memory deficits and hippocampal neuronal
abnormalities (31). My data regarding APPSwe regulation of CHT activity offer a
mechanistic explanation for this observation and highlight the importance of future
studies comparing mice over-expressing wild-type human APP695 with Tg2576 mice. In
conclusion, my results support the idea that APPwt plays a physiological role in regulating
the trafficking and activity of CHT through a direct protein-protein interaction. The
Swedish mutation disrupts this interaction and appears to cause changes to CHT function
through increased β-cleavage of APPSwe and subsequent Aβ production, as opposed to an
association between CHT and APPSwe itself.
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Chapter 5

5

Summary of major findings, discussion of results and
future directions3

3

Parts of this work have been published and submitted in the following manuscripts:

Cuddy LK, Winick-Ng W, Rylett RJ. Regulation of the high-affinity choline transporter activity and
trafficking by its association with cholesterol-rich lipid rafts J Neurochem 4 November 2013 128 (5):725740
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5.1 Summary of major findings
5.1.1

Summary of major findings from experiments regarding the
effect of reactive oxygen species ONOO- donor SIN-1 on
CHT activity and subcellular trafficking (Chapter 2)
1.

The mutant L531A-CHT transporter, but not wild-type CHT, is resistant to
SIN-1 effects.

2.

Expression of the DN proteins AP180C and dynamin-K44A expression
block CHT endocytosis and attenuate CHT inhibition by SIN-1.

3.

In both vehicle and SIN-1-treated cells, CHT colocalizes with Rab5positive early endosomes, Rab7 and Rab9-positive late endosomes and
Lamp1-positive lysosomes to a similar extent.

4.

Inhibition of the proteasome by lactacystin and MG-132 treatment
attenuate SIN-1-mediated inhibition of choline uptake.

5.

5.1.2

SIN-1 treatment enhances CHT ubiquitination.

Summary of major findings from experiments regarding the
effect of cholesterol and lipid raft association on CHT activity
and substrate binding (Chapter 3)
1.

CHT is partitioned between lipid raft and non-raft membrane
compartments and tends to be concentrated in lipid rafts.

2.

CHT colocalizes with flotillin and cholera toxin, and to a lesser extent
with EEA1.

3.

Choline uptake activity depends on membrane cholesterol levels.

171

4.

Filipin and MβC cause a decrease in plasma membrane CHT protein
levels from lipid rafts, but not non-raft areas, which is not related to an
accelerated rate of CHT protein internalization.

5.

CHT contains putative cholesterol binding motifs in CHT that are
conserved between rodent and human.

5.1.3 Summary

of

major

findings

from

experiments

investigating whether CHT differentially interacts with
APPwt versus APPSwe and how this affects CHT surface
expression and activity (Chapter 4)
1.

CHT interacts significantly less with APPSwe than with APPwt in SH-SY5Y
cells stably expressing the transporter and in primary cortical neurons.

2.

BACE1 inhibition increases the expression levels of both APP wt and
APPSwe, and enhances both the interaction between CHT and APPwt and
between CHT and APPSwe.

3.

APPwt or APPSwe expression significantly reduced both CHT cell surface
levels and choline uptake activity.

4.

CHT colocalization with EEA1-positive early endosomes is increased in
cells expressing either APPSwe-YFP or APPwt-YFP when compared to
untransfected control cells.

5.

BACE1 inhibition significantly increases CHT cell surface levels in cells
expressing APPSwe when compared to vehicle-treated control cells.
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5.2 Discussion of results and future studies
A wide range of neuron models were used in the experiments described in this thesis to
investigate and validate the mechanisms by which CHT protein function is regulated. The
majority of the studies carried out in this thesis were performed in monolayers of intact
SH-SY5Y human neuroblastoma cells that stably-express FLAG-tagged rat CHT proteins
as an experimental model. These cells were differentiated with all-trans retinoic acid to
cause neurite outgrowth and enhance the cholinergic and neuronal phenotype of the cells.
In several confocal imaging experiments, the FLAG-tagged amino terminus of CHT was
labeled using Zenon Alexafluor-conjugated FLAG antibodies, which allowed us to track
the internalization of CHT from the plasma membrane. Since cell type-dependent
differences in the regulation of CHT trafficking have been observed (1), some studies
performed in this thesis were repeated using different experimental models. In the
investigations described in Chapter 4, transiently transfected cortical neurons cultured
from embryonic mouse brain were used as an experimental model to verify the results
from co-immunoprecipitation experiments carried out in the SH-SY5Y neuronal cell line.
In the studies performed in Chapter 3, mouse brain synaptosomes were utilized as an
experimental model to confirm the plasma membrane distribution of CHT between raft
and non-raft membrane. While these models more closely replicate the endogenous
environment of CHT proteins, mouse cortical neuron cultures have a low percentage of
cholinergic neurons and a low transfection efficiency, which prevented the examination
of either the trafficking or activity of the endogenous or transiently transfected CHT
proteins. Synaptosomes are re-sealed synaptic nerve terminals that are created during the
homogenization of brain tissue and isolated by centrifugation. These likely contain a
higher density of CHT proteins than do cultures of primary cortical neurons since CHT
proteins are found to be concentrated within axon terminals and neuronal processes (2-7).
However, a potential caveat with the use of synaptosomes is that the synaptosomal
membranes may not reseal properly during their isolation. Consequently, they may not be
an ideal model for some experiments performed in the studies outlined in this thesis, and
in this case cultured cells with intact plasma membranes were used in assays to measure
the levels and internalization of cell surface proteins by biotinylation.
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The experiments in Chapter 2 were designed to characterize the effect of the ONOOdonor SIN-1 on CHT activity and trafficking. The first observation that CHT is sensitive
to ONOO- was made by Guermonprez et al. (2001). These authors found that CHT
activity was inhibited by ONOO-, but not H2O2, indicating that CHT displays selective
sensitivity to ONOO-. Further work by Pinthong et al. (2008) found that ONOO- inhibited
choline uptake by reducing the level of cell surface CHT expression. Moreover, these
authors found that ONOO- increased the rate of CHT internalization from the plasma
membrane, and that CHT inhibition occurred at concentrations of SIN-1 that did not
disrupt cell membrane integrity or cause cell death. Taken together, the results of this
previous work suggested that inhibition of CHT activity by SIN-1 is due to a change in
CHT protein localization, as opposed to a change in the conformation of the protein due
to nitration or oxidation. The goal of Chapter 2 of this thesis was to determine the route
of CHT subcellular trafficking under SIN-1 treatment. The results of the initial
experiments in Chapter 2, which examined [3H]HC-3 binding kinetics of CHT under
SIN-1 treatment, and compared high-affinity choline uptake kinetics between cells stably
expressing wild-type CHT or L531A-CHT, which is unable to undergo endocytosis,
confirmed that SIN-1 inhibition is not due to a direct nitrosative or oxidative modification
of CHT protein itself. To assess the route of CHT subcellular trafficking under SIN-1
treatment, I used various different experimental approaches and found that SIN-1 did not
alter CHT endocytosis through a clathrin and dynamin-dependent pathway, or the
movement of CHT through early and late endosomes to lysosomes. Importantly,
exposure of cells to SIN-1 resulted in CHT ubiquitination and blocking the proteasome
restored choline uptake activity in SIN-1 treated cells. Figure 5-1 shows a general
schematic of the results found in Chapter 2 in regard to CHT trafficking in a cholinergic
nerve terminal under ONOO- stress.
The nitration of tyrosine residues is a well-characterized consequence of ONOOtreatment and increased 3-nitrotyrosine (3-NT) immunoreactivity is found in necropsy
AD brain (10). Early studies found that inhibitors of protein nitration did not protect CHT
activity from ONOO- (8) and experiments carried out in our laboratory found no evidence
of nitration of tyrosines in CHT (9). While increased 3-NT levels are the signature
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Figure 5-1 Pathways of CHT subcellular trafficking in cells treated with ONOOdonor SIN-1.
In vehicle and SIN-1 treated cells, CHT is internalized from the plasma membrane
through a clathrin-dependent mechanism. Once internalized, CHT colocalizes with Rab5-positive early endosomes, and can be transported through Rab-7 and Rab-9 positive
late endosomes to lysosomes for degradation. This subcellular trafficking pathway does
not appear to be altered by SIN-1 treatment. My studies suggest that CHT undergoes
polyubiquitination following SIN-1 treatment, and that this then can result in the
subcellular trafficking of the transporter to the proteasome for degradation.
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marker of ONOO- -mediated damage in post-mortem AD brain, it can be expected that
other direct modifications to proteins, including oxidation, or nitrosylation of amino acids
(11), or indirect changes to protein function, for example, through the activation of
phosphorylation pathways by ONOO- (12-14) are occurring in the brain under
pathological conditions. The production of ONOO- depends on the availability of its
precursors, O2 and NO, which are not normally produced in large quantities in the brain.
However, under certain conditions associated with AD, such as tissue injury and
inflammation, or a reduced antioxidant capacity, ONOO- becomes a significant
pathological risk. The ONOO- treatment used in this study parallels physiological levels
of ONOO- produced in the brain under multiple disease conditions including AD, thus the
observed alteration in CHT trafficking could occur in the cholinergic nerve terminal
microenvironment in the brain.
The results of experiments in Chapter 2 reveal that the loss of CHT activity in cells
treated with ONOO- is mediated by proteasomal degradation of the protein. ONOO-treatment also results in enhanced CHT ubiquitination. Although not tested, the
internalization of modified or damaged CHT proteins into ONOO--treated cells may
result

in

either

polyubiquitination,

which

promotes

protein

degradation,

or

monoubiquitination, which alters protein trafficking, as a measure of quality control
within the cell. My results show the addition of approximately four ubiquitin molecules
to CHT, which could indicate the presence of a short polyubiquitin chain. A very recent
study by Hartnett et al. (2014) confirmed my observation that CHT undergoes
polyubiquitination using tandem ubiquitin binding entities technology. These authors also
found that CHT interacts with ubiquitin carboxyl-terminal hydrolase L1 (UCHL1), a
deubiquitinating enzyme involved in the ubiquitin-proteasome system, and showed that
UCHL1 knockdown increases CHT polyubiquitination and decreases CHT protein
expression level. Interestingly, UCHL1 activity is altered (16, 17) and down-regulated
(18) by its oxidation in the brains of patients with AD. Another recent study found that
CHT interacts with the exogenous ubiquitin ligase Nedd4-2 causing a reduction its cell
surface levels (19). Nedd4-2 has also been shown to cause the internalization of other
membrane proteins, including the neurotransmitter transporter hDAT and the voltage176

gated potassium channel (20, 21). ONOO- inhibits hDAT function (22), suggesting the
possibility that during pathological conditions ONOO- regulates the production or activity
of Nedd4-2, which in turn mediates the ubiquitination of membrane proteins altering
protein degradation or subcellular trafficking. It is clear that the ubiquitin-proteasome
system is disrupted in AD based on the observation that hallmark features of AD, for
example the deposition of amyloid fibrils and the formation of tau helices, are the product
of ubiquitin-mediated protein defects (23). It is not understood how CHT is regulated by
the ubiquitin-proteosome system, and how this is altered by pathological conditions
associated with AD. Future studies investigating an association between CHT and
Nedd4-2 or UCHL1 could provide interesting and novel information regarding the
mechanisms involved in CHT regulation during AD, in particular under conditions of
oxidative stress.
In addition to oxidative stress, a second important modifiable risk factor for AD is high
serum cholesterol level at midlife. Cholinergic neurons rely on cholesterol for synapse
formation and membrane integrity, thus changes in cholesterol homeostasis in the brain
could potentially lead to changes in the microenvironment of the cholinergic nerve
terminal, leading to alterations in the function of CHT. Early reports regarding CHT
regulation by cholesterol are limited and contradictory. One report shows that lowering
cholesterol in rat brain synaptosomes reduced choline uptake activity (24), whereas
another study found that membrane cholesterol depletion did alter choline uptake (25).
The experiments proposed in Chapter 3 were focused on defining the mechanistic
changes occurring to CHT in response to changes in membrane cholesterol levels. Here, I
found that membrane cholesterol and lipid rafts serve as an important regulator of CHT
trafficking and activity by retaining functional CHT proteins at the cell surface.
In these experiments, I used a variety of drug treatments to manipulate membrane
cholesterol levels with the goal of disrupting lipid rafts and specific cholesterol-protein
interactions. While many studies have looked at the effect of statin drugs on the
development and pathology of AD, I did not use statins to manipulate membrane
cholesterol levels in the experiments performed in Chapter 3 due to their pleiotropic
effects. The majority of cholesterol-independent, pleiotropic effects of statins come from
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their ability to block the synthesis of critical isoprenoid intermediates. Isoprenylation is
an important post-translational modification of the Ras superfamily of G-proteins,
including Rab proteins (26). The inhibition of Rab GTPase isoprenylation by statin
treatment causes these proteins to lose their normal function and leads to dysfunction in
protein trafficking and cellular signalling (27). Importantly, Rab proteins facilitate the
movement of CHT through endosomal and lysosomal compartments, and therefore statin
treatment could have a compounding influence on CHT function through inhibition of
both cholesterol and isoprenoid synthesis. Future studies assessing the individual effects
of cholesterol and isoprenoids on CHT trafficking and activity could provide vital
information about the underlying mechanisms involved in statin-mediated AD risk
reduction.
The results of experiments in Chapter 3 revealed that CHT association with lipid rafts is
critical for its function. As depicted in Figure 5-2, lipid rafts could play a role in
regulating the amount of CHT at the cell surface by altering its internalization rate and/or
its recycling back to the cell surface. In this study, I found that CHT internalization was
not altered by raft disruption, suggesting that decreased recycling of transporters to the
cell surface could be responsible for the reduction in CHT plasma membrane levels and
choline uptake activity following lipid raft disruption. Thus, the mechanism by which
CHT is targeted to rafts is of particular importance. My results show that CHT has a
conserved motif within TMD12 that could serve both as a cholesterol-binding motif and
as a protein dimerization motif these data reveal the presence of a homo-oligomer of
CHT protein within lipid raft fractions. However, it cannot be ruled out that other
modifications to CHT protein may be responsible for its inclusion into lipid rafts. For
example, protein-protein interactions or post-translational modifications of CHT, such as
phosphorylation, could be involved in the targeting of CHT to raft areas of the plasma
membrane. Previous work done in our lab found treatment of cells with the PKC
activator PMA increases choline uptake activity by diminishing CHT endocytosis and
increasing CHT recycling to the cell surface (28). A potential mechanism underlying this
observation may be that specific residues, when phosphorylated, promote the retention of
CHT at the plasma membrane. It is also possible that there is differential phosphorylation
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Figure 5-2 CHT trafficking is regulated by its association with lipid rafts.
The results of my experiments in Chapter 3 show that CHT association with lipid rafts is
critical for its function. Lipid rafts could play a role in regulating the amount of CHT at
the cell surface by altering its lateral movement at the plasma membrane, altering the
transporters internalization either through clathrin-mediated endocytosis, or through
clathrin-independent caveola. Lipid rafts found in endosomal or synaptic vesicle plasma
membrane could alter the subcellular trafficking pathway of CHT. Lipid rafts may also
play a role in altering the rate of CHT internalization and/or its recycling back to the cell
surface. CHT internalization was not altered by raft disruption, suggesting that decreased
recycling of transporters to the cell surface could be responsible for the reduction in CHT
plasma membrane levels and choline uptake activity following lipid raft disruption.
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of CHT proteins in raft and non-raft areas of the plasma membrane, with this potentially
modulating its membrane retention and trafficking. This is the case for PKC-induced
internalization of the DAT that, like CHT, is dynamin- and clathrin-dependent, but is
independent of lipid rafts. DAT in rafts has a lower constitutive level of phosphorylation,
but a higher level of PMA-induced phosphorylation when compared to non-raft DAT,
indicating that rafts are preferential sites for PKC-mediated phosphorylation (29).
The movement of CHT to lipid rafts could also be influenced by protein-protein
interactions. One protein of interest is APP, which binds to CHT and plays a role in
regulating its subcellular trafficking, as demonstrated by the results of experiments
described in Chapter 4 of this thesis. APP is found in lipid rafts; however, it is not known
whether APP and CHT interact in raft or non-raft membrane and what affect this has on
the function of CHT. Amyloidogenic processing of APP by BACE1 occurs in lipid rafts
(30), thus modulating the properties of rafts to reduce the association of APP or BACE1
with these microdomains could reduce the production of Aβ and slow the progression of
AD. In contrast to this, my observations suggest that altering raft properties to exclude
CHT would reduce choline available for ACh synthesis and diminish cholinergic
neurotransmission. Several lines of evidence suggest that the organization of lipid rafts is
disrupted in AD brains (31) and a strong link between cholesterol and AD comes from
the identification of the ε4 allele of APOE as the strongest genetic risk factor for the
development of late-onset AD (32). Alterations in cholesterol homeostasis in the brain, as
a result of hypercholesterolemia or the APOE genotype, could result in reduced
membrane cholesterol levels in cholinergic neurons and cause the disruption of lipid
rafts. Alternatively, increased cholesterol levels in the brain could result in the formation
of lipid rafts, or reduce the fluidity of the plasma membrane, causing raft disruption
and/or inhibition of lateral protein movement. It is unknown how altered cholesterol
homeostasis, and lipid raft disorganization, affects the plasma membrane distribution and
function of raft-associated proteins, such as CHT and APP, in the AD brain. Future
studies should investigate whether APP and CHT interact in raft or non-raft membrane,
how this is altered by cholesterol manipulation and the impact on CHT function and APP
processing.
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The goal of the experiments carried out in Chapter 4 was to further investigate how APP
regulates CHT trafficking and activity, and to determine whether this interaction is
altered by the Swedish mutation. In this study, several experiments were carried out in
neural cells treated with either vehicle or a BACE1 inhibitor. BACE1 inhibition
represents an important therapeutic strategy for lowering Aβ generation, and several
BACE1 inhibitors are currently being tested in clinical trials for their efficacy and safety
for use in individuals with AD. The experiments performed in Chapter 4 provide
important mechanistic data regarding CHT and APP that suggest BACE1 inhibition may
have beneficial effects that are not directly related to lowering Aβ generation in patients
with AD. First, I found that BACE1 inhibition increased the cell surface levels of both
APPwt and APPSwe. This could potentially increase the movement of APP through the
non-amyloidogenic pathway and increase production of the sAPPα, which is thought to
have neuroprotective properties. Second, I made the critical observation that, unlike the
APPwt/Swe-mediated reduction in cell surface CHT levels observed in vehicle-treated cells,
treatment of cells expressing either APPwt or APPSwe with a BACE1 inhibitor restores the
cell surface levels of CHT protein either to (APPwt) or above (APPSwe) that found in
vector-expressing cells. The mechanism underlying this observation was not investigated
further in this study. BACE1 inhibition blocks the production of both Aβ and βCTF. I
hypothesized that lowering Aβ concentration in the culture medium of cells expressing
APPwt or APPSwe by BACE1 inhibition could be responsible for the preservation of CHT
cell surface levels, particularly in cells expressing APPSwe that produce much more Aβ.
However, it is possible my observations are due to the reduction of βCTF generation by
inhibiting BACE1. While my study examined the interaction of CHT with full-length
APP, the carboxyl-terminal domain of APP is sufficient to immunoprecipitate CHT (33).
It is possible that the interaction of CHT with the βCTF alone, rather than with full-length
APP, is required for the internalization of CHT. BACE1 inhibition would result in less
βCTF available for interaction with CHT, thus reducing its endocytosis. Therefore,
BACE1 inhibition could preserve the levels of CHT at the cell surface, thereby
maintaining CHT activity and ACh production, and have a positive effect on cholinergic
neurotransmission in patients with AD.
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In these studies, I observed important differences in the regulation of CHT by APP wt and
APPSwe. I found that CHT interacted significantly less with APPSwe than with APPwt, but
caused a similar level of decrease in CHT activity and cell surface expression. The results
of my study, and those of the study done by Wang et al. (2007), support the hypothesis
that APPwt plays a physiological role in cholinergic neurons by facilitating CHT
presynaptic localization and endocytosis through a direct interaction with the transporter,
while APPSwe-mediated inhibition of CHT function could be caused by the susceptibility
of the transporter to Aβ that is found in the extracellular environment. This suggests that
independent therapeutic strategies for maintaining cholinergic neurotransmission could
be designed for AD patients depending on whether they have sporadic AD or familial AD
caused by the Swedish mutation. In the case of a patient in the early stages of sporadic
AD, a therapeutic strategy targeted towards promoting the interaction between CHT and
APPwt could maintain the normal trafficking and activity of CHT in cholinergic neurons.
As the disease progresses and Aβ accumulates, lowering Aβ generation through BACE1
inhibition may be more relevant to maintain CHT cell surface levels, choline uptake
activity and ACh production. In the case of a patient in the early stages of familial AD
caused by the Swedish mutation, my results suggest that the normal physiological
interaction between CHT and APP is disrupted, with much higher levels of Aβ produced.
Thus, in individuals with AD caused by the Swedish mutation, targeting BACE1 early on
in the course of the disease may be the most effective strategy to promote cholinergic
neurotransmission.
The Swedish mutation of APP is quite rare, found in less than 1 percent of the general
population. However, there are more than 50 different mutations in the APP gene that can
cause early-onset AD and these account for up 10 percent of all early-onset cases of the
disorder (34). It is possible that other mutations of APP could also alter the interaction of
APP with CHT. The underlying reason for the reduced interaction of CHT with APPSwe
compared to APPwt was not investigated in my study. However, I hypothesize that it is
likely related to differences in subcellular location and trafficking of APPSwe compared to
APPwt. A recent study examining APP trafficking found distinct intracellular trafficking
pathways of APPSwe, as well as APP containing the London mutation, when compared to
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APPwt (35). If less APPSwe than APPwt interacts with CHT proteins as a result of
differences in their subcellular trafficking pathways, and various other APP mutations
also alter the trafficking of APP, it is reasonable to conclude that other mutations of APP
could also alter the interaction of APP with CHT. To test this, the experiments outlined in
Chapter 4 could be repeated using different APP constructs expressing various other
familial APP mutations, such as the London mutation or the Arctic mutation. Despite the
fact that the Swedish mutation affects only 1% of the general population, the human
mutant APP mouse Tg2576, which overexpresses the Swedish mutant form of APP695,
is the most commonly used AD mouse model (36). This is because these mice display an
AD phenotype, exhibiting five times the level of endogenous murine APP in the brain
and develop plaque-like deposits of Aβ in the brain at an early age. However,
experiments carried out in Chapter 4 reveal important differences in protein regulation,
subcellular trafficking and subcellular processing between APPwt and APPSwe. Therefore,
depending on the type of study to be performed, a mouse model overexpressing wild-type
APP could be a more appropriate choice.

5.2.1

Significance

Several reports have suggested that the cognitive deficits seen in AD are related to the
loss and dysfunction of cholinergic neuron signalling. However, the specific changes that
occur in the aging brain that result in cholinergic dysfunction, and the extent to which
they can be prevented or reversed, is still unclear. Understanding the mechanisms
involved in CHT protein trafficking is critical since this regulates CHT activity, thereby
sustaining ACh production and maintaining cholinergic neurotransmission. Three
important risk factors for AD include high serum cholesterol level at midlife, mutations
in genes encoding APP and increased generation of ROS and RNS in the brain. Gaining a
greater understanding of the molecular events occurring in the cholinergic presynaptic
nerve terminal that could alter CHT activity in these pathological situations is essential
for developing new treatment methods for AD and was the overall goal of this thesis.
Within the cholinergic nerve terminal microenvironment, changes in APP processing and
Aβ generation, ONOO- production, or plasma membrane cholesterol levels, could cause a
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decrease in CHT activity, thereby reducing high-affinity choline uptake and diminishing
ACh production. The binding of ACh to certain mAChR subtypes is thought to promote
the non-amyloidogenic cleavage of APP (37), while Aβ inhibits various steps involved in
both ACh synthesis and release (38-41). As a result of a decrease in CHT activity, less
ACh would be available to bind to mAChR, which could potentially reduce the
movement of APP through the non-amyloidogenic pathway and result in more APP
available to undergo amyloidogenic processing and generate Aβ. The results of
experiments reported in Chapter 4 of this thesis, as well as those of other groups, show
that Aβ can inhibit high-affinity choline uptake (42, 43), which could potentially be
through a direct interaction with CHT (44). Interestingly, Aβ can indirectly impair CHT
activity by causing the activation of microglia and the production of ONOO- (45).
Aggregated forms of Aβ can also bind to cholesterol and interfere with the plasma
membrane lipid bilayer (46), which could cause a disruption of lipid raft organization and
a decrease in CHT activity. Since the uptake of choline by CHT is the rate-limiting step
to ACh production, a decrease in CHT activity would critically impair ACh synthesis and
release, potentially causing more Aβ to be produced, which could result in a further
reduction in CHT activity. This reciprocal relationship is shown schematically in Figure
5-3. Therefore, promoting CHT activity and ACh production may not only be important
for supporting cognition and memory, but could also critically affect the progression of
AD pathology by preventing the generation of Aβ. The studies reported in this thesis
reveal important mechanistic information regarding the regulation of CHT trafficking and
activity under pathological conditions where cholinergic signalling is compromised. This
information may aid the design of therapeutic strategies to protect against pathological
situations in the cholinergic nerve terminal, which could play an important role early on
in the course of the disease by maintaining CHT activity and ACh signalling, which is
critical to many diverse biological processes.
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Figure 5-3 The relationship between APP and the cholinergic system.
Following the release of ACh into the synaptic cleft, the binding of ACh to certain postsynaptic mAChR subtypes promotes the non-amyloidogenic cleavage of APP, resulting
in the production of non-pathogenic peptides. Alternatively, Aβ, produced as a result of
amyloidogenic processing, can inhibit various steps involved in both ACh synthesis and
release. Aβ can potentially inhibit CHT activity directly or indirectly by activating
microglia and causing ONOO- production or through effects on lipids at the plasma
membrane. Inhibition of CHT activity would impair ACh synthesis. Less ACh would be
available to bind to mAChR, which could potentially reduce the movement of APP
through the non-amyloidogenic pathway and result in more APP available to undergo
amyloidogenic processing and the generation of toxic Aβ peptides.
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